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Semiconducting polymer nanospheres are organic conjugated polymer nanoparticles which are 
synthesized from benign materials and exhibit excellent fluorescence properties. The nanoparticles 
are generally larger than inorganic quantum dots with a relatively broad size distribution. Quantum 
dots, on the other hand, which have extensively been developed and synthesized with precise and 
narrow distributions of a few nanometers in dimensions, are now being widely investigated as bio-
imaging agents, despite the rising concerns about their toxic compositions. Therefore, advances in 
the synthesis of the organic nanoparticles and investigations into their suitability as alternatives to 
quantum dots need to be explored. 
The ‘size problem’ of semiconducting polymer nanospheres – polymer particles are 
significantly larger than quantum dots – was first tackled in this work. With modifications to the 
miniemulsion-evaporation synthesis method, narrowly distributed quantum dot-sized nanoparticles 
with diameters as small as 2 nm were synthesized. These organic nanoparticles which were 
capped/entwined with poly(ethylene) glycol (PEG), a Food and Drug Administration (FDA) 
approved surfactant, were found to conserve most of the optical properties of their constituent 
polymers, and are therefore expected to be useful in bio-imaging applications similar to their larger 
counterparts. 
A second nanoparticle system with a dual-modality was then prepared; semiconducting polymer 
nanospheres capped/entwined with three amphiphilic lipids one of which was gadolinium – 
diethylene triamine pentacetate, a Magnetic Resonance Imaging (MRI) active ligand. These 
bimodal nanoparticles also maintained their optical properties, were readily taken up by two cell 
lines, were distinguishable from the auto-fluorescence of animal tissue, and were found to be MRI-
active as revealed by their MRI relaxivity measurements. 
Finally, the optimized organic nanoparticles and similarly coated quantum dots were 
investigated for their potential to interact with human blood components, a physiological system 
which may be very relevant for semiconducting polymer nanospheres used as medical diagnostic 
agents. The preliminary ex-vivo studies performed revealed that similarly coated organic 
nanoparticles and quantum dots did not induce platelet aggregation or alter aggregation behaviour 
in response to a physiological agonist.  Further, no evidence of platelet activation, neutrophil 
activation or increases in platelet-monocyte adhesion was observed. This implied that introduction 
of the nanoparticles to the blood stream at the concentrations tested may not elicit acute pro-
inflammatory effects or alter normal coagulation pathways, although further rigorous evaluation in 
this area is still required. Fluorescence imaging showed that the organic nanoparticles were taken 
up by different blood cells and also showed some evidence of adhesion to their surfaces, a property 
which might find an application in the future. Ultimately, more short-term and long-term safety 
studies (in-vitro, ex-vitro, and in-vivo) must be conducted before deriving any further conclusions. 
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The prefix “nano” is the Greek word that means “dwarf” [1]. The prefex “nano” is a scale of 
length and refers to 10
-9
 of a metre. i.e. 1 nm equals 0.000000001 m. 
Although the concepts of nanotechnology were first referred to by Richard Feynman in 1958, 
the term “nanotechnology” was not introduced until 1974 [1-3]. By then, Taniguchi et. al. defined 
nanotechnology as “the processing, separation, consolidation, and deformation of materials by 1 
atom or by 1 molecule” [3]. 
In 2004, “nanotechnology” was defined by the Royal Society/Royal Academy of Engineering in 
the United Kingdom as “the design, characterisation, production and application of structures, 
devices and systems by controlling shape and size at nanometre scale”, and “nanoscience” was 
defined as “the study of phenomena and manipulation of materials at atomic, molecular and 
macromolecular scales, where properties differ significantly from those at a larger scale”.[1]  
Research in nanoscience and nanotechnology has combined many disciplines such as physics 
[4], chemistry [5], biology [6],  engineering [7-9], and medicine [3, 10-12]  into one identity. 
Scientists with different expertise, who previously worked only within the realm of their expertise, 
now work together and share their knowledge to achieve their multidisciplinary goals. Because of 
this multidisciplinary manner of such an emerging field, research is dramatically increasing, with 
the number of published documents, including articles and books, rising almost exponentially [13-
14] over the years (Figure 1). 
 
Figure 1 The number of published documents which are related to nanoscience and 
technology throughout the years. Data collected from the Web of Knowledge, All 
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Databases, King’s College London’s access, on 20 May 2012. Search done in 
English, on: (nanotechnolog* OR nanoscience OR nanomaterial* OR 
nanoparticle* OR nanotube* OR nanorod* OR nanosphere* OR "quantum dot"* 
OR nanosheet* OR nanowire*), under the (topic) category. 
1.1 Nanoparticles 
1.1.1 Definition and History 
With the development of nanoscience and technology, official attempts to define the newly 
arising nanomaterials were also made. According to the Royal Society/Royal Academy of 
Engineering, July 2004, nanoparticles were defined as follows: “We classify nanoparticles to be 
particles of less than 100 nm in diameter that exhibit new or enhanced size-dependent properties 
compared with large particles of the same material” [1]. Another general definition was made by 
the British Standards Institution (BSI), in their PAS71:2011 document, describing a nanoparticle to 
be a material with its three external dimensions in the nano-scale, clarifying a nanoscale to be a size 
range between approximately 1 and 100 nm [15]. 
1.1.2 Nanoparticles Synthesis Routes in a Nutshell 
Nanoparticles have existed on earth for thousands of years; nanoparticles have been produced 
by plants, natural erosion processes, and volcanic activities.[16-17] Man-made nanoparticles, 
however, were initially generated unintentionally for some time. Metal nanoparticles imbedded in 
glass, for example, were made by glass craftsmen in a process invented to produce light-induced 




The first reported synthesis of nanoparticles was in 1857 by Faraday, who synthesised and 
studied the colour of gold nanoparticles which he referred to as colloidal gold.[18] Since then, the 
syntheses of many nanoparticles, under various names, were reported, until the nomenclature 
“nanoparticle” was introduced. 
Nowadays, the synthesis methods of nanoparticles usually follow a top-down or a bottom-up 
synthesis route [1] or a combination of both [19-20]. In the top-down approach, materials with 
large scales are reduced in size to smaller dimensions. Examples of well established synthesis 
methods that use this approach are nano-imprint lithography [21], photolithography [21], and e-
beam lithography [22]. In the bottom-up approach, atoms, molecules, or smaller nanoparticles are 
used as the building blocks in the synthesis of the required nano-structures. Such an approach 
usually involves chemical reactions as in the syntheses of most quantum dots [23] or self-assembly 
as in the formation of polymer nanoparticles from ready-made polymers via emulsion-solvent 
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evaporation or precipitation techniques [24], self-assembly with the assistance of biological 
reactors as in the synthesis of antimony sulphide nanoparticles using microorganisms [25], or a 
combination of techniques as in miniemulsion polymerisations which involve both physical actions 
and chemical reactions [26]. The combined top-down and bottom-up approaches are sometimes 
used to overcome obstacles or to improve the outcomes of the synthesis of a certain type of 
nanoparticles using only one of the approaches [19-20]. 
Regardless of the synthesis method used, nanoparticles can be directly synthesised in solution, 
or they can be etched or formed by deposition on different surfaces. 
1.1.3 Common Properties of Nanoparticles and their Applications in Biology  
1.1.3.1 Common Properties of Nanoparticles 
Nanoparticles can be synthesised in different shapes which, if specified, can be used to denote 
different nomenclatures to the nanoparticles. For example, spherical nanoparticles are 
interchangeably called “nanospheres”, rod-shaped nanoparticles are usually called “nanorods”, and 
polyhedron-shaped nanoparticles are sometimes called “nanoprisms”.  
Nanoparticles can be organic or inorganic, they can exist as crystalline or amorphous structures 
[27], and they can be in a single core construction, or in a core/shell or core/multi-shell 
construction. Quantum dots and polymer nanoparticles are examples of such systems. 
An important feature which distinguishes nanoparticles from bulk materials is the increase in 
their surface-to-volume ratio as their size decreases. This results in an increase in their surface-
related properties, such as reactivity. Therefore, nanoparticles can be highly reactive, favouring 
aggregation or adsorption of certain molecules, and they can be extremely interactive with their 
surrounding environment. An example of a highly reactive surface is that of a crystalline 
nanoparticle which includes “dangling-bonds” from the atoms in the incomplete lattice units of its 
outer surface.  
To stabilise the surface and reduce these bare-surface related phenomena, nanoparticles can be 
coated with different coatings which occupy and neutralize their reactive sites and sometimes 
produce an electrostatic repulsive force between the nanoparticles, especially those tending to 
aggregate. Examples of such coatings are silica shells, molecular ligands, amphiphilic polymers, or 
functionalized alkyl chains [28-30]. 
 Capping of the nanoparticles also facilitates the functionalisation of their surfaces for specific 
applications such as molecular targeting. It can also be used to phase-transfer the nanoparticles and 
change their solubility which depends on the chemical structures of the nanoparticles’ capping 
agents. For example, nanoparticles which are not dispersible in water can be made aqueous by 
capping the particles with amphiphilic molecules which have a hydrophobic part that adsorbs on 
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the nanoparticles’ surfaces and a hydrophilic part which assists their aqueous dispersion in water. 
Another important feature is that they have unique properties which arise from their nanometre 
sizes. When the dimensions of materials are reduced to this scale, their properties are solely 
governed by quantum mechanics. These quantum mechanical effects are usually dominated when 
the nanoparticle’s dimensions are below a specific value such as the excitonic Bohr radius in 
inorganic semiconductors [31] and the characteristic Weiss domain in superparamagnetic and 
magnetic materials [32]. 
Therefore, many nanoparticles have unique optical and electrical properties which are size and 
shape dependent. Examples are noble metal nanoparticles and inorganic semiconductor 
nanoparticles. Noble metal nanoparticles have changeable plasmonic properties which are observed 
as a change in the nanoparticles’ colour with the change in their size or shape, while inorganic 
semiconductor nanoparticles have size and shape-dependent tuneable bandgaps which result in 
changeable electrical and fluorescence properties. 
1.1.3.2 Biological Applications of Nanoparticles 
Due to the above mentioned phenomena, nanoparticles found many applications and are being 
proposed as alternatives to many conventional materials in numerous research areas. In biology, 
nanoparticles are beings studied as medical diagnostic and therapeutic tools.[33] This is because 
they have comparable sizes to many biological species and are able to interact with their 
environment while conserving their properties of interest such as magnetism and fluorescence. 
Therefore, many nanoparticles are now being explored as fluorescence imaging probes [34-36], as 
magnetic resonance imaging contrast agents [37-41], as drug delivery vehicles [42-44], as 
radioactive agents for cancer treatment [45], and in many pathological studies [46]. 
Capping of the nanoparticles can be used to improve their bio-compatibility, increase their 
circulation time, decrease their non-specific binding to the contents of their environment, and 
phase-transfer them to aqueous media in preparation for their use within biology.[47] 
Many nanoparticles have already proved efficient in cell imaging, enhancing the sensitivity and 
improving the resolution of many conventional diagnostic techniques, and increasing our current 
knowledge of the cellular interactions and processes.[48] With further developments, nanoparticles 
can be very powerful tools in medicine and can serve as effective imaging agents for more 
sophisticated methods such as multiphoton fluorescence imaging [49] and single molecule 
spectroscopy [50-51]. 
1.1.4 Nanoparticles as Fluorescence Bio-imaging, Labelling, and Tracking Agents 
All materials absorb electromagnetic waves (photons) with certain energies and therefore have 
unique absorption spectra. These absorption spectra are associated with the energy levels of the 
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materials where electrons from the ground states absorb only the photons which have energies 
equal to the energy difference (gaps) between their ground state and excited states and therefore 
travel to the excited states. Those excited electrons decay to their ground state either radiatively or 
non-radiatively depending on the type of material. Radiative decay of the electrons results in the 
emission of a photon. 
Fluorescence is the emission of light with a lower energy than that of the absorbed exciting 
energy. This is because both radiative and non-radiative processes occur where an excited electron 
first decays non-radiatively within its excited states reaching the excited state with the lowest 
energy, then decays radiatively to its ground state emitting the excess energy as a photon, as 
illustrated in Figure 2. 
Because fluorescent materials emit light with a different wavelength than that absorbed, they 
were found to be useful in many applications such as biological imaging, labelling and tracking. 
 
Figure 2 An illustration of the energy levels of a fluorescent material. During fluorescence, a 
photon with a suitable energy is absorbed and an electron is excited from its ground 
state to an excited state (path A). Then it decays non-radiatively within the excited 
states (path B), and finally decays radiatively and returns to its ground state (path 
C) emitting a photon with a lower energy than that of the absorbed photon. 
Biological studies involve the experimentation with, and observation of, the biological samples 
in one or more of the following main settings; in-vitro (in a laboratory vessel), in-vivo (within the 
natural setting or living organism), and ex-vivo (outside the living organism).  
The organelles of cells in-vitro are almost optically transparent, therefore, to distinguish 
between the different organelles some form of colour labelling is required.[52] This can be 
achieved by the use of suitable non-toxic fluorescent labels which can be excited with an 
undamaging tuned frequency of light and detected with conventional optical microscopes. In the 
imaging process, the natural fluorescence which is emitted from some parts of the cells under 
excitation, auto-fluorescence, is easily compensated for, and currently cell imaging using this 
fluorescence labelling technique is widely used. In more complex biological samples however, this 
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process is more complicated because the absorption of a substantial region of the light spectrum is 
present and auto-fluorescence of the biological samples is increased, therefore, special labels which 
absorb and emit in the available transparent optical window, such as the near-infrared region [53], 
are required. 
Traditional organic fluorescent probes which are currently being used as cell imaging agents are 
organic fluorophores. The fluorophores’ fluorescent property arises from their chemical structure 
(see section1.3.3 for further details on the relationship between the chemical structure of molecules 
and their optical properties). The functional groups of the fluorophores, which can be chemically 
modified prior to the imaging process, enable them to be directly attached to the biological sample 
under study, or to be attached to a targeting biomolecule such as an antibody which can then bind 
to the sample of interest.[52, 54] 
Although these conventional imaging probes proved relatively safe and efficient, they have their 
limitations which restrict their use in many areas. For example, many fluorophores have wide 
emission spectra, a problem which limits their use in multicolour imaging.[55] Moreover, 
fluorophores are prone to fast photo-bleaching under exposure to prolonged optical excitations. 
Photo-bleaching is the weakening and eventual disappearance of fluorescence due to irreversible 
photo-induced reactions such as oxidation. Traditional fluorophores are also very sensitive to their 
environment; they change their conformation with the fluctuations of temperature, for example. 
Conformational damage causes a loss in fluorescence and conformational fluctuations induce 
fluorescence blinking. Fluorescence blinking is a phenomenon where the fluorescence of single 
molecules is switched “on” and “off”, a phenomena which is not always desired.[52, 56]   
Fluorescent nanoparticles were found to overcome many of these problems.[6, 57-59] Examples 
of such nanoparticles are some noble metal nanoparticles [60-61], fluorescent silica nanoparticles 
[62-63], fluorescently labelled micelles [64], quantum dots [56], and semiconducting polymer 
nanospheres which are the main focus of this thesis. 
1.2 Quantum Dots 
1.2.1 Definition and History 
Quantum dots (QDs) are nano-sized crystals (nanoparticles) of inorganic semiconducting 
materials [46] which were first synthesised in the 1980s [14]. The nano-sizes of these inorganic 
semiconductor nanoparticles cause their electrons to be confined in all three dimensions so that 
they are localised in discrete energy levels controlled by quantum mechanical laws.[65] Due to the 
three dimensional confinement of electrons, these nanoparticles are often called zero-dimensional 
structures (0-D) [66], and because of their size-related arising quantum effects, they are also called 
quantum dots (QD) [14]. 
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QDs not only exhibit unique electrical properties which make them useful in the semiconductor 
industries [67-68], but also fluoresce in the visible region when exposed to suitable higher energies 
which also makes them possible alternatives to conventional fluorophores in the bio-imaging and 
medical diagnostic fields.[14, 46, 54, 56, 69-70] 
1.2.2 An Overview of the Physical and Chemical Properties of Quantum Dots 
1.2.2.1 Composition and Physical Properties of Quantum Dots 
QDs are crystalline in structure. i.e. their atoms are arranged in a three-dimensional periodic 
order so that their smallest repetitive unit is identified as a lattice with characteristic lattice 
constants.[71] The atoms which form these nanocrystals are those of the periodic table which are 
known to be compositions of bulk, elemental or compound, semiconductors in either an intrinsic 
[23] or extrinsic [72-74] form. Silicon [57, 75] and germanium [23, 76] QDs are examples of 
inorganic elemental semiconductor nanoparticles, while CdSe [74], CdTe [48], ZnSe [73] and 
HgSe [77] QDs (II-VI semiconductors), InP [48] and GaSb [78] QDs (III-V semiconductors), or 
PbS [68] QDs (IV-VI semiconductors) are examples of inorganic compound semiconductor 
nanoparticles. Furthermore, QDs can be synthesised from a single semiconductor such as silicon 
QDs [57, 75] and CdSe QDs [79], or from several semiconductors in core/shell or core/multi-shell 
structures such as CdSe/ZnS [80] and CdTe/CdSe/ZnSe [81] QDs. Depending on the QDs’ 
synthesis parameters, they can be formed with specific shapes such as rods [65, 80], spheres [65], 
pyramids [82], or tetrapod-shaped heterostructures [80], etc, they can also be tuned [83] to different 
sizes, ranging between 1 – 20 nm [14] with very low  polydispersities [81]. 
1.2.2.2 Chemical Stability, Surface Modifications and Coatings of Quantum Dots  
QDs are typically stored in temperatures below 4 ºC under light exclusion [84]. QDs are very 
sensitive and fragile nanomaterials. They can undergo rapid oxidation when exposed to different 
environments (e.g. PbSe nanocrystals oxidise rapidly when exposed to air [85]), their elemental 
ions can leach from their core materials [86], and they can be very reactive with their environment 
because of their increased surface areas. Such chemical instability can cause a rapid loss of their 
desired optical properties (quenching), with many non-chemically stable QDs reported to have a 
very short shelf life.[87] 
Surface modifications were found to improve the QDs’ chemical stability (decrease ionic 
leaching and prevent oxidation), conserve their optical properties, and improve their bio-
compatibility.[88] Surface modifications were also performed to phase-transfer QDs from their 
usual organic solvents to aqueous media in preparation for their use in many applications such as 
bio-imaging. An example of such surface modifications is the addition of a ZnSe shell to 
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CdTe/CdSe core/shell QDs which acts as an electron-hole internaliser and a cadmium-leaching 
preventer.[81] Another example is capping CdS QDs with silica shells to improve their bio-
compatibility and photostability and increase their shelf life.[88] 
1.2.3 General Applications of Quantum Dots 
Quantum dots, with their unique optical and electrical properties proved highly useful in many 
applications. Most importantly, in both electrical applications, such as transistors, light emitting 
devices, lasers, and photovoltaics [67-68, 72, 89-92], and in biological applications, such as cell 
imaging, and bio-labelling and tracking [46, 48, 54, 56-58, 69, 93-97]. 
As our focus in this work is on providing organic semiconducting polymer nanoparticles, which 
might be good alternatives to QDs for bio-imaging applications, the following sections will only 
consider relevant studies done using QDs. 
1.2.4 Quantum Dots as Fluorescence Bio-imaging, Labelling, and Tracking Agents 
The fundamental studies using quantum dots as fluorescence imaging agents were reported in 
1998 by Bruchez et al. [55] and Chan et al. [98]. Both groups used CdSe/ZnS QDs, which were 
made aqueous by either coating them with silica shells or by attaching a linking molecule to their 
surfaces which made them water soluble.[81] 
Since then, among all types of nanoparticles, quantum dots have received the most attention in 
this field.[29, 47, 49, 52, 94, 99-102] Before the emergence of alternatives to quantum dots, such as 
semiconducting polymer nanospheres, quantum dots were found to be the best imaging agents in-
vitro and in-vivo exceeding conventional fluorophores in several aspects [52, 55]. Quantum dots 
have size and material-tuneable emission peaks (400 nm – 2 µm [55]) which are separated from 
their excitation peaks with considerable Stokes shifts. Their emission spectra are narrow and 
symmetric (typical emission widths of 20 – 30 nm in the visible region [55]) while they absorb 
light in a very wide range, facilitating multiplex detection [103] and conserving the characteristics 
of the emission peaks regardless to the excitation energy used [55]. They do not photo-bleach as 
fast as fluorescent dyes (typical CdSe/ZnS QDs are 100 times more stable against photo-bleaching 
than conventional organic dyes [98]), and are considered very bright. Also, quantum dots have 
tunable-surface properties which can be modified by functionalisation with a range of 
surfactants.[29, 52, 56, 96]  
However, significant issues evolved regarding the safety of use of these materials in the 
biological and medical fields because many quantum dots contain toxic inorganic elements such as 
mercury and cadmium. These will be discussed in detail in section (1.2.5). 
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1.2.5 Limitations of Quantum Dots’ use as Bio-imaging Agents 
Until recently, the most suitable and commercially available quantum dots were cadmium-
based. Cadmium is toxic in its ionic form [54, 103-104], therefore, many toxicity studies were 
conducted on those quantum dots and several issues were revealed.[104-109] Other than the toxic 
contents which were found to leach from the QDs into the biological environment [110], it has 
been reported that the surface interactions of the QDs with their surroundings can also cause a 
problem [111]. It has also been reported that QDs can cause DNA damage [112-113]. 
To prevent the surface interactions and leaching of the toxic contents of QDs and to increase 
their biocompatibility, QDs can be coated with effective coatings such as silica shells and 
polymers.[88, 110-111, 114-115] However, this gives rise to another problem, especially if used in-
vivo,  as their increased size disables them from being renal-cleared.[116] This can also give rise to 
long term toxicity issues.[103] 
Another limitation which hinders the QDs’ use as bio-imaging agents, other than their toxicity 
issues, is the high sensitivity of their optical properties to their structure. Any damage to part of 
their surface can cause a loss of fluorescence. Damage can occur with phase-transfer or with the 
capping treatments needed to increase their biocompatibility [117]. Damage of the QDs’ optical 
properties can also occur during the procedures involved prior to the imaging of the biological 
samples. 
With these limitations, the search for alternative nanoparticle probes, for in-vivo and in-vitro 
bio-imaging applications, with competing properties is now under study.[36, 70, 118-123] 
1.3 Semiconducting Polymer Nanospheres 
1.3.1 Definition and History 
1.3.1.1 Polymers 
The word “Polymer” is derived from two Greek words; “Poly” meaning “many” and “meros” 
meaning “parts”. This Greek naming is directly related to a common property of these materials 
which is their huge chemical structure that is composed of many parts. 
Polymers have occurred in nature since the beginning of life, in the form of proteins, fibres, and 
rubbers etc. After the development of polymer chemistry, these were given the name “naturally 
occurring polymers” or biopolymers. During the 19th century, experimentalists tried to improve the 
properties of these natural materials by mixing them with different chemicals and exposing them to 
severe conditions.[124] The discovery of the first synthetic polymer was announced in 1907 by Leo 
Baekeland, given the name Bakelite.[124] During the 20
th
 century, extensive work was done to 
explore, experiment, and develop a theoretical understanding of these large molecules [124], and at 
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present, polymers have a well defined chemistry. They are easily synthesized and are used in a 
wide range of applications: in coatings, textiles and ceramics, electronic and optical devices such as 
LEDs, and in many other commercial products. 
Polymers are composed of a chain of carbon atoms covalently bonded forming the back-bone of 
the polymer. The structure of a polymer can be described by a repeated unit, called a monomer, 
which is repeated many times. Figure 3 shows the chemical structure of a well known simple 
polymer, polyethylene (PE). The number of the repetition of the monomer unit is called the degree 
of polymerization (n in Figure 3). A small polymer is called an oligopolymer or oligomer, which 
has a very low degree of polymerization (less than 10 repeated units). There are many different 
types of polymers which can be grouped according to their chemical structure, constituents, or 
orientation.[125]  
 
Figure 3 The chemical structure of polyethylene (PE). The polymer is synthesised from 
ethylene, the monomer, which is the structure between the square brackets but with 
a double bond between the carbon atoms. The degree of polymerisation is (n). 
1.3.1.2 Conjugated (Semiconducting) Polymers 
Conjugated polymers are polymers which have alternating multiple and single bonds along their 
backbone as illustrated in Figure 4. The length of uninterrupted conjugated chain segments in a 
polymer is called the conjugation length. The conjugation along the chains gives these polymers a 
bandgap which enables them to be thought of as alternatives to inorganic semiconducting materials 
and are therefore interchangeably called “semiconducting polymers”. Also, many conjugated 
polymers have the potential to fluoresce when excited with a suitable energy, a property which is 
unobtainable with non-conjugated organic materials. These opto-electrical properties will be 
discussed in detail in section 1.3.3. 
 
Figure 4 The backbone chain of a simple conjugated polymer. 
 The first conjugated polymer was discovered by mistake in 1974.[126] After that, extensive 
research in the synthesis of conjugated polymers with different properties started to take place, and 
numerous conjugated polymers were reported over the years. At present, many fluorescent 
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commercially available. Taking this advantage, we used five of these polymers in this work: 
poly[2-(2’,5’-bis(2’’-ethylhexyloxy)phenyl)-1,4-phenylenevinylene] (BEHP-PPV, minimum MW 
30000 g/mol), poly[2-methoxy-5-(2-ethylhexyloxy)-1,4-phenylenevinylene] (MEH-PPV, MW 
40000 – 70000 g/mol), poly[(9,9-di-n-octylfluorenyl-2,7-diyl)-alt-(benzo[2,1,3]thiadiazol-4,8-
diyl)] (F8BT, MW 5000 – 8000 g/mol), poly[2,5-di(3’,7’-dimethyloctyl)phenylene-1,4-ethynylene] 
(PPE, MW 4122 g/mol), and poly[(9,9-dioctyl-2,7-divinylene-fluorenylene)-alt-co-(2-methoxy-5-
(2-ethyl-hexyloxy)-1,4-phenylene)] (ADS108GE, MW 111000 g/mol). Their structures and their 
absorption and emission spectra are presented in Figure 5. 




Figure 5 The chemical structures [127-129] and optical properties of  five fluorescent 
conjugated polymers; BEHP-PPV, MEH-PPV, F8BT, ADS108GE, and PPE; (A) 
Their chemical structures,  and (B) their absorption (blue line) and emission (red 
line) spectra in solution (dissolved in DCM). 
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1.3.1.3 Semiconducting Polymer Nanospheres 
Semiconducting polymer nanospheres (SPNs) are spherical shaped nanoparticles composed of 
semiconducting polymers. Semiconducting polymer nanospheres are also called “conjugated 
polymer nanoparticles”. 
SPNs can be synthesised without any coatings [130], or they can be coated or entwined with 
different molecules[36]. The synthesis of SPNs will be discussed in section 1.3.6. An illustration of 
SPNs stabilised and coated with amphiphilic molecules is presented in Figure 6. 
 
Figure 6 An illustration of a semiconducting polymer nanosphere stabilised by three 
different amphiphilic molecules. 
1.3.2 Physical and Chemical Properties of Semiconducting Polymer Nanospheres 
1.3.2.1 Composition and Physical Conformation of Conjugated Polymers in Good and Poor 
Solvents 
As previously mentioned, conjugated polymers are composed of repeating monomers which are 
attached together to form a central back-bone chain of alternating single and double bonds. Many 
conjugated polymers also contain side chains which can be functionalised to give them different 
properties such as differing solubility. The solubility of a conjugated polymer in a specific solvent 
depends on the molecular structure of both solvent and solute, and it directly affects the polymer’s 
physical conformation in that solvent. Solvents can therefore be categorised as good or poor for a 
particular conjugated polymer. 
A good solvent is a solvent where the polymer chains are in  an uncoiled conformation [131]. In 
this situation, the interactions between the polymer chains and the molecules of the solvent are 
energetically favourable. A poor solvent, on the contrary, is a solvent where the polymer chains 
form coils to minimise the non-favourable interactions between them and the molecules of the 
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solvent. An illustration of the conformations of the polymer chains in a good and a poor solvent is 
presented in Figure 7. 
 
Figure 7 Polymer conformation when dissolved in (A) a good solvent and (B) a poor 
solvent. The polymer chains acquire an uncoiled conformation in a good solvent, 
while they prefer to collapse into a coiled conformation in a poor solvent.  
For example, MEH-PPV has a non-polar aromatic backbone and slightly polar alkoxy side 
chains. In a non-polar solvent, the solubility of the aromatic backbone of MEH-PPV is favoured; 
therefore, the polymer maintains an extended conformation to increase the exposure of its 
backbone to the “good” solvent. In a polar solvent, the solubility of the backbone is unfavoured, 
therefore, its aromatic backbone chain coils up and collapses to limit its exposure to the “poor” 
solvent.[131] 
1.3.2.2 Physical Conformation of Conjugated Polymers in Solid Films 
The production of solid polymer films is important in electronic and optical device applications 
[132]. One way to produce solid polymer thin films is by drop-casting a solution containing the 
polymer onto substrates and evaporating the solvent.[133] It has been reported that polymers have 
a “memory effect” where their conformation in solid films adopt their original conformations in the 
solvents used.[134] Therefore, if drop-cast using a poor solvent, polymer films tend to have coiled-
up and collapsed chains, while if drop-cast using a good solvent, they tend to have layers of 
polymer chains in an uncoiled conformation and minimum aggregation dependent upon 
concentration. The conformation of polymer chains in solid films was found to greatly affect the 
solid films’ electronic and optical behaviour. This is discussed in detail in section 1.3.3. 
1.3.2.3 Physical Conformation of Conjugated Polymers in Nanoparticles 
The physical conformation of conjugated polymers in a nanoparticle form is not yet thoroughly 
explored. However, it was reported that conjugated polymers collapse in single or multiple chains 
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to form nanoparticles.[130] This implies an increase in folds and entanglements of the polymer 
chains which can be explained by the change in the electronic and optical behaviour of the 
nanoparticles in comparison to their behaviour in solution.[135] 
1.3.2.4 Shape, Size, Chemical Functionalisation,  Surface Morphology and Coatings of SPNs 
Previously reported SPNs were always found to be approximately spherical in shape as 
suggested from TEM and AFM images, a property most probably influenced by the synthesis 
methods used. The spherical shape was reported by Moon et al. [136], Landfester et al. [26], and 
McNiell et al. [130, 137-138]. 
Different groups reported different diameters for their SPNs which had different coatings and 
were functionalised with different methods. For example,  Landfester et al. reported the production 
of sodium dodecyl sulphate (SDS) stabilised SPNs with diameters ranging between 70 and 250 nm 
[139]. Moon et al. reported the production of uncoated functional SPNs as small as 25 nm in 
diameter. The chemical functionality was made by modifying the polymers used before synthesis 
[136, 140-141]. Chen et al. reported the formation of SPNs with sizes between 10 nm and 10 
microns stabilised by different amphiphilic molecules which can be modified for different 
functionalities [142]. McNeill et al. reported the synthesis of non-coated, non-functionalised SPNs 
with diameters between 3 and 100 nm [143], they also reported the synthesis of silica capped SPNs 
functionalised with amine groups which were relatively large [137], and they recently reported the 
synthesis of bioconjugatable functionalised SPNs with diameters around 10 – 15 nm [144-145]. 
Our group reported the production of both PEG capped/entwined SPNs with diameters as small as 
13 nm [118] and phospholipid capped/entwined SPNs with average diameters between 59 and 74 
nm [36]. 
In general, most of the reported SPNs were substantially larger than the average diameters of 
QDs with relatively large size distributions. A few reports exist on the synthesis of QD sized 
fluorescent polymer nanoparticles, but either the method involved complicated methods with the 
use of toxic reagents, or the nanoparticles lacked surface functional groups which is an important 
feature for in-vivo administration [34, 130, 137, 146]. Therefore, further experimentations were 
needed with the use of one of the simplest, less toxic, synthesis routes to improve the sizes and size 
distributions of the produced SPNs to be comparable to QDs. The work reported in this thesis 
explored the preparation of QD-sized SPNs (Chapter 2). 
1.3.3 Opto-electrical Properties of Semiconducting Polymer Nanospheres 
Similar to quantum dots, the semiconducting and luminescent properties of semiconducting 
polymer nanospheres arise from their electronic structure which is similar to the electronic 
structure of their constituent polymers but is modified by the spatial configuration of their chains, 
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i.e. by the degree of packing of the chain segments and their folds and entanglements in solution, 
solid, or nanoparticle form. 
1.3.3.1 Electrons in an Organic Molecule  
Atoms in general are bound together by one or more of the different bonds: covalent, ionic, 
and/or metallic. These bonds cause the electrons of the solid/molecule to be delocalised to move in 
bands of energy instead of being highly localised in discrete energy levels as in the case of single 
atoms. In theory, each atom has a number of atomic orbitals where the probability of finding an 
electron is high. These atomic orbitals are described in quantum mechanics as electronic 
wavefunctions. Free atoms which are not full in their outer electronic orbitals tend to bond to other 
free atoms to reach a stable state where their outer orbitals are entirely full. We will first consider 
the H2 molecule which is the simplest molecule to illustrate the molecular orbital model that leads 
to the band theory of materials. As shown in Figure 8, each hydrogen atom has a single electron in 
its atomic s-orbital. If two hydrogen atoms were brought together, at a certain distance, their atomic 
s-orbitals will begin to overlap and they will start to attract each other, and as they become closer 
the interactions between their orbitals increase until they combine and split into two molecular 
orbitals (MO); a bonding MO that corresponds to an inphase interaction of the atomic s-orbitals 
and has a lower energy than that of the individual atomic orbitals, and an anti-bonding MO that 
corresponds to an out-of-phase interaction and has a higher energy. In a non-excited state, i.e. when 
the H2 molecule is in its ground state, both electrons of the two hydrogen atoms occupy and fill the 
bonding MO, and the molecule is said to be in its most stable condition. 
 
Figure 8 (right) The electronic energy levels of the H2 molecule as a function of distance (r) 
between the nuclei of the two H-atoms. The curve (E(bonding)) is the energy of the 
bonding state, and (E(anti-bonding)) is the energy of the antibonding state. The 
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molecule is most stable when the distance between the atoms is (R). (left) A 
simplified molecular orbital diagram, representing the bonding and antibonding 
molecular orbitals in the stable H2 molecule. The electrons (represented by arrows) 
occupy the lowest energy level of the system (the σ – bonding molecular 
orbital).[147] 
As the backbones of polymers are typically composed of covalently bonded carbon atoms, a 
discussion of the electronic orbitals of two or more carbon atoms bonding together in an organic 
molecule applies here. Similar to hydrogen atoms in a hydrogen molecule, each carbon atom has a 
number of atomic orbitals where the probability of finding an electron there is high. If two carbon 
atoms were put together, their atomic orbitals interact to form molecular orbitals (MO) which can 
be bonding or antibonding. Figure 9 (A) shows the formation of the 1s and 2s molecular energy 
levels of molecules composed of two multi-electron atoms such as two carbon atoms. The highest 
occupied molecular orbital in a molecule is called the HOMO, and the lowest unoccupied 
molecular orbital is called the LUMO. The HOMO and LUMO are separated by an energy gap that 
is characteristic of the atoms, their quantity, and the type of bond forming that molecule. If the 
molecule is excited with an energy equivalent to or more than that of the energy gap, an electron 
will absorb that energy and set off from the HOMO to the LUMO. 
If more than two carbon atoms form a molecule (Figure 9 (B)), other energy levels appear so 
that the number of molecular orbitals of the system equals the addition of the number of atomic 
orbitals of the constituent atoms, and if the number of atoms forming this molecule becomes very 
large (Figure 9 (C)), as is the case of polymers, the energy levels become bands.[148-149] 
The energy gap between the bands is a forbidden area for electrons. An electron cannot jump a 
gap from one band to the other except if it is excited with an amount of energy that is equal to or 
more than that of the band gap. However, the bands are not always separated by a band gap, some 
bands can overlap so that the highest level in one band is above the lowest level in its upper 
neighbour. 




Figure 9 (right) The electronic energy levels of molecules formed from multi-electron atoms 
as a function of distance (r) between the nuclei of the atoms. (left) A corresponding 
simplified electronic energy diagram. Only the (1s) and (2s) orbitals are shown. 
The combination and splitting of the atomic orbitals happens when molecular 
orbitals are formed in (A) a two-atom molecule and (B) a three-atom molecule. The 
molecular electrons occupy and fill the lowest available energy states first before 
filling available states in higher energy levels. The spacing between the split 
molecular orbitals is reduced as the number of atoms in the molecule is increased 
and (C) with an infinitely large molecule the energy levels become bands.[147] 
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1.3.3.2 Optical and Electrical Properties of Conjugated Polymers in Free Spatial 
Configuration 
Like inorganic solids, polymers can be insulators, conductors, or semiconductors. If we consider 
non-conjugated, single-bond chained, polymers, the molecular orbitals of such systems do not 
overlap because they are orbitals that emerge from the sigma bond which has a large separation 
between its bonding and antibonding states. Therefore, the electrons in such systems are highly 
localised around their atoms. This gives rise to a very wide bandgap between the HOMO and 
LUMO levels and gives the polymers an insulating electronic structure. The molecular orbitals of 
double or even triple bonded polymers, on the other hand, emerge from a sigma bond and a pi bond 
(or two pi bonds in the case of triple bonded polymers). In contrast to sigma bonds, pi bonds do not 
have a large separation between their bonding and antibonding states. Therefore, the relatively 
weaker pi bonds extensively overlap delocalising their electrons along their double- or triple-
bonded chains. The bandgaps, here, decrease with the increase of chain-lengths, and with very long 
chains, the polymers become conducting. However, when the double and single bonds alternate, 
developing conjugation along the chains, a midpoint between the two situations takes place, and 
small bandgaps similar to the bandgaps of inorganic semiconductors are formed. Such a conjugated 
polymer, therefore, has a semiconducting property and is called an organic semiconductor.[148, 
150] 
Organic semiconductors exhibit changes in their energy levels with the presence of “defects”. 
Defects are interruptions of the conjugation along the polymers’ chains which were argued to arise 
from bending and twisting of their chains in non-free, i.e. real, configurations. However, it was 
recently proved by a quantum chemical approach that only chemical defects cause such 
interruptions.[151] Electrons in organic semiconductors are therefore confined in a one-
dimensional quantum well, with the potential barrier of the well changing with the change in the 
conjugation length.  The average un-interrupted conjugation lengths in conjugated polymers are 
called “effective conjugation lengths”, and these are the conjugated segments which define the 
semiconducting polymers’ electrical and optical properties.[127, 152] 
For an organic semiconductor to fluoresce, its carbon skeleton should be conjugated, it should 
have a separation between its ground state and first excited state, and it should have a good 
separation between its excited singlet and triplet states with a relatively stable singlet state.  
The un-interrupted conjugated segments which are responsible for the fluorescence property of 
the polymers are called “chromophores”. Because these chromophores have different chain lengths, 
the absorption spectra of the fluorescent conjugated polymers are usually wide and featureless. 
This, however, is not the case with the emission spectra of the polymers because excited electrons 
tend to travel to the chromophores with the lowest energy before decaying radiatively especially 
when the polymer chains are in near proximity from each other.[153] 
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1.3.3.3 Optical and Electrical Properties of Conjugated Polymers in Different Dilute 
Solutions 
The conformation of the conjugated polymer, and therefore its optical and electrical behaviour, 
is governed by the medium which surrounds the polymer such as the pH of the sample, its 
temperature, and most importantly, the influence of other molecules also present in the sample such 
as the molecules of the solvent.[154] 
Conjugated polymers dissolved in a good solvent have an uncoiled conformation. In a dilute 
solution, there is little interaction between the different polymer chains, i.e. interchain interactions, 
and little interaction between the chromophores of the same chain, i.e. intrachain interactions. In 
this situation, excitons mostly form from the excitation of electrons of the chromophores to higher 
energies in the same chromophores and radiatively decay in the same manner.  
Conjugated polymers dissolved in a poor solvent have a coiled up and collapsed conformation. 
Therefore, the chromophores of the polymer chains have an increased contact and both interchain 
and intrachain interactions happen. The site where such interactions happen is called an 
aggregation site. Aggregation sites are not always emissive. Excitons formed in an aggregation site 
of two chromophores situated in a parallel position to each other tend to decay radiatively, 
however, they tend to have lower energies than those excitons created in non-aggregation sites due 
to the increased delocalisation of the electrons there. Therefore, such excitons from those new 
emissive species contribute to a new red shifted emission peak in the emission spectrum of the 
conjugated polymer. An example of MEH-PPV dissolved in a good and a poor solvent is presented 
in Figure 10. 
 
Figure 10 The emission spectra of MEH-PPV dissolved in (left) a good solvent and (right) a 
very poor solvent. (Modified image from [135]) 
1.3.3.4 Optical and Electrical Properties of Conjugated Polymers in Concentrated Solutions 
and in Solid Films 
The conformations of conjugated polymers in amorphous solid films were reported to be similar 
to their conformations in the solutions they were cast from. This also contributes to a similar 
optical and electrical behaviour to the polymers in solution. An increase in the concentration of the 
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solution causes the polymer chains to entangle. Therefore, if cast from a good solvent for example, 
the spatial gap between different polymer chains in the solid film decreases while the polymer 
chains remain in an extended conformation. This causes an increase in interchain interactions.[134] 
In such interactions, electrons tend to migrate from the chromophores of higher energies to near-by 
chromophores of lower energy before decaying to emit photons. Therefore, the emission spectra of 
conjugated polymers tend to be skewed towards the red emissive species of the sample causing an 
over-all shift and narrowing of the emission peaks but maintaining the same emission profile. 
Figure 11 illustrates this phenomenon in the emission spectra of MEH-PPV in a solid film (right) 
cast from a good solvent (left). 
 
Figure 11 The emission spectra of MEH-PPV (left) dissolved in a good solvent and (right) as 
a solid film cast from a good solvent. (Modified image from [135]) 
1.3.3.5 Optical and Electrical Properties of Conjugated Polymers in Nanoparticle Form 
The optical and electrical behaviour of conjugated polymers in nanoparticle form was reported 
by Grey et al. and Howes et al. [36] to be similar to their optical and electrical behaviour in solid 
films [155] with the emission entirely red-shifting [135]. This was observed in MEH-PPV SPNs 
ranging between 10 nm and 100 nm in diameter.[155]  Another group reported that SPNs with 
sizes ranging between 70 nm and 160 nm did not have a size dependent change in their 
photoluminescence properties.[156] As those nanoparticles are relatively new, further experimental 
and computational optical and electrical studies need to be conducted to further understand their 
behaviours. 
1.3.4 General Applications of Semiconducting Polymer Nanospheres 
Polymers in general have found many applications within nanoscience.[157-158] Research is 
ongoing in incorporating polymers in nanolithography [157], nanoelectronics [159], light-emitting 
devices and solar cells [132], nano-based cancer treatments [160], MRI signal enhancement [161], 
drug delivery [162-163], and nanocomposites for food packaging [164]. This is mainly due to their 
wide-ranging well controlled properties associated with their nanoscale lengths, configurations, and 
chemical functionalities.[124, 157]  
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Conjugated polymers, in particular, were found to be useful in many applications. For instance, 
conjugated polymers were good candidates for the emergence and development of molecular 
electronics [165]. This included both organic light emitting devices (O-LEDs) [153] and organic 
solar cells [132, 166]. Conjugated polymers in their nanoparticle form were also investigated and 
were found to be useful specifically in O-LEDs fabrication. In such devices, SPNs were deposited 
from an aqueous suspension to form an active layer of light emitting nanoparticles which had a 
bandgap that is the same as that of the nanoparticles’ [139, 167]. 
With their functionalisable side chains [168], their high brightness [137], and their composition 
being benign [169], conjugated polymers were also found to be good materials in the biological and 
medical fields. This will be discussed in detail in the next section. 
1.3.5 Semiconducting Polymer Nanospheres as Bio-imaging, Labelling, and Tracking 
Agents 
Polymers have many desirable properties which made them attractive in the biological and 
medical fields from as early as the 1980s [169]. Conducting polymers, for example, were used in 
bio-sensing [170] and enzyme entrapment [171]. They were found to change cellular activities 
[172], transfer charge in biomedical processes, and electrically interact with cardiac and nerve 
cells.[169] 
Semiconducting polymers, which also share the property of being benign with many conducting 
polymers [169], exhibit stable and high fluorescence brightness [137]. This allows them to be 
considered as possible fluorescent probes. However, many conjugated polymers are hydrophobic in 
nature. This was overcome by chemically modifying their side chains [173]. Despite the fact that 
this process significantly agitated their fluorescent properties, such conjugated polymers were able 
to be used as oxygen sensors [174], as bacteria detectors [175], and in DNA assays [176-178].  
As described in section 1.3.3, most of the optical properties of semiconducting polymers can be 
reserved by incorporating them into nanoparticles [139]. This also enables them to be 
functionalised as desired. SPNs are therefore being developed and studied as bio-imaging and 
sensing agents [36, 179] such as multiphoton fluorescence imaging [143] and oxygen sensing 
[180]. They are also being developed as bioconjugates for specific cellular targeting [144] and were 
used in targeting tumour cells [145]. They were also found to be good tracking agents for tracking 
cellular processes with nanoscale 3D tracking methods [181]. By doping the SPNs with singlet 
oxygen photosensitizers, the SPNs were able to damage DNA, and are therefore proposed as 
promising materials for cancer treatment by photodynamic therapy [138]. SPNs were also modified 
to incorporate more than one property to be used in more than one imaging technique. An example 
is imbedding iron oxide nanoparticles inside the polymeric core of the SPNs for both fluorescence 
and magnetic resonance imaging [182]. With this rapid increase in experimentation with such 
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recent nano-materials especially in the biological and medical fields, it is therefore important to 
develop their synthesis methods to be as effective as possible and as green as possible as well as to 
conduct toxicity and safety assessment studies to estimate how safe they are for use in their 
proposed applications. 
1.3.6 Synthesis Routes of Semiconducting Polymer Nanospheres 
The synthesis of semiconducting polymer nanospheres (SPNs) for biological applications is 
relatively new.[36, 183] In general, two approaches can be taken here. Synthesis can be performed 
using pre-formed polymers, or by in-situ polymerization.[130, 146, 184-186] Polymerization of 
dispersed monomers in-situ is problematic because of toxic residues of monomers, oligomers or 
catalysts [187], while polymerization with dendritic routes is complicated and lengthy [186]. 
Therefore, methods for nanoparticle preparation from ready-made, well studied, and non-toxic 
synthetic-polymers have subsequently been developed.[184, 187-188] Notably, Landfester et al. 
produced SPNs from three preformed polymers by a miniemulsion – solvent extraction method. 
The miniemulsion – solvent extraction method is described in detail in chapter 2, but briefly, it 
involves the mixing/stirring of a water immiscible solvent, which contains the polymer chains, in 
water under high shear. Under these conditions, nanodroplets containing some polymer chains 
form. The polymer nanoparticles are then formed by extracting the solvent from these 
nanodroplets. In Landfester’s work, the nanoparticles were stabilised using sodium dodecyl 
sulphate (SDS), and exhibited diameters in the range of 70 – 250 nm, with their main applications 
envisaged to be film formation for electronic devices such as organic-light-emitting diodes 
(OLEDs) as SDS is toxic.[139, 167, 189] Landfester et al. mostly focused on miniemulsion 
polymerisation of monomers, but recently reported the use of pre-formed polymers again using the 
same method used by McNeill et al. [190]. 
McNeill et al. concentrated mainly on the use of commercially available polymers, with a 
similar method to the miniemulsion method which they referred to as a reprecipitation method. In 
the reprecipitation method, a water miscible solvent, such as tetrahydrofuran (THF), which 
contains the polymer chains is injected/stirred/mixed with water, then the solvent is extracted. The 
polymer chains, which must be hydrophobic, collapse with the contact with water to form polymer 
nanoparticles. The miscible solvent is then removed in various ways. McNeill et al. used the 
reprecipitation method to first prepare surfactant-free polymer nanospheres of diameters between 3 
and 100 nm. The fluorescent nanoparticles were envisaged to be useful in photovoltaics as well as 
biological applications. Although the resulting polymer nanoparticles were of a medically-desired 
diameter, they initially lacked a surface functionality which limited their biological 
applications.[34, 130, 191] To improve fluorescence and stability of the polymer nanoparticles as 
well as allowing functionalisation, the nanoparticles were encapsulated with silica shells, to which, 
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for example gold nanoparticles could be attached.[137] However, this step contributed significantly 
to the particle diameters and has not, to date, been developed any further by this group. McNeill et 
al. further developed their method to prepare functionalised polymer nanoparticles by adding 
functionalised amphiphilic polymers to their polymer mixtures before synthesis. These 10 to 15 nm 
sized functionalised SPNs which were prepared at the same time as the research presented in this 
thesis were able to be bioconjugated with streptavidin or antibodies and were used in labelling 
specific human cells [144-145]. The same idea was used to dope their SPNs with tetraphenyl 
porphyrin (TPP) for photodynamic therapy applications [138]. 
Moon et al. used the same method as McNeill et al. but they called it a phase-inversion method 
[136, 140-141]. Moon et al. used a preformed, but modified, polymer to synthesise nanoparticles 
which they measured to be as small as 25 nm (dynamic light scattering). Larger nanoparticles, with 
an average of 70 nm in diameter, were observed by TEM but the group stated that the smaller 
nanoparticles which they believed were the majority of the population were not able to be imaged 
due to a technical difficulty. Modification of the polymer was essential to make the nanoparticles 
useful in biological applications. Such modified polymers are not commercially available, thus a 
separate polymerization step was needed before the nanoparticles’ formation process.  
Chen et al. reported the formation of water-soluble fluorescent nanoparticles which contain 
fluorescent polymers entangled with amphiphilic molecules.[142] The polymers used were 
commercially available, and the resulting nanoparticles formed were of sizes between 10 nm and 
10 microns in size. These particles were suggested to be useful as probes for cell imaging and 
similar biological applications. 
In previous work, our group used a miniemulsion – solvent extraction route to produce BEHP-
PPV and MEH-PPV fluorescent nanoparticles capped/entwined with poly(ethylene glycol) 
molecules, which were in some cases as small as 13 nm (BEHP-PPV) as measured from TEM 
images [118, 192]. With some modification to the synthesis method and the addition of several 
phospholipids to the polymer mixture, which are amphiphilic in nature, phospholipid 
capped/entwined SPNs were also produced. These SPNs were slightly larger than the PEG 
capped/entwined SPNs with average diameters ranging between 59 and 74 nm as measured from 
TEM images [36], but both SPN systems were found to be extremely good fluorescent probes in 
cell imaging.[36, 118, 192] For a dual-modality, iron oxide nanoparticles were embedded in the 
phospholipid capped/entwined SPNs. The produced nanoparticles were found to be MRI active as 
well as fluorescent [182]. However, the fluorescence of the nanoparticles was significantly 
quenched due to the iron oxide nanoparticles’ absorption, and their sub-micron sizes were 
significantly larger than the other two SPN systems. Further work was needed to provide bimodal 
SPNs with better properties to compete with QDs prepared for similar applications. 
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1.3.7 Semiconducting Polymer Nanospheres – still young in comparison to quantum dots 
but can they be greener? 
Semiconducting polymer nanospheres can be synthesised in simple ways in comparison to QDs. 
When prepared from pre-formed conjugated polymers, SPNs do not need to undergo any chemical 
reaction. SPNs can be synthesised and stored in ambient conditions with most of their properties 
being conserved for a relatively long time. There is a good range of solvents which can be used to 
initially dissolve the conjugated polymers in the synthesis process. This gives one the option to use 
one of the least toxic solvents such as dichloromethane (DCM) making the synthesis process less 
toxic than the processes usually used in the preparation of QDs. 
In terms of functionalisation, conjugated polymers can be functionalised with different side 
groups before nanoparticle synthesis. These can give the conjugated polymers different solubilities. 
Also with pre-functionalised conjugated polymers, SPNs can be prepared with different 
functionalities such as carboxylation for further bioconjugation.[144] Functionalities can also be 
introduced by using functional capping agents such as carboxylated amphililic molecules.[36] 
The fact that SPNs are prepared from benign conjugated polymers [114] gives the SPNs the 
potential to be less toxic than QDs with the same fluorescent properties. However, this cannot be 
certain without proper safety assessment experiments as the nanosizes of nanoparticles in general 
are also an arguable issue. 
Another drawback which hinders the investigation of SPNs use in bio-medical applications is 
that, up to the time of this research, SPNs were usually prepared with larger diameters than QDs 
with relatively larger size distributions. With a less monodispersed population of nanoparticles, 
SPNs could not compete with QDs in such studies. Therefore, the synthesis methods of these SPNs 
need to be developed to produce better, smaller, more monodispersed populations. 
 Also, many QDs are already commercially available. This makes them easily obtainable by 
research groups in the biological and medical fields, pushing research using QDs forward despite 
the fact that most of these QDs contain toxic materials and are still under study in nanotoxicology.  
Conjugated polymer nanoparticles were reported to be roughly 15 times brighter than QDs with 
similar properties.[145] The nanoparticles were also reported to be highly efficient in energy 
transfer.[193] With such competing optical and electrical properties, and with established studies 
pointing towards the toxicities of many QDs, SPNs stand a chance to be effective alternatives to 
QDs especially if they are optimised to have similar diameters. However, extensive toxicological 
studies have to be made on both nanoparticle species before a solid conclusion such as the above 
can be made. The question raised in the title of this thesis and the research presented here are 
therefore a few steps towards achieving this goal. 
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1.4 The Current Work 
1.4.1 Scope and Objectives 
Our first objective was to synthesis PEG capped/entwined semiconducting polymer nanospheres 
with diameters similar to those of QDs, i.e. around 10 nm and less, using a miniemulsion-
evaporation method and pre-prepared, commercially available, conjugated polymers. Then, with 
modifications to the surface capping agents of the SPNs, we aimed to produce bi-modal 
nanoparticles (Gd-SPNs) which are proposed to be suitable for fluorescence bio-imaging and as 
MRI contrast agents.[97, 194-195] These bi-modal Gd-SPNs are proposed to be alternatives to 
similar bimodal QDs [97]. Finally, to be suitable alternatives to QDs, monomodal and bimodal 
SPNs need to be proven to be both safe and efficient. Therefore, our third and final objective was to 
conduct some preliminary investigations about the interactions between nanoparticles both SPNs 
and Gd-SPNs and cells in comparison to QDs with similar surface coatings. This study, which was 
the first nanoparticle-cell interactions study reported on such organic nanoparticles was aimed to 
investigate the nanoparticles’ behaviour in synthetic and biological media and their interactions 
with human blood components as they will most likely be administered intravenously if used as 
medical diagnostic and bio-imaging tools. 
1.4.2 Overview of Thesis 
An introduction to the basic scientific background information, definitions, properties, 
applications, and syntheses of quantum dots and semiconducting polymer nanospheres was 
presented in this chapter. The work done for the completion of this thesis is presented in the next 
chapters where the PEG capped/entwined SPNs are presented in chapter 2, followed by the 
bimodal gadolinium containing SPNs (Gd-SPNs) in chapter 3, and the preliminary nanoparticle-
cell interaction investigations of the SPNs and Gd-SPNs in comparison to similarly coated QDs and 
carboxylated QDs in chapter 4. The experimental methods which include chemicals, equipment, 
characterisation techniques, and detailed synthesis descriptions are included in chapter 5. A 
conclusions chapter, which summarises the work presented in the three core chapters of this thesis 
and proposes routes for future work, is presented in chapter 6, followed by all the references, and 
finally some complimentary information (chemical structures and definitions) are added in two 
appendixes attached at the end of the thesis.   
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2 Quantum Dot Sized PEG Capped/Entwined Semiconducting 
Polymer Nanospheres 
Conjugated polymers are organic semiconductors which exhibit strong photo- and 
electroluminescence. They can undergo intense fluorescence under excitation with suitable electric 
or electromagnetic stimulation, with high quantum yields and improved fluorescence properties 
compared to many other organic materials.[196-197] Many conjugated polymers are biocompatible 
and environmentally benign.[114] These properties have brought them to the attention of groups 
trying to synthesise fluorescent nanoparticles.[130] 
Ideally, for any fluorescent material to be used for biological labelling applications and function 
as desired, it should be non-toxic, non-immunogenic, non-aggregating, and should not accumulate 
in the body, decompose in ambient conditions, or adsorb non-specifically to other biological 
molecules. It has been proposed that for inorganic quantum dots (QDs), there is a diameter 
threshold of ca. 5.5 nm, above which renal clearance from the body will not be possible.[116] 
Quantum dots can be synthesized with such small diameters, less than 5 nm, but are typically 
composed of toxic materials, such as cadmium. For this reason, quantum dots are encapsulated 
with biocompatible materials for use in biological applications.[110-111, 114-115] However, this 
addition substantially increases the hydrodynamic diameter of the particles. Additionally, the risk 
from the presence of non-capped quantum dots, or the aggregation and decomposition of the 
particles in the body cannot be neglected, and long term toxicity will always be a concern. 
The synthesis of semiconducting polymer nanospheres for biological applications is relatively 
new.[183, 194] While synthesised from benign materials, most of the methods reported until now 
resulted in nanoparticles with relatively large diameters when compared to QDs. A few reports 
exist on the synthesis of QD-sized fluorescent polymer nanoparticles, but either the method 
involved polymerization or the nanoparticles lacked surface functional groups which is an 
important feature for in-vivo administration.[34, 130, 137, 146] 
In this chapter, we introduce our work in controlling and optimising the miniemulsion-
evaporation method to produce QD-sized poly(ethylene glycol) (PEG) capped/entwined SPNs from 
ready-made polymers. This method was previously used by our group to prepare SPNs with larger 
diameters. In the introduction of this chapter, the miniemulsion-evaporation method is explained in 
detail, and then the previously prepared larger SPNs are briefly described. This is followed by the 
results and discussion sections which describe the work towards the synthesis and characterisation 
of QD-sized SPNs and finally an investigation into the role PEG, the capping agent, played. 




2.1.1 The Miniemulsion – Evaporation Method for Nanoparticle Formation 
The miniemulsion method is a method derived from the well established emulsion process 
[198]. In an emulsion, two immiscible liquids are mixed together to form liquid droplets (the 
dispersed phase) dispersed in a liquid medium (the continuous phase), as illustrated in Figure 12. 
To stabilise the dispersion a third component, an emulsifier, is usually used and is initially 
dispersed in one of the liquids before they are combined. The final emulsified systems can be 
classified according to the types of liquids used (oil in oil (O/O), oil in water (O/W), water in oil 
(W/O), or water in oil in water (W/O/W), etc), and/or the nature of the emulsifier (small molecules, 
surfactants, non-ionic polymers, solid droplets, mixed emulsifiers, etc). Figure 13 shows examples 
of emulsified systems. The emulsifier is also responsible for the long-term stability of the emulsion, 
however, other factors can also cause emulsion breakdown and are well reported in the 
literature.[199] 
 
Figure 12 The emulsion process. 
 
Figure 13 Different emulsified systems. 
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In the emulsion process, normal shear is used to mix the liquids such as stirring with a magnetic 
bead. This produces droplets with micrometre sizes. In miniemulsion, high shear is used, such as 
ultrasound or a high-pressure homogenizer, and a nanometre-size-droplets dispersion is 
obtained.[26] See Figure 14.  
 
Figure 14 An illustration of a miniemulsion. 
For nanoparticle formation (nanocapsules, nanoshells, or solid nanospheres, etc.), the 
nanoparticle constituents are initially dispersed in the emulsified solvent which forms the droplets 
of the system.  The emulsion or miniemulsion process is then followed by a solvent extraction 
technique, such as evaporation, which transforms the droplets into particles after the extraction of 
the emulsified solvent from the micro- or nano- droplets, as illustrated in Figure 15. Miniemulsions 
were used to synthesise nanoparticles composed of various organic and inorganic materials, such as 
metals [200-201], ceramics [202], different biomolecules [203], and polymers [204-205]. For 
polymer nanoparticles formation in particular, two types of miniemulsions can take place: an active 
miniemulsion or a passive miniemulsion. In an active miniemulsion, the droplets initially contain 
monomers which are then activated by a chemical reaction within the droplets, the nanoreactors 
[198, 206], to create polymer nanoparticles in a process called miniemulsion polymerization [26, 
184-185, 198, 202, 207]. In a passive miniemulsion no chemical reaction takes place and the 
droplets initially contain preformed polymers which are then transformed into nanoparticles [118, 
139, 184, 192, 208]. Due to limitations and complexity of the active form as described in section 
1.3.6, the relatively simple route of polymer nanoparticles formation, the passive form, was used in 
our syntheses.  




Figure 15 Nanoparticle formation with a miniemulsion-evaporation technique. 
2.1.2 The Synthesis of PEG Capped/Entwined Semiconducting Polymer Nanospheres with 
Large Diameters 
The first synthesis of PEG capped/entwined SPNs in water was reported by our group [118, 
192]. In a typical synthesis, dichloromethane (DCM) containing 20 ppm (by weight) of 
hydrophobic conjugated polymer was added to water containing PEG8000. The beaker holding the 
combined solutions was exposed to ultrasound in a heated water bath for 25 minutes. The high 
shear caused the production of a miniemulsion while the heating promoted DCM evaporation. The 
reaction turned clear by the end of the exposure indicating the full evaporation of DCM and the 
formation of aqueous SPNs with diameters as small as 13 ± 5.4 nm [192]. A centrifugation and 
filtration step was also included to remove the large particles and any dispersed bulk material. The 
same method was also used with a higher polymer concentration and resulted in  nanoparticles with 
a mean diameter of 100 nm.[118]  
In the above synthesis, DCM was chosen as the polymer medium because it is immiscible with 
water, is a good solvent for many hydrophobic conjugated polymers, and has a low boiling point 
(40 °C) which enabled its evaporation after the formation of the miniemulsion droplets. 
Also, PEG with a molecular weight of 8000 g/mol was used as an emulsifier which enabled the 
two immiscible solutions, DCM and water, to be emulsified. Figure 16 shows the chemical 
structure of PEG. PEG is a polymer used as a surfactant in many industries. It was selected in this 
synthesis instead of an initially used toxic emulsifier; sodium dodecylsulphate (SDS) [118], used in 
reference to similar work done by Landfester et al.[139]. PEG is an extremely useful capping agent 
especially if the nanoparticles are aimed to be used in biological applications such as fluorescence 
bio-labelling. This is because PEG is non-toxic, non-immunogenic, soluble in most solvents 
including water, and approved for human use [209], whilst exhibiting a wide range of chemistries 
which could be exploited to allow further functionalisation with biological materials. PEG has also 
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been shown to significantly reduce nonspecific binding of the surrounding biological molecules to 
nanoparticles, which is essential for successful in-vivo applications.[210] Thus, the use of PEG in 
the syntheses produced SPNs with biologically desirable properties, and provided a potential route 
for bio-functionalisation. 
 
Figure 16 The chemical structure of PEG. 
Although particles as small as 13 nm were obtained using the above described synthesis 
procedure and parameters, the miniemulsion was not fully controlled and a considerable volume of 
the non-aqueous phase remained separated from the aqueous phase while the mixture was under 
high shear.[135] This resulted in the precipitation of a large amount of polymer which was 
discarded in the purification step. 
Our group further refined the above synthesis to be as follows; 16 mL of dichloromethane 
containing 40 ppm (by weight) of hydrophobic conjugated polymer was added to 30 mL of water 
containing 0.5 mg PEG300. The mixture was stirred for 10 minutes, then it was ultrasonicated for 
10 minutes at room temperature or at 30 °C, and finally the miniemulsion was stirred on the bench 
until DCM had fully evaporated and the nanoparticles had formed. The nanoparticle solution was 
then centrifuged and filtered through filter paper.[135] 
The increase in the volume ratio of water to DCM, the use of PEG with a lower molecular 
weight, and the incorporation of a stirring step before the exposure of the mixture to the high shear 
all contributed to a better emulsion and therefore a better reaction yield. It is believed that this also 
contributed to a better size distribution of nanoparticles. This will be discussed in detail in section 
2.2. 
2.2 Factors to Consider for a Reproducible, Narrow Size Distribution, of QD-
sized PEG Capped/Entwined SPNs 
At the beginning of this work, the synthesis technique was studied thoroughly and according to 
research and first experimental observations it was concluded that to achieve a reproducible, good, 
and possibly narrow size distribution of SPNs, the following need to be considered: 
1.  The emulsion needs to be fully controlled. 
2. The solvent used to dissolve the polymer needs to be a “good” solvent [135]. 
3.  The evaporation of the solvent in the droplets needs to be avoided until the 
emulsion/miniemulsion is complete.  
However, to produce significantly smaller nanoparticles, other factors need to be considered:  
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1. The initial polymer concentration in the solvent [118, 192]. 
2. The high shear used. 
3. The amount [199, 211] and type [212-213] of emulsifier.  
The above listed factors are discussed in detail in the following subsections. 
2.2.1 Factors Affecting Reproducibility and Broadening of the SPNs’ Size Distributions 
Two droplets in an emulsion lead to two nanoparticles with different diameters following one of 
two scenarios: either the droplets were of different diameters but contained the same concentration 
of nanoparticle constituents, or the droplets had the same size but contained different 
concentrations of nanoparticle constituents, as illustrated in Figure 17 (A and B). The former 
scenario is supported by the reported observation that with smaller droplets, due to high shear in a 
miniemulsion for example, the emulsion produces smaller nanoparticles [206], while the latter is 
supported by the reported observation that a change in polymer concentration leads to a change in 
the nanoparticles average diameters [118, 192]. Therefore, to achieve a monodispersed nanoparticle 
system, ideally, the droplets of the emulsion need to be of the same size and they should contain the 
same concentration of nanoparticle constituents. This ideal situation could be true if no other 
factors affecting the final nanoparticles’ diameters took place in the solvent evaporation step, and if 
the final density of the nanoparticles was the same. Although the droplets of an emulsion cannot 
reach the ideal situation discussed above, the distribution of their diameters can be controlled and 
practically reproduced by obtaining a successful emulsion that is well controlled. The polymer 
concentration in the droplets, on the other hand, can be fairly equalised by using a good solvent and 
by prohibiting its evaporation during the emulsification step. 
 
Figure 17 Different nanoparticle sizes obtained from (A) droplets with different droplet sizes 
having the same polymer concentration, and (B) droplets with the same size but 
containing different polymer concentrations. 
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2.2.1.1 Obtaining a Successful, Well Controlled, and Reproducible Emulsion 
A successful emulsion is obtained when the dispersed solution is fully dispersed in the 
continuous solution. If the high shear is not enough to obtain this condition, then a stirring step is 
required before the high shear to initiate the full emulsion. We therefore introduced 10 minutes of 
stirring as a pre-miniemulsion step mentioned at the end of section 2.1.2. 
A well controlled and reproducible emulsion can be obtained by using a non-changeable shear; 
i.e. stirring two separate emulsions with the same speed and placing them at the same height and 
position in the same ultrasound bath, and by not changing the exposure times, the glassware, the 
size and shape of the magnetic stirring beads, and the volumes of the solutions, etc. The above 
measures become very important in such a synthesis method because it involves a physical reaction 
rather than a chemical reaction. Therefore, the physical aspects such as the size, shape, volume, 
viscosity, and force become the ultimate controllers of the outcomes of an emulsion. 
2.2.1.2 Using a Good Solvent 
The conformation of polymer chains in a solvent depends on their solubility. As discussed in 
section 1.3.2.1, a polymer in a good solvent acquires an uncoiled (extended) conformation, while a 
polymer in a poor solvent tends to aggregate and acquire a coiled conformation. This behaviour 
affects the homogeneity of concentration of the polymer chains in the solvent used. With an 
extended conformation in a good solvent, the polymer is evenly distributed so that the 
concentration of the polymer in the solvent is homogeneous with minimum aggregation. A 
homogeneous concentration of polymer in the solvent is very important in the synthesis of the 
SPNs especially if a reproducible narrow size distribution is desired, as described at the beginning 
of this section (section 2.2.1). Also, the type of solvent used (good or poor) affects the electrical 
and optical characteristics of the polymer and can therefore affect the luminescence properties of 
the SPNs. This was described in detail in section 1.3.3. 
DCM is a good solvent for many hydrophobic polymers and is therefore used in our syntheses. 
2.2.1.3 Controlling DCM Evaporation in the Emulsion/Miniemulsion Steps 
If DCM is allowed to evaporate while the emulsion/miniemulsion is incomplete, a significant 
amount of polymer will precipitate as observed in our first syntheses [118, 192]. The quick 
evaporation of DCM can also lead to droplets with different polymer concentrations and therefore 
to a broader size distribution of nanoparticles. DCM has a very low boiling point (40 ºC). It can 
evaporate at room temperature with a steady, relatively low, speed of stirring. Therefore, to avoid 
its evaporation in the synthesis of the SPNs, the reaction’s temperature must be decreased by 
decreasing the solutions temperatures before the synthesis and adding ice cubes to the ultrasound 
bath. DCM evaporation can also be restricted by using a flask with a narrow neck and closing it 
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with a suitable lid throughout the emulsion and miniemulsion processes. It can also be restricted by 
controlling the speed of stirring and changing the position of the flask in the ultrasound bath to 
avoid splashing of the mixture. 
2.2.2 Factors Affecting the Average Size of the SPNs 
The nanoparticles’ sizes can be reduced by decreasing the droplets diameters. This can be 
achieved by increasing the shear such as using high shear instead of normal shear, by controlling 
DCM so that it does not evaporate until such small droplets are formed, and by increasing the 
amount of surfactant so that the increased surface area of the droplets can be stabilised [199, 211]. 
Another way to reduce the nanoparticles sizes is by using shorter surfactants, such as using PEG 
with a molecular weight of 300 g/mol instead of 8000 g/mol [212-213]. This reduces the diameter 
of the surfactant shell, while maintaining the same diameter of the polymer core. 
A third way to reduce the nanoparticles sizes is by reducing the initial concentration of the 
polymer in DCM which results in smaller polymer cores [118, 192]. 
Landfester et al. reported that some parameters were shown not to have a systematic affect on 
the particles’ size in the miniemulsion process such as the variation of the system’s temperature 
from 0 to 60 ºC. However, in their investigations, they used different solvents which had boiling 
points varying between 80 and 291 ºC [211]. In our syntheses however, DCM which evaporates 
rapidly (boiling point = 40ºC) is used. So, the temperature in our systems has to be decreased if 
smaller, reproducible, and narrow size distributions of nanoparticles are targeted. Also, when 
working with fluorescent molecules, such as the conjugated polymers we used, it is advisable to 
keep the temperature to a minimum to preserve their emission intensities and avoid any 
temperature-related quenching. 
 
With the consideration of all the above factors, the method described in section 2.1.2 was 
further refined, and a narrow size distribution of QD-sized SPNs was prepared. 
2.3 Synthesis of Quantum Dot Sized Semiconducting Polymer Nanospheres 
2.3.1 First Synthesis of QD-sized SPNs using 40 ppm of BEHP-PPV 
The first synthesis was performed using a blue/green fluorescent conjugated polymer: poly[2-
(2’,5’-bis(2’’-ethylhexyloxy)phenyl)-1,4-phenylenevinylene] (BEHP-PPV). The polymer was 
dissolved in DCM to form a 40 ppm (by weight) solution. 8 mL of the polymer in DCM solution 
was added to 20 mL of water containing 0.5 mg PEG300 in a beaker. The beaker was covered with 
filter paper and the solutions were stirred for 10 minutes to initiate the emulsion. Then they were 
ultrasonicated at room temperature for 10 minutes to form the miniemulsion droplets, and finally 
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the miniemulsion was stirred at room temperature until the solution became clear indicating the full 
evaporation of DCM and the formation of the nanoparticles. The nanoparticle solution was filtered 
through filter paper to remove any bulk material but was not centrifuged. 
The physical characteristics of the resulting nanoparticles were analysed by transmission 
electron microscopy (TEM) and dynamic light scattering (DLS), while their optical properties were 
analysed by absorption and emission spectroscopies. The aqueous nanoparticles’ solution was 
found to contain nanoparticles with polymer cores as small as 4 nm in diameter as measured from 
TEM images. Figure 18 shows two TEM images of the spherical nanoparticles. Because PEG is not 
TEM visible, the dark spots in the images show the polymer cores of the nanoparticles without any 
indication of PEG. 
 
Figure 18 TEM images of the first synthesis of QD-sized SPNs using 40 ppm BEHP-PPV in 
DCM. Scale bars are (A) 50 nm and (B) 20 nm. 
The other sizing method, DLS, was used to determine the hydrodynamic diameters of the 
nanoparticles in water. The hydrodynamic diameter is a measure of the diameter of the nanoparticle 
core, any capping agents or molecules which are attached to it, and the electronic cloud that 
surrounds it as shown in Figure 19. With limited characterisations of the newly produced SPNs, the 
DLS measurements could not be executed without the assumption that the SPNs are similar to 
polystyrene beads and therefore have the same parameters. The average diameter determined by the 
DLS intensity distribution was considered here instead of the commonly reported cumulants 
diameter because the samples did not undergo excessive purification as they were not centrifuged 
to remove any large particles. The large particles were found to skew the cumulants results towards 
the larger diameters giving a faulty determination of a significantly larger population than that of 
the actual. The average hydrodynamic diameter determined by the DLS intensity distribution 
therefore cannot be directly linked to the average diameter measured from TEM images. However, 
Zeina M. A. Hashim,   PhD Thesis 
36 
 
it can give an indication of the range of hydrodynamic diameters in the sample if, and only if, the 
assumption made above is true. This is discussed in detail in the methods chapter (section 5.7.2). 
The hydrodynamic diameters of the nanoparticles in the above sample were found to range between 
60 nm and 400 nm with their average diameter being around 179.3 ± 68.1 nm. 
 
 
Figure 19 The hydrodynamic diameter of a nanoparticle. 
Absorption spectroscopy is one of many chemical analysis methods used to determine the 
chemical composition of any sample. It is also a direct indicator of the concentration of those 
chemical constituents. Absorption spectroscopy was used here to determine the presence and 
preservation of the polymer in the aqueous nanoparticles sample after synthesis. Emission 
spectroscopy was used to determine the fluorescence of the nanoparticles. Figure 20 shows the 
absorption and emission spectra of the BEHP-PPV SPNs solution compared to the absorption and 
emission spectra of BEHP-PPV in DCM. The absorption peak around 400 nm was conserved when 
the polymer chains were converted from an extended conformation in DCM to aqueous 
nanoparticles. This indicates that the chemical structure of the polymer was conserved. The 
emission spectra were also similar and no significant shift in the emission’s peak of BEHP-PPV 
was observed. However, there was an increase in the intensity of the second optical transition 
(around 520 nm) and an increase in the intensity of the tail of the spectrum between that optical 
transition and 720 nm. These attribute to a slight increase in the emissive aggregates which indicate 
an increase in the interchain interactions due to the folds and entanglements of the polymer chains. 
This also indicates that the chain segments of the same polymer became of near proximity to each 
other which means that the nanoparticles were formed from one, or a few, polymer chains.  




Figure 20 The normalised (A(1)) absorption and (B(1)) emission spectra of the first synthesis 
of QD-sized SPNs using 40 ppm BEHP-PPV in DCM compared to the normalised 
(A(2)) absorption and (B(2)) emission spectra of BEHP-PPV in DCM.  Emission 
was under λex= 400 nm excitation. 
2.3.2 Syntheses using Different BEHP-PPV Concentrations 
In an attempt to study the effect of polymer concentration on nanoparticle size, four different 
polymer concentrations were used in the synthesis method described above (in section 2.3.1); 40, 
10, 5, and 1 ppm, and four aqueous SPN solutions were obtained.  
Figure 21 shows TEM images of the BEHP-PPV SPNs prepared using 40 ppm and 1 ppm of 
polymer concentration. Both images show the presence of small nanoparticles, whilst the SPNs 
prepared from the 1 ppm solution were observed to be generally smaller with a mean diameter of 
only 2 nm compared to 4 nm for the SPNs prepared using 40 ppm.   
 
Figure 21 TEM images of BEHP-PPV nanoparticles synthesised using (A) 40 ppm, and (B) 1 
ppm of polymer in DCM. Scale bars are 50 nm. 
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The average hydrodynamic diameters of the nanoparticles determined from the nanoparticles 
DLS intensity distributions were also found to decrease as the polymer concentration decreased. 
Table 1 shows the average diameters determined by DLS intensity distribution for each 
concentration. This is a direct indicator of the decrease in the average diameters of the QD-sized 
nanoparticles as discussed earlier. 
Table 1 BEHP-PPV initial concentrations and their resulting nanoparticles hydrodynamic 
diameters and standard deviations as determined by their DLS intensity 
distributions: 
 
The emission spectra of the SPN solutions are shown in Figure 22. The sequential blue shift in 
the emission peaks of the SPNs in Figure 22 suggests an increase in the bandgap of the system with 
the decrease in nanoparticles diameters, most probably arising from a decrease in effective 
conjugation length. This occurred probably because of the intense aggregation of the polymer 
chains when they were confined in smaller structures. 
With this increase in physical defects in the smaller nanoparticles, a considerable amount of 
fluorescence quenching is proposed. The quantum yield (QY), which is the measure of 
fluorescence efficiency of the system calculated as the number of photons emitted divided by the 
number of photons absorbed, could not be measured for the four SPNs due to the extremely dilute 
solutions. However, this phenomenon was investigated previously using a high polymer 
concentration of four different conjugated polymers [135]. The QY was measured before and after 
centrifugation, which removed the larger particles, and was found to drop for all four SPN 
solutions. This consistent drop in QY with the decrease in the SPNs average size suggests an 
increase in fluorescence quenching in the smaller SPNs. 
BEHP-PPV Concentration 
before Synthesis (ppm) 
DLS Intensity Distribution 
Average Diameter (nm) 
DLS Intensity Distribution 
Standard Deviation (nm) 
40 179.3 68.1 
10 146.1 50.5 
5 138.5 60.3 
1 123.3 54.1 




Figure 22 The normalised emission spectra of four BEHP-PPV aqueous nanoparticle 
solutions synthesised using polymer concentrations = 40 ppm, 10 ppm, 5 ppm, and 
1 ppm, under λex= 400 nm. 
2.3.3 Synthesis using Prolonged Ultrasound Exposures 
The synthesis of the nanoparticles using 1 ppm BEHP-PPV was repeated with a modification of 
the ultrasound exposure time from 10 minutes to 45 minutes. The produced nanoparticles were also 
of QD-sizes as shown in the TEM images in Figure 23. The average hydrodynamic diameters of 
the nanoparticles prepared using 45 min of ultrasound exposure was 133.5 ± 47.6 nm as suggested 
by the DLS intensity distribution. This was not significantly different than that of the nanoparticles 
prepared under 10 minutes exposure (123.3 ± 54.1 nm). However, the ultrasound exposure was not 
modified further and no further characterisations were made, therefore no systemic effect was 
studied.  
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Figure 23 TEM images of BEHP-PPV nanoparticles synthesised using 1 ppm of polymer in 
DCM under 45 minutes ultrasound exposure. Scale bars are (A, B) 50 nm and (C, 
D) 10 nm. 
2.3.4 The Role of PEG in the Synthesis, and the Effect of Changing its Concentration and 
Molecular Weight 
For the emulsion preparation to be fully successful and stable, the presence of PEG was 
essential. This was observed when performing the same experimental procedures described 
previously but using a red emitting polymer; poly[2-methoxy-5-(2-ethylhexyloxy)-1,4-
phenylenevinylene] (MEH-PPV) in DCM with/without PEG in water. Both experiments performed 
with and without PEG resulted in the formation of SPNs. This was confirmed with the observation 
of a homogeneous suspension of clear, red coloured, aqueous solution after DCM evaporation, and 
both had similar absorption and fluorescence spectra. However, mixing the conjugated polymer 
solution in water at the beginning of the synthesis was problematic in the absence of PEG, and the 
resulting emulsions were not fully stable after the ultrasonication step, while the systems containing 
PEG formed a relatively stable, milky coloured, emulsion. 
To study the effect of the PEG concentration and molecular weight, a series of experiments 
using BEHP-PPV were undertaken with different quantities and different molecular weights of 
PEG. The change in the amount of PEG or molecular weight resulted in a consistent change in 
polymer yield and fluorescence intensity of the produced SPNs. For example, in syntheses using 8 
mL/40 ppm BEHP-PPV in DCM in 20 mL of deionised water, the use of very low amounts of 
PEG300 (below 0.005 g) or very high amounts of PEG300 (above 0.01 g) resulted in low reaction 
yield, while using an amount of PEG300 between the above mentioned values enhanced the 
formation of SPNs and increased the final absorption and emission intensities as shown in Figure 
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24 (A). However, the change in the amount of PEG did not contribute to any change in the SPNs 
size. This was concluded from comparisons of the normalised fluorescence spectra which did not 
show any shifts (Figure 24 (B)). 
As mentioned earlier, the presence of PEG facilitated the formation of a stable emulsion. 
However, when the concentration of PEG in the water was substantially increased, the stirring rate 
was observed to decrease, suggesting that the solution became more viscous. This had a negative 
effect on the stability of the emulsion, changing the rate at which DCM is emulsified in water, and 
therefore increasing the percentage of its non-emulsified portion. Consequently, we suggest the 
majority of the conjugated polymer in the non-emulsified portions of DCM precipitated onto the 
walls of the reaction vessel after DCM evaporation. This resulted in a lower yield of SPNs in water. 
Similarly, using a very low concentration of PEG in water resulted in a partially successful 
emulsion and the same argument applies. The stirring rate also decreased with the increase in the 
molecular weight of PEG, leading to the same effects. As a result, the final concentration of the 
QD-size SPNs was found to be controlled by the amount and molecular weight of PEG in water, 
and the SPNs synthesised using the optimum amount of PEG were found to be more concentrated 
than the SPNs synthesised without PEG. This was also observed with the use of a high 
concentration of conjugated polymer (by Dr Philip Howes [135]) (ca. 1000 ppm), PEG was 
essential in obtaining a high yield of SPNs, which approached 100%. Without PEG in the system, 
the vast majority of the polymer precipitated. These results indicate that PEG has a direct influence 
on the formation yield of the SPNs. 
 
Figure 24 The emission spectra of BEHP-PPV SPNs prepared using 8mL/40ppm polymer 
solution and different amounts of PEG300 (A) Not normalised, (B) Normalised. 
2.3.5 The Refined and Final Synthesis of QD-sized SPNs using BEHP-PPV 
The synthesis described in section 2.3.1 was further refined and the following changes were 
made: a conical flask was used instead of a standard beaker which was covered throughout the 
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emulsification process to discourage DCM evaporation. The ultimate amount of PEG300 which 
was found to give the highest reaction yield as described in section 2.3.4, in this case 0.01 g, was 
used instead of an excessive amount of PEG300 (0.5 g in the first synthesis). The addition of the 
polymer in DCM solution to the water solution was further controlled by adding it drop-wise to the 
water solution while stirring. The stirring speed and the position of the flask in the ultrasound bath 
were adjusted to avoid splashing of the mixture. After 5 minutes of ultrasound exposure, the 
miniemulsion droplets were assumed to be formed and the lid was removed to enable some DCM 
evaporation. The solution was kept under high shear for another 15 minutes to encourage the 
droplets to stay separated in this process. This was because a very small amount of PEG was used 
compared to previous syntheses. The solution remained opaque throughout the 20 minutes of 
ultrasound exposure which indicated a decrease in the rate of DCM evaporation with the 
modifications done in this synthesis. Finally, the emulsion was transferred to a beaker and stirred 
rapidly to evaporate the remaining DCM. The resulting SPNs solution was then filtered through 
filter paper and centrifuged to remove any large nanoparticles or bulk materials. (See chapter 5 for 
full description of the synthesis procedure) 
The sizes of the resulting nanoparticles were found to be similar to those of the nanoparticles in 
the first synthesis, as shown by TEM images of both syntheses (see Figure 25). However, with the 
above modifications; the reaction yield was higher, and the reproducibility of the refined synthesis 
was achieved. 
 
Figure 25 TEM images of BEHP-PPV SPNs prepared using (A) the first synthesis of QD-
sized SPNs and (B) the refined and final synthesis. Bar-scales are 20 nm. 
2.3.6 The Final Synthesis using Polymers Emitting in Different Colours 
Five polymers were used in this work; poly[2,5-di(3’,7’-dimethyloctyl)phenylene-1,4-
ethynylene] (PPE) which emits in the blue region of the visible light, BEHP-PPV which emits in 
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the blue/green region, poly[(9,9-dioctyl-2,7-divinylene-fluorenylene)-alt-co-(2-methoxy-5-(2-ethyl-
hexyloxy)-1,4-phenylene)] (ADS108GE) which emits in the green region, poly[(9,9-di-n-
octylfluorenyl-2,7-diyl)-alt-(benzo[2,1,3]thiadiazol-4,8-diyl)] (F8BT) which emits in the yellow 
region, and MEH-PPV which emits in the orange region. 
The polymers were dissolved in DCM to form 40 ppm (by weight) solutions. 8 mL of each 
polymer solution was used independently in syntheses identical to the synthesis described in 
section 2.3.5. The resulting purified aqueous QD-sized SPN solutions were stable at room 
temperature for months. 
2.3.6.1 Optical Properties 
The absorption and emission spectra of the five aqueous SPN solutions are presented in Figure 
26 (A, B), and a photograph of the SPNs, under light exclusion and excitation with a 365 nm UV 
lamp, is shown in Figure 26 (C). Summaries of the optical properties of the produced SPNs and 
their constituent polymers in dichloromethane (DCM) are presented in Table 2 and Table 3.  
The peaks of absorption and emission spectra of the SPN solutions were shifted compared to the 
spectra of the constituent polymers in DCM (Table 2 and Table 3). This was attributed to the 
aggregation of the conjugated polymer chains when transferred from the DCM solution into a solid 
particle, similar to previous reports of polymer aggregation in solution [214-216] and thin-films 
[134, 217]. Both MEH-PPV and PPE SPNs showed a significant red-shift in their emission relative 
to the polymer in DCM (31 and 48 nm respectively). This was partially attributed to the 
aggregation of the chains, resulting in π-orbital overlap and delocalisation of electronic charge 
across several chains. This resulted in a reduced bandgap when comparison with the polymer in 
DCM is considered. However, F8BT, ADS108GE, and BEHP-PPV SPNs did not exhibit a 
significant red-shifted emission, which is as a result of the manner in which these polymers pack 
into a solid. Previous reports studying polyfluorenes have suggested that tight packing of the 
chromophores would not necessarily lead to rearrangement of energy levels.[218] All of the 
polymers (except F8BT) exhibited broadening in their emission tails, and PPE and BEHP-PPV 
SPNs also exhibited an increased intensity of their secondary (lower energy) emission peak. This is 
indicative of the formation of emissive aggregates due to the close proximity of chains.[218] It is 
likely that aggregates also formed in the other SPNs, but these did not contribute strongly to the 
lower energy emissions. The absorption spectra also tended to broaden. This broadening is 
demonstrative of the distribution of the electronic charge between the different chain segments in 
the nanoparticles due to the π-orbital stacking (intrachain and interchain).[131] 




Figure 26 The (A) absorption and (B) emission spectra of the five aqueous SPN solutions, 
and (C) a photograph of the SPN solutions under 365 nm UV-lamp exposure. 
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Table 2 A summary of the optical properties of the aqueous SPNs: 
 













Absorption Peak (nm) 383 391 480 447 497 
Emission Peak (nm) 422 481 507 537 562 







56.47 9.9 113.07 59.84 85.05 
 
Table 2 and Table 3 also show the quantum yields of the QD-size SPNs and of their constituent 
polymers in DCM (refer to section 5.6.4 for quantum yield measurements method). A reduction in 
quantum yield was observed with the SPNs in water as compared to their constituent polymers in 
DCM. This was attributed in part to the formation of non-radiative species across the polymer 
chains because of their tight packing in the particles, and has been observed previously in thin-
films of MEH-PPV [217]. Excitons can move to structural defects where they decay nonradiatively 
to the ground state, and increased overlap of π-orbitals can result in the formation of electronic 
species, such as excimers and aggregates, which quench emission.[134, 217, 219] However, it 
seems that the final quantum yield was strongly dependent on the initial quantum yield of the 
polymer, and when polymers with high quantum yields were used, nanoparticles with relatively 
high quantum yields were obtained. 
Due to the nature of the reaction we were unable, at that time, to calculate an exact reaction 










under 363 nm UV-Lamp 
Blue Blue/green Green Yellow Orange 
Absorption Peak (nm) 388 400 451 475 496 
Emission Peak (nm) 470 482 510 539 593 







18.3 ≤ ε ≤ 
1830 
10.47 ≤ ε ≤ 
1047 
7.49 ≤ ε ≤ 
749.9 
0.707 ≤ ε ≤ 
70.7 
1.556 ≤ ε ≤ 
155.6 
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yield which therefore hindered our calculations of extinction coefficients. Therefore, the extinction 
coefficients of the SPNs were estimated to range between two extremes; 100% and 1% reaction 
yields (refer to section 5.6.5 for extinction coefficients calculations method). The lowest estimated 
possible values of the extinction coefficients are still considered high (ca. 0.7 Lg-1cm-1) and 
comparable to QDs (CdSe extinction coefficients 1.31 – 2.72 Lg-1cm-1) [220], with the theoretical 




). Observations of the syntheses suggest they are 
likely to be nearer the higher values of these ranges. The extinction coefficients of the polymers in 
DCM were also measured and were found to be within those ranges. The high extinction 
coefficients compensated for the low quantum yields, and our SPNs were observed to be of high 
brightness under UV excitation (365 nm). 
2.3.6.2 Nanoparticles Size Distributions 
TEM images of the SPNs are shown in Figure 27. Diameter measurements from these images 
showed a range of 0.5 – 6 nm for BEHP-PPV, MEH-PPV, and PPE. Larger nanoparticles were 
present in the ADS108GE and F8BT samples, with the largest being 21 nm and 14.4 nm in 
diameters, respectively. However, most of the SPNs of all five polymers were less than 5 nm in 
diameters, averaging between 2 and 3 nm as shown in the number distribution presented in Figure 
28. The number distribution graph also shows that the number of larger nanoparticles in F8BT is 
significant. TEM examination confirmed that there were no large clusters, suggesting that the 
synthesis method produces very well defined and QD-sized nanoparticles only.  
The average SPNs diameters as determined by TEM and the average diameters of the same 
samples as suggested by DLS (intensity distributions) are presented in Table 4. The diameters 
determined by the intensity distribution of DLS were substantially higher than the diameters 
determined by TEM. However, it is not possible to compare the two values especially that the DLS 
intensity distributions are considered here and not the DLS number distributions. The average DLS 
diameters presented in Table 4  give an insight of the presence of nanoparticles in the samples, 
however they do not represent their average hydrodynamic diameters. The latter should be 
obtainable from the DLS number distributions of the samples, however, accurate and reproducible 
number distributions of the SPNs were not obtainable (see section 5.7.2 for further details). 
 
 




Figure 27 TEM images of (A) PPE SPNs, (B) BEHP-PPV SPNs, (C) ADS108GE SPNs, (D) 
F8BT SPNs, and (E) MEH-PPV SPNs. Scale bars are (1) 50 nm, and (2) 20 nm. 




Figure 28 The five SPNs’ number distributions measured from TEM images. 
Table 4 A summary of the average SPNs’ core diameters as measured from TEM images, 
and the average intensity distribution diameters of the same samples as measured 
by DLS: 









TEM average diameter ± 
standard deviation (nm) 
2.92 ± 0.55 2.93 ± 0.62 3.16 ± 2.90 4.78 ± 2.42 3.33 ± 0.76 
Average hydrodynamic 
diameter (intensity 
distribution in DLS) 
194.1 199.13 184.1 273.86 323.53 
 
2.3.7 Investigations about the Capping Agent after Synthesis 
Determining the identity of purely organic “capping agents” in organic nanoparticles presents 
numerous problems. To this end, in one variant of the synthesis, we employed thiolated PEG in our 
systems, allowing sulfur to be a reporter group that could be detected by mass spectrometry. The 
synthesis was performed exactly as the refined synthesis described above (section 2.3.5).  The 
PEG-dithiol capped/entwined SPNs were extensively purified by a dialysis method ensuring that no 
free PEG-dithiol molecules were present in the purified solution (section 5.2.2 and section 5.3 for 
experimental details). The water used to wash the samples during dialysis was examined and no 
trace of emission was observed although mass spectrometry detected the presence of PEG-dithiol, 
therefore we can suggest that the nanoparticles did not pass through the dialysis membrane in 
contrast to the free PEG-dithiol molecules. Mass spectrometry of the purified sample detected a 
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sulfur concentration of 297.4 µg/L (compared to 11337.3 µg/L before dialysis), suggesting that, 
even after the excessive purification process, a ratio of more than 12 PEG-dithiol molecules to 1 
polymer chain were present. We conclude that although a significant amount of PEG is needed for 
a high yield synthesis, not all of PEG molecules were capping or entwined with the SPNs. It is 
possible that a number of PEG molecules were initially loosely entwined with the polymer particle 
but then preferably diffused out. However, the loose PEG molecules were dialysed away and the 
SPNs were still found to be capped/entwined with a considerable amount of PEG. 
2.4 Conclusions 
The size and surface morphology of a nanoparticle play an important role in its properties and 
applications. This is because a decrease in size leads to a substantial increase in surface area, and 
therefore leads to a considerable increase in the nanoparticles’ surface related properties. Also, 
nanoparticles with specific sizes and usually with the lowest size distribution available are 
preferred in many applications such as to facilitate renal clearance at the end of the nanoparticles 
use in medical applications. Therefore, if one nanoparticle type is to be proposed as an alternative 
to another, it has to have competing properties as well as a similar shape and size distribution. 
Semiconducting polymer nanospheres are fluorescent nanoparticles which were previously 
reported to be significantly brighter than quantum dots, with their optical properties being 
conserved for relatively longer periods of time. However, SPNs were always reported to have 
relatively larger diameters and a relatively larger size distribution. 
In this chapter we report the synthesis of SPNs with diameters similar to those of QDs in an 
attempt to improve organic SPNs to the level of inorganic QDs when size is concerned. With 
modifications to the miniemulsion-evaporation method used previously by our group, reproducible 
PEG functionalised QD-sized SPNs were successfully prepared from five commercially available 
conjugated polymers. The SPNs had narrow size distributions with average diameters between 2 
and 5 nm, and were fluorescent across the visible spectrum. PEG was found to control the 
concentration of SPNs in water without a significant contribution to their size, providing a new 
feature which, to our knowledge, was not previously reported.  
Control of the miniemulsion-evaporation synthesis method was vital for the production of such 
small nanoparticles with a high yield. This included the use of PEG, the emulsifier, with a certain 
molecular weight and a certain concentration, the use of a high shear which is preceded by an 
initiated emulsion through stirring, the use of a good solvent, DCM, and preventing the solvent’s 
evaporation until the miniemulsion is complete. Another factor was the initial polymer 
concentration in DCM, with a decrease in polymer concentration leading to a decrease in the 
nanoparticles’ average diameters. 
The final SPNs were found to be capped/entwined with PEG as suggested by mass spectrometry 
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of a purified sample. Their quantum yields were measured and extinction coefficients estimated. 
The particles were found to be considerably bright and are expected to be effective in various 
fluorescence applications.[181]  
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3 Bimodal Gadolinium-Containing Semiconducting Polymer 
Nanospheres – For MRI and Fluorescence Bio-Imaging 
The search for bimodal nanoparticles that act as molecular imaging agents recently began to 
increase [221-223]. Bimodal nanoparticles in this context refer to nanoparticles which have two 
probing properties and can be used simultaneously in two bio-imaging techniques such as 
fluorescence imaging, magnetic resonance imaging (MRI), X-ray computerised tomography (CT), 
or positron emission tomography (PET). In any diagnosis, more than one bio-imaging technique 
may identify the problem in hand and each imaging technique can provide complementary 
information. Imaging agents or probes are usually used to enable, enhance, or improve the contrast 
of the images obtained by these techniques, or to probe the environment [224-225]. The use of two 
techniques to probe one species therefore ideally requires a single imaging agent which has the two 
required probing properties for both techniques, i.e. requires a bimodal imaging agent.[222] The 
use of nanoparticles as imaging probes has several advantages over conventional imaging agents. 
Loadability is one of the advantages where the concentration of the imaging agent can be 
controlled within each nanoparticle during the synthesis process. Another advantage is the 
tunability of the surface of the nanoparticles which can extend the circulation time of the agent in 
the blood or target a specific location within the body [70]. With a bimodal nanoparticle system, all 
the above advantages can be integrated into one system. 
In this chapter, we introduce our work in the synthesis of bimodal gadolinium-containing 
semiconducting polymer nanospheres (Gd-SPNs) which were both fluorescent and MRI active. In 
the introduction of this chapter, the science behind magnetic resonance imaging and gadolinium as 
a contrast agent is briefly introduced, followed by a literature review on bimodal nanoparticles. 
Then, our experimental work towards the synthesis and characterisation of reproducible Gd-SPNs 
is thoroughly discussed. This is followed by their use in cell imaging and cellular uptake, 
preliminary tests towards their potential use in-vivo, and a measure of their MRI activity. 
3.1 Introduction 
3.1.1 T1–weighted Magnetic Resonance Imaging and Contrast Agents 
Magnetic resonance imaging (MRI) is a medical diagnostic technique which uses signals from 
the nuclei of hydrogen atoms present in the sample to generate an image. 
When a hydrogen atom is placed in an external magnetic field, the magnetic momentum (spin) 
of its proton aligns with the direction of the field while undergoing precession. Precession, which is 
a change (wobbling) in the orientation of the proton’s rotational axis occurs in a certain frequency 
called the Larmor frequency (given by Equation 1) that depends on the strength of the external 
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magnetic field and the type of spinning system involved (the proton in this case). 
         
Equation 1 Larmor frequency equation, where    is the Larmor frequency in megahertz 
(MHz),    is the gyromagnetic ratio and is specific to the particular nucleus 
involved, and    is the strength of the magnetic field in tesla (T). The 
gyromagnetic ratio of protons is 42.58 MHz/T. 
In a magnetic field, a proton’s spin is aligned either parallel or anti-parallel to the direction of 
the magnetic field with more spins energetically favouring the parallel alignment resulting in a net 
longitudinal magnetisation. When an electromagnetic wave with a frequency equivalent to the 
Larmor frequency is applied to this stable spin system in the form of an exciting radiofrequency 
pulse, the longitudinal magnetisation is rotated 90º to the transverse plane and is now called 
transverse magnetisation. The transverse magnetisation undergoes precession (rotation) about the 
longitudinal axis generating an alternating voltage in a receiver coil which has the same frequency 
as the Larmor frequency. This MR signal is then collected and processed to generate the MR 
image. However, the MR signal is short lived and the excited spin system decays to its pre-excited 
state, i.e. undergoes relaxation, by two independent but simultaneous processes; spin-lattice 
interactions causing a T1 longitudinal relaxation, and spin-spin interactions causing T2 or T2* 
transverse relaxation. 
 In a T1 relaxation process, the excited nuclei of the hydrogen atoms in the system return to 
their ground states by dissipating their excess energy to their surroundings (lattice) decreasing the 
system’s transverse magnetisation and restoring its longitudinal magnetisation. The time constant 
for this recovery (T1) is therefore dependant on the Brownian motion of the surrounding molecules 
and on the strength of the external magnetic field. 
In a T2 relaxation process, the protons’ spins lose their phase coherence and become out of 
phase cancelling each other’s effects resulting in a decrease and finally a disappearance of their net 
transverse magnetisation without any energy dissipation to their surroundings. Spin de-phasing is 
caused either by energy transfer between the spins which interact with each other under the 
influence of their small magnetic fields causing a transverse relaxation with a time constant (T2) 
that is independent of the external magnetic field’s strength, or by the intrinsic inhomogeneities of 
the external magnetic field which is due to the magnetic field generator and the imaged 
object/person (tissue borders, and local magnetic fields generated by paramagnetic objects/particles 
present) causing a faster transverse relaxation with a time constant (T2*). 
T2 relaxation occurs within the first 0.1 – 0.3 seconds of exposure, while T1 relaxation and full 
longitudinal magnetisation recovery takes 0.5 – 5 seconds. 
To generate a T1–weighted MR image, the tissue/body slice is excited many times and the MR 
signals are collected each time. The time interval between two successive excitations is called the 
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repetition time (TR). If TR is short (less than 0.6 sec), tissues with a short T1 have enough time to 
relax and restore much of the longitudinal magnetisation before the next excitation. With most of 
the longitudinal magnetisation restored, the second excitation results in a large MR signal. 
Therefore, these tissues appear bright in the MR image. On the other hand, tissues with a long T1 
do not experience much relaxation and not a lot of the longitudinal magnetisation is restored before 
the next excitation. With small longitudinal magnetisation available for the second excitation, a 
small MR signal is obtained. Tissues with a long T1 therefore appear dark in the MR image.  
If TR is fairly long, all tissues including those with long T1 values have enough time to relax 
and restore the longitudinal magnetisation and therefore they all give similar signals and result in 
an image with a very poor contrast. Because the different T1 values of the different tissues do not 
contribute much to the contrast of the image it is said that the measurement has low T1–weighting. 
Therefore, to obtain a T1–weighted image with a high contrast between the different tissues, strong 
T1–weighting has to be used by the use of a short TR. The contrast of the image is therefore 
dependent on the intrinsic properties of the tissues and on the pulse sequences of the MR scanner. 
To further enhance the natural contrast of an MR image, pharmaceutically prepared contrast 
agents are sometimes administered prior to and/or during the MRI measurements. Contrast agents 
are also used to determine pharmacokinetic information. 
Contrast agents alter the contrast of the obtained image either directly by changing the density 
of protons in the tissue, or in-directly by changing the local magnetic field or the resonance 
properties of the tissue and hence the tissues T1 and/or T2 values. 
The relaxation efficiency of an MR contrast agent, relaxivity (   in T1–weighted imaging, and 
   in T2–weighted imaging), is defined as the reciprocal of the relaxation time T1 (or T2) in a one-
molar solution at a temperature of 20 ºC and a given Larmor frequency/field strength. The higher 
the relaxivity, the better the interaction of the contrast agent with its nearby water protons, and 
therefore the more efficient the contrast agent is in speeding up their relaxation (in the example of 
T1–weighted imaging) and hence increasing the MR signal.[226] 
The relaxivity of a contrast agent also depends on other factors such as its rotational correlation 
time associated with its Brownian motion (with a higher correlation time corresponding to a more 
efficient contrast agent), the number of water–agent interaction sites, and the water residence time 
(which is the time the water molecule stays bound and interacting with the contrast agent).[227] 
3.1.2 Gadolinium as a Contrast Agent in MRI 
3.1.2.1 Gd-DTPA as a T1–weighted MRI Contrast Agent 
Gadolinium (as well as manganese, chromium, and iron) is a paramagnetic metal ion. It contains 
7 unpaired electrons, and therefore its paramagnetic moment is relatively high. Paramagnetic ions 
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were found to affect the contrast of MRI images indirectly by decreasing the T1 relaxation time of 
the surrounding hydrogen protons in water, resulting in a brighter area in the image. 
However, most of these ions are extremely toxic and cannot be used in MRI imaging of live 
cells without a reduction of their toxicity. One way to reduce the toxicity of gadolinium was found 
by chelating the gadolinium atoms with diethylene triamine pentaacetic acid (DTPA, see Appendix 
1 for chemical structure) and forming what is known as a water soluble Gd-chelate called 
gadopentetate dimeglumine (Gd-DTPA). Gd-DTPA has a high binding constant, therefore the 
probability of finding free Gd radicals is significantly low which is considered an advantage.[228] 
The first trial of experimenting with Gd-DTPA in human volunteers was in 1983 which was 
followed by future trials [229], and now, the clinical use of Gd-DTPA is approved.[230] 
Gd-DTPA is a low molecular weight chelate, has a short rotational correlation time (τr) 
associated with its Brownian motion, and a low energy exchange rate since it has only one water 
coordination sight. Therefore, for a considerable contrast, a very high concentration of Gd-chelates 
should be present in the imaged tissue. This is far from ideal, and the efficiency of using Gd-
chelates in imaging is significantly low (several % of what is theoretically predicted). Several 
approaches were encountered to circumvent this problem, one of which is by increasing the number 
of active ions per particle by incorporating many Gd-chelates in dendrimers, micelles, liposomes, 
or nanoparticles.[230-231] 
3.1.2.2 Gd-DTPA-BSA as a T1–weighted MRI Contrast Enhancing Bipolar Lipid 
As mentioned in the previous section, one of the solutions for a better MRI contrast agent using 
Gd-DTPA is by attaching multiple Gd-chelates to one particle. One route to achieve this is by 
synthesising Gd-DTPA bipolar lipids to form liposomes or to coat readily made nanoparticles.[231-
232] Bipolar lipids (also called amphiphilic molecules) are molecules which have hydrophilic 
heads and hydrophobic tails. When dispersed in water, their hydrophobic tails tend to aggregate 
together pointing their hydrophilic heads towards the surrounding water forming micelles, 
liposomes, or bilayer sheets as illustrated in Figure 29. 




Figure 29 A schematic of a micelle, a liposome, and a bilayer sheet. The white spheres 
represent the hydrophilic parts of the amphiphilic molecules (heads), while the 
yellow lines represent the hydrophobic parts of the amphiphilic molecules 
(tails).[233]  
Bipolar lipids were also found to be useful in stabilising emulsion systems. In an oil-in-water 
emulsion, for example, lipids favourably aligned themselves on the interface between oil bubbles 
and the surrounding water, pointing their tails towards the bubbles and their heads towards water, 
forming well dispersed micelles which contained the hydrophobic solution in their cores. In water-
in-oil emulsions, however, they align themselves the other way around, forming what are known as 
inverse micelles which stabilise the water bubbles in oil. This simple principle allowed the 
formation of drug containing liposomes and micelles in drug delivery studies [234], and facilitated 
the dispersion of hydrophobic nanoparticles in water.[194] 
 The first bipolar lipid formed using Gd-DTPA is Gd-DTPA-bis(stearylamide) (Gd-DTPA-
BSA).[235-236] Its structure is presented in Figure 30. Liposome agents made using Gd-DTPA-
BSA were found to be large MR signal enhancers in T1–weighted MRI, and were found suitable 
for imaging several organs such as the liver and bone marrow.[231, 236] Other Gd-DTPA lipids 
were synthesised after that [231], however, since we used Gd-DTPA-BSA in our syntheses, which 
was already commercially available in contrary to many others, we did not consider the other Gd-
DTPA lipids any further. 




Figure 30 The chemical structure of Gd-DTPA-BSA.[237] 
3.1.3 Bimodal Nanoparticles 
Different bimodal nanoparticles which act as fluorescent probes for optical imaging and contrast 
agents in MRI have been reported. For the fluorescence property, either inorganic quantum dots 
[38, 97], fluorescent dyes [119, 238], or fluorescently labelled lipids [239] were used. As MRI 
contrast agents, either superparamagnetic agents such as iron oxide (Fe3O4) nanoparticles [38, 240] 
or paramagnetic agents such as gadolinium (in the form of Gd-lipids [97] or as doping atoms [241]) 
were used. Different methods of synthesis have produced various modes for incorporating multiple 
imaging agents.  For example, one component of the system may be coating the other or they may 
be covalently attached [38], both agents may be embedded in a carrier such as a silica [238, 242] or 
a polymer [119, 243] nanoparticle, one agent may be embedded in a carrier which is coating the 
second agent [243], or both agents may be incorporated together into a micelle or liposome [122, 
239]. Several articles have been published recently reviewing fluorescent and MRI active bimodal 
nanoparticles’ properties, their synthesis, and applications [70, 221-223, 243]. 
As introduced at the beginning of this thesis, conjugated polymer nanoparticles or 
semiconducting polymer nanospheres (SPNs) are fluorescent organic nanoparticles which are 
synthesised from benign conjugated polymers [114]. These nanoparticles may be used in similar 
applications to QDs and may even be superior to QDs due to their high fluorescence stability and 
enhanced biocompatibility [34, 36, 136, 196, 244]. The use of conjugated polymers in bimodal 
systems was reported previously, however, the systems were composed of aqueous conjugated 
polymers which were covalently bound to gadolinium containing molecules [245-246]. These 
systems therefore lacked the advantages of nanoparticle systems and limit the syntheses to 
hydrophilic conjugated polymers only. 
Bifunctional (bimodal) phospholipid capped/entwined SPNs embedded with iron oxide 
nanoparticles were reported previously by our group [182]. The SPNs had diameters ranging 
between 160 and 380 nm after centrifugation, and they had very low fluorescence quantum yields 
in comparison to non-iron oxide phospholipid encapsulated SPNs [36, 182]. The strong iron oxide 
nanoparticles’ absorption of the wavelengths of light used to excite the nanoparticles contributed 
significantly to the final quantum yields of the SPNs, a problem which can be avoided by using less 
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light absorbing MRI active components. These bimodal iron oxide containing SPNs compare non-
favourably to similar bimodal quantum dots due to their larger diameters, lower QYs, and higher 
polydispersity [97]. 
Bimodal, MRI active and fluorescent, systems containing Gd-DTPA-BSA in the form of dye-
labelled liposomes were synthesised and were found useful for both probing techniques [93, 121-
122, 230, 247-249]. Recently, the same group used quantum dots for the source of fluorescence and 
coated them with Gd-DTPA-BSA and PEGylated lipids to form bifunctional nanoparticles [97]. 
Inspired by their work, the work of our group [36, 135], and the work of others [250], we 
investigated a new bimodal SPN system comprised of SPNs coated/entwined with a layer of mixed 
phospholipids including Gd-DTPA-BSA as the MRI active lipid. The work towards the synthesis 
of these Gd-SPNs is presented in the following section. 
3.2 Towards the Synthesis of Reproducible MEH-PPV Gd-SPNs 
3.2.1 Non-Reproducible Synthesis Attempts of MEH-PPV Gd-SPNs 
First attempts to produce Gd-SPNs were carried out using the same synthesis method described 
by Howes et al.[36]. The same materials were also used but with the modification of the lipids’ 
contents to incorporate Gd-DTPA-BSA instead of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
(DPPC, see Appendix 1 for chemical structure of DPPC) while conserving the same total number 
of lipids used. 
In the first synthesis, 7.6 mg 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethyleneglycol)-2000] (ammonium salt) (PEG2000-PE, see Appendix 1 for chemical 
structure) and 4.5 mg Gd-DTPA-BSA were dispersed in a 16 mL polymer solution containing 40 
ppm MEH-PPV in DCM by stirring for 10 minutes. Then, the polymer solution was added to a 
beaker containing 20 mL water under high shear (35kHz ultrasound bath). After 1 minute, an 
electric mixer was introduced and the solution was mixed vigorously under ultrasound exposure. 
This setting was maintained until the solution turned from milky orange to clear red (within 
minutes) indicating the full evaporation of DCM and the formation of the particles. The particles 
solution was then filtered through filter paper and centrifuged (10,000 rpm ~ 5,600xg) for 10 
minutes to remove the large particles and any dispersed bulk polymer.  
The synthesis method described above produced a system of different nanoparticles which were 
not all perfectly spherical in shape as shown in the TEM images in Figure 31 (A and B). The 
nanoparticles were of dimensions ranging between a few nanometers and a micron. Many of the 
formed particles were also not densely packed as seen in Figure 31 (A), and a good amount of 
polymer was dispersed without forming a defined shape as shown in Figure 31 (C). Figure 31 (D) 
is a magnified section of the bundled and dispersed polymers with the sub-nanometer sized dark 
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dots possibly representing the semiconducting segments of the chains or representing non-capped 
nanoparticles formed from single polymer chains which collapsed and precipitated due to the 
vigorous and abrupt mixing in the synthesis method. It is probable that with the increase in the 
centrifugational time, most of the dispersed polymers would have been removed. However, 
prolonged centrifugation was shown to break down most of the particles in the majority of our 
syntheses. 
 
Figure 31 TEM images of the first synthesis of Gd-SPNs. 
In an attempt to reduce the nanoparticles’ sizes and obtain a better nanoparticle suspension, the 
same synthesis method was repeated but with half the amount of polymer solution (a ratio of 8 mL 
to 20 mL emulsified solution to water instead of 16 mL to 20 mL). The isolated nanoparticles of 
three repetitions of the synthesis are presented in Figure 32 (first synthesis in (A and B), second 
synthesis in (C and D), and third synthesis in (E and F)). Despite the fact that all three syntheses 
produced very small SPNs similar to those produced in the first synthesis (dark dots in the images), 
each synthesis also produced a different system. Figure 32 (A), for example,  shows a system of 
large nanoparticles most probably stabilised by the lipids used, while Figure 32 (C) shows a 
micellar system with QD-sized SPNs attached to the surfaces of the micelles. Figure 32 (E) shows 
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a liposomic structure with empty bubble-like areas filled with one or a few nanoparticles. With 
such a huge variation in the systems produced, the synthesis method had to be further revised. 
Other synthesis attempts, this time using exactly the same method as that used in the synthesis of 
PEG capped/entwined QD-sized SPNs (presented in Chapter 2), were also not successful. 
 
Figure 32 TEM images of three syntheses of MEH-PPV Gd-SPNs using the same synthesis 
method as in the first synthesis but with half the volume of polymer solution. 
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3.2.2 A Modified Synthesis Method for Reproducible MEH-PPV Gd-SPNs with Large Sizes  
Further investigations revealed that the main reasons behind the non-reproducible Gd-SPNs 
systems were both the robust synthesis method used and the low concentrations of the lipids in the 
emulsified system. This conclusion coincided with a publication by Liu et al. [251] who 
synthesised biodegradable polymer nanoparticles capped with 1,2-dilauroylphosphatidylocholine 
(DLPC) lipids using a very high concentration of lipids compared to our first trials. The lipids were 
first dispersed in water under four cycles of ultrasound exposure in an ice bath (60 seconds 
exposure followed by 30 seconds rest), then the polymer in DCM solution was stirred in the 
aqueous solution and the mixture was sonicated with an ultrasonicating probe in an ice bath. The 
emulsion was then stirred to evaporate DCM.  
In our modified synthesis, we used a similar synthesis method as that described above. In the 
synthesis, 38.2 mg PEG2000-PE, 10.5 mg DPPC, and 15.3 mg  Gd-DTPA-BSA were suspended in 
25 mL of deionised water in a round-bottom flask similar to Liu et al. [251]. The lipid suspension 
was then magnetically stirred for 1 minute and 1.6 mL of the polymer solution was introduced with 
a syringe over a period of 60 seconds. The volume of polymer solution to the volume of water was 
also the same as that used by Liu et al. (they used 16 mL polymer solution in 250 mL water) and 
similar to the volume ratio used in our final synthesis of QD-sized SPNs (section 2.3.5). The flask 
was covered and stirred vigorously for 10 minutes to initiate the emulsion. Then it was sonicated in 
an ultrasound ice water bath for 90 seconds. Finally, the created miniemulsion was gently stirred 
overnight to form the nanoparticles by full evaporation of DCM. 
Figure 33 shows TEM images of the produced Gd-SPNs. The nanoparticles were perfectly 
spherical in shape and a large number of them were of sub-microns in size. Figure 33 (B) also 
shows that there was a large amount of excess lipids which were not associated with the 
nanoparticles. The smaller the nanoparticles, the larger their surface areas, and the more lipids are 
needed to cover these surfaces. Therefore, if the nanoparticles were decreased in size, it is 
suggested that less excess lipids will be present at the end of the synthesis. 
 




Figure 33 TEM images of the first MEH-PPV Gd-SPNs prepared with the modified synthesis 
method. 
3.3 The Final Synthesis of MEH-PPV Gd-SPNs  
To reduce the average nanoparticles’ diameters in the above synthesis, half the amount of 
polymer solution was used (a ratio of 0.8 mL to 25 mL emulsified solution to water instead of 1.6 
mL to 25 mL). The produced nanoparticles shown in Figure 34 were similar in shape to the 
previous nanoparticles (Figure 33) but were of smaller diameters. The observed conservation of the 
spherical shapes of the nanoparticles in both syntheses proved that the modified synthesis was 
successful in reproducing the desired Gd-SPNs system. 
Most of the SPNs in this final synthesis were of diameters below 50 nm as shown in Figure 34 
(A, B and C), with a few larger SPNs with diameters around 100 nm (Figure 34 (D)). All the 
nanoparticles were densely packed (Figure 34 (B)) compared to the SPNs prepared in our first 
attempts (Figure 31(A)). Figure 34 (D) also shows that the samples contained some excess lipids 
which were not attached to the nanoparticles (the medium grey between the dark grey which 
represents the nanoparticles and the light grey which represents the background). However, the 
excess lipids were less than those in the previous synthesis (Figure 33 (B)). The remaining lipids 
were necessary at the beginning of the synthesis to stabilise all the polymer-containing DCM 
droplets in water, as the reduction in the amount of lipids with the use of the same method was 
found to precipitate bulk polymer on the flask at the end of the synthesis.  




Figure 34 TEM images of the final MEH-PPV Gd-SPNs. 
3.4 The Synthesis and Characterisation of Gd-SPNs with Different 
Fluorescent Colours 
3.4.1 Synthesis of the Final Gd-SPNs 
The final synthesis described in the previous section (section 3.3)  which is a similar 
miniemulsion-evaporation technique to that used in the synthesis of the QD-sized SPNs (see 
Chapter 2) was used here, and four colloidally stable gadolinium-containing conjugated polymer 
nanoparticles (Gd-SPNs) in aqueous media were successfully synthesised from the following 
polymers; MEH-PPV, F8BT, PPE, and ADS108GE. Again, three lipids were used as the emulsion 
emulsifier in the synthesis; PEG2000-PE, DPPC, and Gd-DTPA-BSA.  
In a typical synthesis, 25 mg of the conjugated polymer was dissolved in 8 mL of 
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dichloromethane (DCM). 11.2 mg DPPC, 37.4 mg PEG2000-PE, and 13.9 mg Gd-DTPA-BSA 
were suspended homogeneously in 25 mL of deionised water in a round-bottom flask, (section 
5.2.3 for details). The lipid suspension was then magnetically stirred for 1 minute and 0.8 mL of 
the polymer solution was introduced with a syringe over a period of 60 seconds. The flask was 
covered, stirred vigorously for 10 minutes to initiate the emulsion, then sonicated for 90 seconds at 
7°C to complete the miniemulsion. Finally, the miniemulsion was gently stirred overnight to 
promote full DCM evaporation and nanoparticle formation. The excess lipids were removed via 
dialysis and the Gd-SPNs solution was filtered through 0.2 µm cellulose acetate filters and stored 
in glass vials at 4°C, refer to section 5.3 for details. The polymers formed the inner cores of the 
nanoparticles while the lipids formed the outer shells. A schematic of the Gd-SPNs is presented in 
Figure 35 (A).  
3.4.2 Optical Properties of the Gd-SPNs 
The optical properties of the Gd-SPNs are presented in Table 5. The absorption and emission 
spectra of the four aqueous Gd-SPNs produced in this study are presented in Figure 35 (B and C). 
They were found to be similar to the spectra of the free polymers in organic solvents and of 
previously reported SPNs [36, 182, 244]. Photographs of the Gd-SPNs under ambient light and 
exposed to the excitation of a 365 nm UV lamp in the dark are shown in Figure 35 (D and E). 
The brightness of the nanoparticles is very important in fluorescence cell imaging. Brightness 
depends on two factors; the fluorescence quantum yield (QY) and the wavelength-dependent 
extinction coefficient. The higher those two values are, the greater the brightness. The quantum 
yields of the purified Gd-SPNs are shown in Table 5. They are slightly lower than the QY of the 
same Gd-SPNs before purification and considerably lower than the QY of the constituent polymers 
dissolved in DCM, also shown in Table 5. It has been noted previously [244] that the increased 
bending and twisting of the polymer chains in the SPNs in general and with the decrease in their 
size, results in a decrease in their QY. The slight decrease in QY of the SPNs after purification can 
therefore be attributed to the removal of bulk polymer and nanoparticles larger than 200 nm. 
Furthermore, the QYs of the Gd-SPNs are comparable to the QYs of the non-gadolinium-
containing SPNs prepared previously by our group [36] (also shown in Table 5) verifying that the 
inclusion of gadolinium onto the nanoparticles surfaces in the manufacturing process is not 
detrimental to the fluorescence properties of the bimodal SPNs in comparison to the bimodal SPNs 
imbedded with iron oxide nanoparticles which suffered from a substantial fluorescence quenching 
[182]. The QYs of three of the four Gd-SPNs prepared here also confirm that the higher the QY of 
the polymer in its free configuration form, the higher its QY in its nanoparticle form, similar to our 
observation in the QYs of the QD-sized SPNs (section 2.3.6.1) [244]. 
In addition to QY, the second factor which affects brightness is the wavelength-dependent 
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extinction coefficient. In order to calculate the extinction coefficient from Beer-Lambert’s Law, the 
concentration of the polymer in the sample after purification and filtration must be determined. 
Therefore, a method for determining the final polymer concentration was developed (section 5.5.3). 
To this end, the nanoparticles had to be dissolved in a solution which perfectly dissolves both the 
polymers and the lipids. Dissolving the nanoparticles means unpacking them gently from their 
nanoparticle form to their neat (free) form. This required full evaporation of water and then the 
introduction of the ultimate solution CHCl3 + 1% methanol. DLS was used to determine full 
dissolution before the measurement of the concentration was conducted. The extinction coefficients 
of the dissolved polymers from the Gd-SPN suspensions were calculated and are presented in Table 
5. The high extinction coefficients combined with the considerable QYs of the Gd-SPNs yield high 
brightness as observed under the UV-light in Figure 35 (E). 










Absorption peak (nm) 388 450 460 495 
Emission peak (nm) 470 & 440 508 539 592 
Quantum yield of  
purified Gd-SPNs (%) 
22.01 6.98 33.15 1.50 
Quantum yield of  
non-purified Gd-SPNs (%) 
25.59 6.90 35.81 1.71 
Quantum Yield of  
polymer in DCM (%) 
59.2 92 68.6 15.9 
Quantum Yield of 
reference SPNs [36]  







at wavelength (nm) 
65.98 ± 0.35 
at 
λ = 390 
91.32 ± 0.57 
at 
λ = 450 
41.36 ± 0.15 
at 
λ = 450 
74.47 ± 0.17 
at 
λ = 490 
 




Figure 35 (A) A schematic representing a Gd-SPN. The (B) absorption and (C) emission 
spectra of the four aqueous Gd-SPN solutions, and two photographs of the SPN 
solutions under (D) ambient light and (E) 365 nm UV-lamp. 
3.4.3 Nanoparticle Size and Colloidal Stability 
TEM images of the purified Gd-SPNs are presented in Figure 36 (A – D), and a TEM image of 
non-purified MEH-PPV Gd-SPNs prepared using double the volume of polymer solution (i.e. 1.6 
mL instead of 0.8 mL) is presented in Figure 36 (E). The initial volume of the polymer solution 
was found to be one of the crucial factors affecting the final particle diameter. Decreasing volumes 
of polymer solution were found to produce corresponding decreases in nanoparticle diameters. The 
use of 1.6 mL polymer solution in the pre-final synthesis produced polymer nanoparticles with 
diameters ~200 nm as shown in Figure 36 (E). By using half that volume in the final syntheses 
presented here, one ensures that most of the nanoparticles were below 200 nm in diameter before 
the purification process. During purification, 0.2 µm filters were used to remove any dust, bulk 
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polymer, or remaining large nanoparticles. This is very important because the samples were 
exposed to the air overnight during synthesis, and is also important for the DLS measurements 
which are very sensitive to large particulates. The suspensions were found to pass through the 
filters smoothly which is another observation that suggested smaller nanoparticles.  
 
Figure 36 TEM images of purified (A) PPE Gd-SPNs, (B) ADS108GE Gd-SPNs, (C) F8BT 
Gd-SPNs, (D) MEH-PPV Gd-SPNs, and non-purified (E) MEH-PPV Gd-SPNs. 
Bar-scales are 200 nm in (A, D), and 1 µm in (B, C, E). 
The number-based particle size distributions of the purified Gd-SPNs as derived from the TEM 
images are shown in Figure 37. For all four Gd-SPN systems, diameters varied between 6 - 140 
nm, with average diameters below 35 nm and standard deviation values between 7 - 22 nm (Table 
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6). Table 6 also shows the average diameters of the nanoparticles in water measured using DLS 
(cumulant results). The randomly measured diameters using DLS for all four particle types were 
found to be similar (~111-117 nm) with low standard deviations. The average hydrodynamic 
diameters which also take into account the non-TEM visible lipidic shells of the Gd-SPNs, 
measured using NanoSight nanoparticle tracking analysis (NTA) (by Ms. Agnieszka Siupa, 
NanoSight NTA Company), ranged between 66 – 128 nm (also shown in Table 6). Similar to the 
average diameters measured from TEM, the average hydrodynamic diameters of the Gd-SPNs also 
had low standard deviations (27 – 39 nm). 
The polydispersity index (PDI), measured by DLS, gives an insight of how polydisperse a 
nanoparticle system is, with 0 PDI being an ideally monodisperse system and 1 PDI being a highly 
polydisperse system. The PDI of the Gd-SPNs, also shown in Table 6, was found to be around 0.2. 
This correlates well with the low standard deviations and the TEM images where nanoparticles’ 
diameters of a few nanometres up to 140 nm were observed. 
 
Figure 37 Gd-SPNs’ number distributions measured from TEM images. 
Table 6 A summary of the Gd-SPNs diameters and polydispersity indices as measured from 










TEM mean diameter (nm) 31.50 34.61 18.96 30.34 
TEM standard deviation of 
diameters (nm) 
21.53 17.23 7.48 18.00 
DLS cumulants diameter in 
water (nm) 
119.6 110.8 111.9 117 
DLS poly-dispersity index 0.259 0.191 0.238 0.179 
NTA (mean ± SD) (nm)  128 ± 37 66 ± 28 70 ± 27 118 ± 39 
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The nanoparticles were also found to be colloidally stable in more complex media. This was 
concluded from a study measuring the hydrodynamic diameters of similarly synthesised MEH-PPV 
Gd-SPNs in water and in cell culture medium (CCM) over a period of 24 hours (Figure 38). The 
colloidal stability of the nanoparticles in more complex media is especially important in bio-
imaging applications since an aggregation state may influence their fluorescence properties, as well 
as the cells interactions. 
 
Figure 38 Diameters of MEH-PPV Gd-SPNs, measured by DLS (cumulant results) in water 
and in cell culture medium (CCM) over a period of 24 hours. 
3.5 Bio-imaging In-vitro and Cellular Uptake of MEH-PPV Gd-SPNs  
The uptake of MEH-PPV Gd-SPNs in two different cell lines was investigated using confocal 
laser scanning fluorescence imaging: the human epithelial-like cell line, HeLa (performed by Dr 
Pei-Hua Chung, King’s College London) shown in Figure 39, and the murine macrophage-like cell 
line, J774 (performed by Raha Ahmadkhanbeigi, King’s College London) shown in Figure 40, 
(section 5.8.1 for methods, and Appendix 2 for definitions). As is typical for interactions between 
PEGylated particles approximately 100 nm in diameter and epithelial-like cells [42, 252], a limited 
internalisation of MEH-PPV Gd-SPNs was observed in HeLa cells after overnight incubation of the 
particles with the cells.  The diffuse green fluorescence observed in the optical sectioning of the 
HeLa cells in Figure 39 is indicative of endocytic (see Appendix 2 for definition) uptake of very 
small particles, while the brighter spots of fluorescence denoted by arrows may be indicative of the 
uptake of aggregated particles or vesicular fusion within the cell.  In contrast, a qualitative 
comparison of the uptake of MEH-PPV Gd-SPNs in the macrophage-like cell line, J774, shows a 
much higher internalisation of particles after only two hours of incubation. This is typical of 
professional phagocytic cells (see Appendix 2 for definition), such as macrophages, which unlike 
epithelial cells, are designed to efficiently ingest large amounts of particulate matter (even when 
PEGylated) [253-254]. As expected, the pattern of Gd-SPN derived fluorescence (pseudo-coloured 
golden-red) in the J774 cells is indicative of vesicular uptake; however, in contrast to the HeLa 
epithelial-like cells, the fluorescence signal is much sharper, possibly indicating a greater number 
of particles per vesicle. 

















 Gd SPNs in Water (100% of Intensity)
 Gd SPNs in CCM (100% of Intensity)




Figure 39 A cross-sectional scan of live epithelial-like HeLa cells incubated overnight with 
0.05 mg/mL MEH-PPV Gd-SPNs under bright field (left column) and fluorescence 
excitation (middle column). The right column is an overlay of the bright field and 
fluorescent images. Optical sections of the cells were taken from the top (A) to the 
bottom (B) of the cell monolayer. 




Figure 40 A cross-sectional scan of fixed J774 macrophage-like cells after a two hour 
incubation period with 0.2 mg/mL MEH-PPV Gd-SPNs. The left image shows the 
nuclear stain fluorescence (DAPI; pseudo-coloured blue), the right image shows 
fluorescence from the MEH-PPV Gd-SPN (pseudo-coloured golden-red), and the 
middle image is an overlay of the two. The optical plane was set at the midpoint 
between the top and bottom of the cell monolayer. Scale bars are 9.72 µm. 
Both images in Figure 39 and Figure 40 demonstrate that Gd-SPNs are suitable for cellular 
fluorescence imaging applications in different cell types and behave similarly to other types of 
nanoparticles of a similar size with a PEGylated surface chemistry [255-257]. As with other types 
of particulate imaging agents, the surface of Gd-SPNs may be modified to target specific cell types 
or intracellular structures. Further, Gd-SPNs are superior to a variety of fluorescent particles or 
small molecule fluorescent dyes due to their highly stable fluorescence with little to no photo-
bleaching after multiple image acquisitions or long storage periods [34].  
 
Other than the fluorescence intensity used to obtain the images in the imaging technique 
described above, fluorescence lifetime, which is the average time a fluorophore maintains its 
excited state before emitting a photon, is another fluorescence parameter which can be used to 
obtain optical images in a technique called fluorescence lifetime imaging microscopy (FLIM).[225, 
258] The fluorescence lifetime of a fluorophore can vary according to its geometrical 
conformation, internal rotation, and twisting, and its interactions with its surroundings such as 
nearby molecules [258]. Therefore, the fluorescence lifetimes of the nanoparticles prepared in this 
study are expected to be different from the fluorescence lifetimes of their constituent polymers. The 
fluorescence lifetime of MEH-PPV Gd-SPNs in solution (water) was measured (by Dr Pei-Hua 
Chung, King’s College London) to be 0.12 ns (89.4 %), 0.55 ns (9.3 %) and 1.67 ns (1.3 %)  
yielding an average lifetime of 180 ps (amplitude-weighted) and 429 ps (intensity-weighted) as 
seen in Figure 41 (section 5.6.6 for method). The increased coiling up and packing of the polymer 
chains in the nanoparticles was expected to cause an increase in the fluorescence lifetime of the 
polymer. Zhang et al. reported the fluorescence lifetime of MEH-PPV in a good solvent was 0.35 
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ns (single exponential fit), and in a good and poor solvent mixture was 1.29 ns (7.2%) and 0.57 ns 
(92.8%) [259], yielding an average  lifetime of 662 ps (intensity-weighted) for the coiled up 
polymer in the solvent mixture (Figure 41 Insert). However, this was not the case in the 
fluorescence lifetime measurements of the Gd-SPNs where the lifetime was found to be 
substantially lower than that reported for MEH-PPV in its neat form. Compared to QDs (lifetimes 
between 10 – 30 ns and up to 500 ns) [258], the fluorescence lifetime of MEH-PPV Gd-SPNs is 
much shorter. 
Despite the fact that dyes with longer fluorescence lifetimes are desired in some applications, 
such as for finger-print detection, where the background fluorescence is comparably strong [258], 
the ability to detect the fluorescence lifetime of MEH-PPV Gd-SPNs, which is very short, enables 
their use as dyes for FLIM imaging which is an imaging technique preferred for its independence 
on the fluorophor’s concentration [260]. 


























Figure 41 The fluorescence lifetime of MEH-PPV Gd-SPNs. The decay is fitted by a three-
exponential function using B&H SPCImage software. The insert is the 
fluorescence decay of MEH-PPV in two solvents: a good solvent, and a mixture of 
a good and a poor solvent. Insert copied from reference [259]. 
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3.6 Assessment of Nanoparticle-Antibody Conjugation for Future In-vivo 
Administration and Specific Ligand Targeting 
To conjugate the nanoparticles with any type of antibody, the nanoparticles must include 
conjugation sites (such as carboxylic groups) on their surfaces. Carboxylation can be introduced to 
the nanoparticle surfaces by substituting the non-carboxylated PEGylated lipid (PEG2000-PE) with 
a carboxylated PEGylated lipid (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[carboxy(polyethylene glycol)-2000] (ammonium salt)) (DSPE-PEG2000, see Appendix 1 for 
chemical structure) in the synthesis process. To this end, carboxylated MEH-PPV Gd-SPNs were 
synthesised and purified from excess lipids with the same method as the non-carboxylated Gd-
SPNs prepared in this chapter (sections 5.2.4 and 5.3 for methods). Then, conjugation with IgG 
(Immunoglobulin G; an immunoglobulin molecule; a plasma or cell-bound glycoprotein with 
antibody activity; IgG has two antigen binding cites [261]) was performed by linking the 
carboxylic groups on the nanoparticles surfaces to the amine groups of the antibodies (method 
similar to Howes et al. [36]). Successful conjugation was confirmed by gel filtration and 
fluorescence detection from washed (Gd-SPNs)-IgG-coated plates but not from washed 
unconjugated-IgG-coated plates (section 5.8.2). With a simple indirect enzyme-linked 
immunosorbent assay (ELISA) test, the bound nanoparticles were found not to affect the 
antibodies’ ability to bind to their target ligands (also section 5.8.2). (Antibody linking and post-
antibody-linking investigations were performed by Nicola J. Commander, DSTL, Salisbury, UK). 
3.7 Assessment of Nanoparticle Fluorescence Against Tissue Auto-
Fluorescence  
In an assessment of Gd-SPNs’ fluorescence against animal tissue’s auto-fluorescence, 100 µL 
F8BT Gd-SPNs (yellow emitting; QY ~ 33% , initial concentration = 110 µg/mL) was injected 
subcutaneously into an euthanized rat’s scruff (performed by Jo Scott, DSTL, Salisbury, UK), and 
the rat was imaged under an Elmer IVIS spectrometer (see section 5.8.3). The Gd-SPNs’ 
fluorescence was found to be visible through the rat’s tissue and distinguishable from the tissue’s 
auto-fluorescence, as shown in Figure 42, which provides promising preliminary results for future 
in-vivo investigations. 




Figure 42 The fluorescence of F8BT Gd-SPNs in an euthanized rat, after subcutaneous 
injection and auto-fluorescence subtraction. The region of interest (ROI) shows a 
radiant efficiency of              . 
In a further investigation, mouse cadavers were injected (by Nicola J. Commander, DSTL, 
Salisbury, UK) at three locations with either antibody-conjugated MEH-PPV Gd-SPNs or 
unconjugated MEH-PPV Gd-SPNs (red emitting; QY ~ 1.5%; concentration ~ 35.6 µg/mL); 100 
µL MEH-PPV (Gd-SPNs)-IgG solution (neat concentration which contained ~ l000x diluted Gd-
SPNs) was injected into the quadriceps muscle of an euthanized mouse, 100 µL MEH-PPV Gd-
SPNs suspension (concentration ~ 35.6 µg/mL) was injected subcutaneously on the ventral surface, 
and 100 µL MEH-PPV Gd-SPNs suspension (concentration ~ 35.6 µg/mL) was injected deep into 
the chest cavity (section 5.8.4). Figure 43 shows fluorescence and ambient images of the mice. 
Considerably high fluorescence intensity was detected from the nanoparticles injected just under 
the skin (located by (A) in Figure 43) which suggests that the MEH-PPV nanoparticles could emit 
through the skin layer and could be distinguished from the mouse’s auto-fluorescence. The 
antibody-conjugated nanoparticles which were injected into the quadricep muscles of the mouse, 
and were ~1000x more diluted in terms of nanoparticle concentration, could also be detected but 
with a lower fluorescence intensity ((B) in Figure 43), which also means that the fluorescence 
could migrate through several tissue layers of the mouse. Finally, injecting the nanoparticles deep 
into the chest cavity resulted in a lost fluorescence signal ((C) in Figure 43). This is because the 
fluorescence of the nanoparticles is attenuated as it passes through the animal tissues, and the 
deeper they are injected, the more the fluorescence is attenuated and eventually lost. The detectable 
nanoparticle fluorescence also depends on their concentration; for a detectable signal from the 
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antibody-conjugated nanoparticles, it was necessary to inject a relatively large amount of 
conjugated antibodies into a certain area within the mouse’s body. If that same amount of 
conjugated (Gd-SPNs)-IgG was to diffuse within the body of a live animal in an in-vivo 
investigation for example, the nanoparticles signal would probably be lost. 




Figure 43 Images of two euthanized mice injected in three locations with (A) 100 µl MEH-
PPV Gd-SPNs subcutaneously on the ventral surface, (B) 100 µl MEH-PPV (Gd-
SPNs)-IgG intramuscular into the quadricep muscle (~1000x less nanoparticle 
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concentration), and (C) 100 µl MEH-PPV Gd-SPNs deep into the chest cavity. 
Image (1) is a photograph of the mice in ambient conditions, image (2) is an IVIS 
image showing the collected fluorescence intensity image against the mice ambient 
image, and image (3) is an IVIS processed image that shows the fluorescence from 
the nanoparticles (red) and the mice’s auto-fluorescence (green). 
Furthermore, MEH-PPV Gd-SPNs injected into the spleen of an euthanized mouse were 
successfully imaged after histology. Figure 44 shows spleen tissue imaged after snap freezing the 
aseptically removed spleen (section 5.8.5). The nanoparticles were readily visible in the tissue and 
were found not to be quenched or destroyed by the fixation process. However, fixing the spleen 
with paraformaldehyde was found to cause a total disappearance of the nanoparticle fluorescence 
which could indicate some interactions between the nanoparticles and the fixing substance. 
However, this cannot be certain without further investigations. 
 
Figure 44 A bio-image of mouse-spleen tissue after MEH-PPV Gd-SPNs injection into the 
euthanized mouse’s spleen and fixing by snap freezing. The red colour indicates 
the fluorescence signal from the nanoparticles after tissue auto-fluorescence 
subtraction.  
To summarize, two differently emitting Gd-SPNs (MEH-PPV Gd-SPNs; red emitting; with QY 
~ 1.5%, and F8BT Gd-SPNs; yellow emitting; QY ~ 33%) were used in an investigation to assess 
nanoparticle visibility through animal tissue. The nanoparticle fluorescence was distinguishable 
from the animal’s auto-fluorescence, however, it was found to be attenuated with injections deeper 
into the animal tissues. Also, the final concentration of the nanoparticles within the area of interest 
was found to be pivotal for success of detection within a whole animal, with a relatively high 
concentration needed for a strong signal. Moreover, preliminary histological tests with MEH-PPV 
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Gd-SPNs revealed that the nanoparticles could be used as tissue-staining substances in such 
applications. However, their successful detection was found to depend on the fixation method used. 
3.8 Nanoparticle Relaxivity Measurements in T1–weighted Magnetic 
Resonance Imaging 
The component in the Gd-SPNs which gives the nanoparticles an MRI active property is 
gadolinium. The concentrations of gadolinium in the purified Gd-SPNs measured by mass 
spectrometry (performed by Mr Andrew Cakebread, Mass Spectrometry Facility in King’s College 
London) are presented in Table 7.  
Table 7 The concentrations of gadolinium, in the purified Gd-SPNs samples, measured by 
mass spectrometry: 
 
Compared to Gd-QDs prepared with similar lipids (gadolinium concentrations between 0.1 – 
0.4 mM) [97], these concentrations were very low (highest being 0.119 mM in the non-
concentrated MEH-PPV Gd-SPNs sample). Therefore, the MEH-PPV Gd-SPNs sample was 
concentrated further to a final gadolinium concentration of 0.3 mM. The relaxation time values 
(T1) of this concentration and two successive dilutions (0.2 and 0.1 mM) under two magnetic field 
strengths (3 Tesla and 7 Tesla) were measured and used to calculate the relaxivity (  ) of the Gd-
SPNs in both fields. The measurements were performed by Dr Andrea Protti and Dr Alkystis 
Phinikaridou, Cardiovascular Division and Division of Imaging Sciences and Biomedical 
Engineering, King’s College London (section 5.8.6 for method). The results, reported in Table 8 
and Figure 45, highlight the linear correlation between Gd concentrations and the relaxation rate 
values (R1) which are the reciprocals of the T1 values. The relaxivity (  ), is calculated for the 
MEH-PPV Gd-SPNs in Figure 45 as the slope of the linear relationship, and is determined to be 
                
       at 3T, and                 















Gadolinium concentration in a 
non-concentrated sample (µM) 
51.28 74.34 77.15 119.34 




Table 8 MRI T1–weighted relaxation times and their corresponding R1 values measured 
for different Gd concentrations (i.e. different MEH-PPV Gd-SPNs concentrations), 


















water 2.62 0.38 water 2.933 0.34 
0.1 0.40 2.5 0.1 0.474 2.11 
0.2 0.29 3.46 0.2 0.28 3.57 
0.3 0.21 4.68 0.3 0.262 3.82 
2 0.024 41.38 2 0.029 34.48 
 
 
Figure 45 The relaxation rates (R1) versus gadolinium concentration of MEH-PPV Gd-SPNs 
at 3T and 7T. The relaxivities (  ) are calculated as the slopes of the linear fittings. 
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Bimodal nanosystems have several advantages over conventional imaging agents in the 
biological and medical fields. This led to an increase in the interest in the synthesis of bimodal 
nanoparticles. QDs were previously investigated as bimodal MRI-optical imaging agents [97]. 
However, because of the increased concerns about the health and safety issues associated with the 
use of QDs within living systems (due to their usual toxic compositions), the search for alternative 
nanoparticles was due to be investigated. In an attempt to provide suitable alternatives, we 
synthesised four fluorescent organic bimodal nanoparticles (Gd-SPNs), with outstanding 
fluorescence properties, such as high fluorescence stability with little to no photo-bleaching after 
multiple cell image acquisitions or long storage periods, which make them excellent imaging 
agents. 
The Gd-SPNs manufactured in this study had average core diameters around 30 nm with 
standard deviations of 7 – 22 nm as measured from TEM images, and hydrodynamic diameters 
around 66 – 128 nm with standard deviations of 27 – 39 nm as measured by NTA. Compared to the 
iron oxide/SPNs [182] these Gd-SPNs showed smaller diameters and also higher quantum yields. 
Their MRI T1–weighted relaxation times were measured revealing a gadolinium concentration 
dependence with a relaxivity of                 
       at 3T, and           
              at 7T.  
Moreover, the Gd-SPNs were found to be taken up by live cells, which is desirable in cell 
imaging applications. Also, their fluorescence was found to be visible through animal tissue when 
injected subcutaneously into euthanized mice and a rat pup. The auto-fluorescence-distinguishable 
nanoparticle signal was dependent on both nanoparticle concentration and how deep the injection 
into the tissue. This observation which can limit the nanoparticle usefulness in the future could 
probably be solved by using Gd-SPNs with different optical properties such as infra-red emitting 
Gd-SPNs. Therefore, these Gd-SPNs, which were colloidally stable in different biological media, 
have potential as bimodal MRI-optical imaging contrast agents in a variety of biomedical 
applications. 
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4 Interactions of Semiconducting Polymer Nanospheres and 
Quantum Dots with Components of Human Blood: Effects of 
Surface Coatings  
4.1 Introduction 
Safety assessment of new nanomaterials [114] has become an increasingly important issue 
worldwide [114, 262-267]. Nanoparticles are being synthesised extensively and are already 
incorporated into many applications in science and industry. ‘The Project on Emerging 
Nanotechnologies’ website identified 1317 commercial products (up until 10 th March 2011) which 
included (or claimed to include) nanoscale materials.[268] Examples are food plastic storage bags 
infused with silver nanoparticles [269], and cosmetic aluminium oxide nanopowders [270]. These 
nanomaterials have different chemical compositions, sizes, surface chemistries and coatings, and 
other properties which make them unique and desirable by the medical, educational, food and 
commercial industries. The study of the short and long term effects of such novel nanomaterials on 
human health and the environment is still immature. Therefore, there is an increased interest in 
safety assessment studies for nanomaterials, especially if the applications involve deliberate 
exposure to the human body, for example as in pharmaceutical and bio-imaging applications. 
The fate of any type of nanoparticle administered into the body depends on its properties. For 
example, the size distribution of nanoparticles, which can vary from a few nanometres to sub-
microns in diameter, has a direct influence on their ability to cross different biological barriers. 
Small nanoparticles, with a few nanometres in diameter, can cross the blood brain barrier [266, 
271], while other nanoparticles with diameters up to 240 nm can cross the human placental barrier 
[272]. Further, nanoparticles with hydrodynamic diameters larger than 5.5 nm cannot cross the 
renal barrier and achieve renal clearance in mice [116]. Nanoparticles trapped within the body can 
be dangerous, as some accumulating nanoparticles were found to be deposited on the walls of 
blood vessels and in some organs [266] causing organ failure and dysfunction [114]. 
The chemical properties of the nanoparticles such as their composition and surface chemistries 
are also important factors governing their safety profile and interactions with physiological 
systems. Nanoparticles composed of toxic chemicals and metals can be very toxic if degraded 
within the body [105, 273]. Moreover, nanoparticles have amplified surface related properties, due 
to the increase in their surface area per unit volume with the decrease in their size. This increases 
the magnitude of their reaction with their surrounding cellular environment [114]. Nanoparticles 
with highly reactive surfaces cause an increased oxidative stress within the body and can stimulate 
the body’s inflammatory response [274]. Inflammation can also be triggered by extremely 
hydrophobic nanoparticle surfaces [275]. Surface modifications with cationic and anionic chemical 
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groups, which are in some cases necessary for the nanoparticles’ use in specific applications, also 
affect their behaviour and therefore change their toxicological profile [107, 262]. Nanoparticle 
surfaces can also be modified in-vivo by the adsorption of proteins to the surface in a process called 
opsonisation or protein corona formation [276]. Opsonisation not only increases nanoparticle 
diameters, but also alters their physio-chemical properties, which can influence their safety profile 
[276-277]. The surface charge (zeta potential) which is also associated with the surface chemistry 
of the nanoparticles as well as the pH of their surrounding also plays a role in influencing the total 
toxicity of any given nanoparticle species [107, 278]. 
4.1.1 Concerns Over Quantum Dot Safety and Rationale for the Development of 
Semiconducting Polymer Nanospheres as Safer Alternatives 
Inorganic quantum dots (QDs) have received much attention in the nanotoxicity and safety 
assessment field, because of safety concerns associated with their chemical composition, 
specifically the potential of cadmium-related toxicity [104-109]. Cadmium has been identified as a 
human carcinogen since 1997 [279-280]; it was reported to interfere with DNA repair processes 
increasing the risk for tumour formation [281]. Targets of cadmium were found to include the 
lungs, thyroids, liver, kidneys, and cardiovascular, immune, and reproductive systems [279, 282-
283] where acute exposures to medium-high doses in-vivo resulted in hemorrhagic injury, organ 
damage, dysfunction, and failure [282-283]. Cadmium is stored in different body organs for years 
(biological half life = 15 – 30 years) [282]. Its accumulation with chronic exposure to low doses 
(blood levels range of 10–100 nM) through inhaling airborn cadmium (e.g. from cigarette smoke) 
and/or eating contaminated foods can therefore result in a long term toxicity (dependent on the 
dose, route, and duration of exposure [282]). Deliberately exposing the body to cadmium, by the 
use of cadmium containing QDs for diagnostic purposes, will therefore increase the body’s burden, 
and can result in cadmium poisoning with clinical misuse or dose mistakes. Moreover, other 
constituents of QDs, such as selenium and tellurium, were also found to cause acute toxicities if 
ingested with high doses [284-286]. 
As noted previously, QDs have excellent optical properties, which make them attractive 
imaging agents. They have small diameters and are known to be less polydisperse than organic 
nanoparticles, which provides the possibility of renal clearance as confirmed by in-vivo studies in 
mice [116, 287]. Further, many QDs are commercially available and are therefore easy to study. 
Due to the fact that QDs are typically composed of toxic materials, they need to be encapsulated 
with biocompatible materials for use in biological applications [110-111, 114-115]. The addition of 
the capping shells or molecules substantially increases the hydrodynamic diameters of the particles. 
Additionally, the risk from the presence of non-capped quantum dots, or the aggregation and 
decomposition of the particles in the body (such as the uptake and decomposition of intravenously 
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injected CdSe QDs by/in the liver, spleen, and kidneys of mice [288]) cannot be neglected, and 
long term toxicity will always be a concern. 
Due to their lack of heavy metal constituents, it has been hypothesized that SPNs could be a 
highly effective, yet safer alternative to QDs. It has been established that organic SPNs have 
comparable optical properties to QDs [36, 182, 244], but demonstrate significantly longer shelf-
lifetimes in terms of fluorescence. For example, the fluorescence of QDs can be quenched within 
days or weeks, however, the fluorescence of the SPNs which we synthesised was conserved for 
several years to date, (refer to section 1.2.2.2 for further details). However, in order to evaluate 
whether SPNs are suitable for use in biological and clinical applications, rigorous safety assessment 
must first be conducted. As diagnostic agents, SPNs are likely to be administered to patients 
intravenously. This means that they will first come into contact with blood plasma and the cellular 
components of blood. Therefore, understanding the interactions between blood components and the 
nanoparticles by performing ex-vivo tests to evaluate whether the nanoparticles promote any of 
these interactions is a vital component in the broader safety assessment of such new diagnostic 
agents. This is especially important, as some nanoparticles are known to negatively affect blood 
clotting pathways [277, 289] as discussed in detail in the following section. 
4.1.2 Effects of Nanoparticles on Blood Components after Intravenous Administration 
Human blood is composed of red blood cells, white blood cells (leukocytes: lymphocytes, 
monocytes, and neutrophils are the three main types), platelets, and blood plasma which contains 
proteins, other biomolecules, and ions. Blood circulates within blood vessels lined with endothelial 
cells, all of which interact together to achieve one goal: delivering oxygen and nutrients to cells, 
removing carbon dioxide and cell waste, coagulating in response to vessel injury, and fighting 
infections via the foreign-body triggered inflammatory response.[290] 
Platelets are disk shaped blood components which originate from the bone marrow in humans 
and play an important role in blood clotting. In healthy humans, platelets adhere together and 
aggregate in the site of injury to stop the bleeding and aid in recovery.[291] In many cardiovascular 
disorders, however, non-favourable platelet aggregation appears to happen. This dangerous 
phenomenon causes fatal diseases such as acute coronary artery diseases, embolism and 
strokes.[292-293] The aggregation of platelets involves platelet activation, adhesion, and secretion 
in a synergetic and multistep process.[291] Endogenous agonists, such as adenosine diphosphate 
(ADP) and thrombin released from activated platelets cause platelet-platelet adhesion and hence 
aggregation.[291] 
Platelet activation not only causes platelet-platelet adhesion as described in the previous 
paragraph, but also causes the platelets to interact with their surroundings and adhere to endothelial 
cells lining the blood vessels and to white blood cells such as monocytes and neutrophils. An 
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increase in platelet activation accompanies and amplifies inflammation, with platelets binding to 
the endothelium and to leukocytes causing leukocytes activation, facilitating their migration 
through endothelial cells to underlying and nearby tissues, and promoting monocyte differentiation 
into macrophages.[294-296] Platelets adhering to monocytes form circulating platelet-monocyte 
complexes which are found to be important factors in disease pathogenesis.[294-295] Likewise, 
platelets adhering to neutrophils form circulating platelet-neutrophil complexes which also have 
similar roles.[297] It was also reported that platelet-neutrophil adhesion can be caused by the 
activation of one of the two species or by both.[298] 
Many nanoparticle types have been found to be treated as intruding foreign objects by the blood 
defence components when introduced to the blood system (e.g. by intravenous injection). They are 
generally opsonised by plasma proteins and cleared away from the blood very quickly to the liver 
and spleen by activated leukocytes such as neutrophils [299-300]. Some nanoparticles have also 
been found to trigger platelet activation leading to platelet-leukocyte interactions and platelet 
aggregation which results in thrombus formation. Examples of such activation events are the 
enhancement of platelet coagulant activity in response to the presence of silver nanoparticles in the 
blood stream [301] and the dysfunction of endothelial cells, platelet activation, and leukocyte 
activation towards atherosclerosis disease with the migration of combustion-derived nanoparticles 
into the cardiovascular system [302]. 
 The surface chemistries of nanoparticles and hence their surface charges were reported to be 
the main influencers of such cell responses [303], with positive charged or highly negative charged 
nanoparticles reported to cause amplified cell-cell and particle-cell interactions in comparison to 
neutrally charged nanoparticles.[278, 289] An example is the increased platelet aggregation in-vitro 
by the incubation of the platelets with carboxylated QDs (which are highly negatively charged; zeta 
potential ~ -57.7 mV in deionised water) as opposed to non-functionalised QDs [278]. 
To increase nanoparticle circulation time, it is necessary to camouflage the nanoparticle surfaces 
through modification so that they are not recognized by the blood components as foreign 
intruders.[304] One surface modification which has been demonstrated to have such an effect is 
PEGylation. PEGylation of nanoparticle surfaces with certain chain lengths of PEG and certain 
surface percentage coverage [305] has been shown to decrease particle-cell interactions resulting in 
an increased circulation time as well as a decrease in undesired adverse events.[306-310] For 
example, a decreased platelet coagulant activity and platelet-monocyte binding of PEGylated 
amorphous silica nanoparticles was observed in contrast to nanoparticles without PEGylation 
[311]. Similar effects have also been observed with a variety of other nanoparticle species that have 
been surface-modified with PEG.[312] For these reasons, in addition to the excellent colloidal 
stability conferred by PEGylated nanoparticles, the majority of systems described in this thesis 
have varying degrees of PEG surface coverage. 
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4.1.3 Study Aims and Hypotheses 
Three main study components are presented in this chapter. First, the physiochemical 
behaviours of the nanoparticles in different control and physiologically relevant media are 
assessed. Secondly, nanoparticle interactions with isolated human platelets are studied, and finally, 
nanoparticle interactions with human whole blood components are evaluated. All studies were 
conducted using the bimodal Gd-SPNs introduced in chapter 3 and on similarly prepared 
monomodal SPNs. Further, to investigate whether CdSe/ZnS QDs with similar surface 
morphologies have any acute effects on whole blood, two QD species were included as 
comparisons in the study: a neutral (QD) and  a partially carboxylated surface modification (cQDs) 
(Figure 46). The partially carboxylated surface modification was introduced to investigate whether 
an elevated negative surface charge will enhance nanoparticle effects on blood cells, such as 
platelet activation and platelet-monocyte adhesion. This phenomenon has been previously observed 
with both cationic, amine-modified and anionic, carboxy-modified polystyrene beads [107, 278, 
289]. To benchmark to the literature, commercially available carboxylated polystyrene beads (cPS; 
50 nm) were also included in the study as a positive control. 
Because all four nanoparticles in this study were partially PEGylated, we hypothesised that they 
will have minimum interactions with the blood, and that they will have minimum non-specific 
binding and opsonisation of proteins on their surfaces, they will not cause any platelet aggregation 
or activation in isolated platelet rich plasma, and they will not cause any platelet-monocyte 
adhesion or neutrophil activation in whole blood. 
4.2 Synthesis and Optical Characterisation of the SPNs, Gd-SPNs, QDs, and 
cQDs 
SPNs and Gd-SPNs with average core diameters of 30 ± 18 nm, as measured from TEM 
images, were synthesised, concentrated, and purified (section 5.2.5 for details). Both polymer 
nanoparticles were composed of a hydrophobic polymeric core of MEH-PPV polymer chains 
packed into a spherical conformation. The hydrophobic core of the SPNs was stabilized in aqueous 
suspension by a phospholipid surface coating composed of a ~1:2 molar ratio of PEG2000-PE and 
DPPC, while the Gd-SPNs were stabilised by a surface coating of ~1:1:1 PEG2000-PE/DPPC/Gd-
DTPA-BSA. Thus, the overall hydrophilic nature of both SPN species, as conferred by the 
PEGylated surface coating, is similar.  Importantly, all SPNs maintained the fluorescence 
properties (Figure 47) of their constituent polymers [36], making them suitable for use in 
fluorescence bio-imaging applications. 
In addition to the two species of SPNs chosen for this study, QDs with similar optical and semi-
conductive properties, as well as surface coatings were investigated. This was to determine whether 
the surface coating only or also the particle core exert an acute influence on the interactions 
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between nanoparticles designed for optical imaging agents and components of blood. CdSe/ZnS 
quantum dots with 4 nm diameters were coated with PEG2000-PE and DPPC (2:1) to imitate the 
SPNs. Also CdSe/ZnS QDs were coated with PEG2000-PE, DPPC, and DSPE-PEG2000 (1:1:1), 
forming partially carboxylated nanoparticles (cQDs) (preparation technique the same as Dubertret 
et al.[47] in section 5.2.6). Preliminary hydrodynamic diameter measurements of the PEGylated 
QDs and cQDs resulted in two size distributions, with one peak at~15 nm and the second at ~100 
nm. Therefore, we hypothesized that both QD systems included a mixture of single, coated QDs 
and micellar structures which contained multiple QDs. A schematic of the cross-sectional 
conformations of the nanoparticles is provided in Figure 46. 
 
Figure 46 A schematic of the four nanoparticles under study: SPNs, Gd-SPNs, QDs and 
cQDs. 
The absorption and emission spectra of the Gd-SPNs and the QDs are shown in Figure 47. The 
spectra of the SPNs and cQDs were not measured, however, they are expected to have the same 
spectra as their counterparts as, from our experience and as reported by others, the lipids used did 
not affect the absorption and emission spectra of the nanoparticles in the 400 – 900 nm region [36, 
244, 313]. As shown in Figure 47, the QDs and polymer nanoparticles under study have similar 
absorption and emission spectra; both systems absorb light with wavelengths below 600 nm, and 
both emit light with an emission peak of ~595 nm. The absorption spectra of the QDs do not have a 
defined peak, while the polymer nanoparticles have a strong absorption peak around 495 nm. 
Moreover, the emission spectra of the polymer nanoparticles are broader than those of the QDs and 
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have an extra shoulder at 650 nm. The broadening of the emission peak and the occurrence of the 
secondary peak in the SPNs emission are characteristic of the polymer used and are influenced 
more by the proximity of the polymer chains in the compact nanoparticle configuration [244]. The 
similar photo-characteristics of the quantum dots to the semiconducting polymer nanospheres make 
them suitable comparison candidates in the nanoparticle-cell interaction investigations which 
follow, especially since some of the assays involved an optical component to the analysis, such as 
turbidity in the platelet aggregation experiments, light scattering in the nanoparticle stability 
studies, and fluorescence in the platelet activation experiments by flow cytometry. 
The concentrations of the prepared nanoparticles were measured and adjusted to a final 
concentration of 4 mg/mL prior to the experiments. 
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Figure 47 Normalised absorption and emission spectra of the Gd-SPNs and QDs. 
4.3 Physiochemical Characterisation of the Nanoparticles 
4.3.1 Nanoparticle Surface Charge 
The nanoparticle zeta potential was measured using laser Doppler anemometry (Nanosizer, 
Malvern Instruments, UK, refer to section 5.9.3 for methods). All four nanoparticle species were 
found to be negatively charged in Chelex
®
-treated pH adjusted (NaOH and HCl) water with zeta 
potentials varying between – 17.90 mV and – 10.70 mV, as seen in Table 9. It is known that the 
higher the magnitudes of the zeta potential values for a particular system, the more colloidally 
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stable it is in aqueous media, where the nanoparticles repel each other and therefore nanoparticle – 
nanoparticle  aggregation is minimised [314]. However, it is also well documented that highly 
charged colloids are more sensitive to the presence of counter ions in media which approach 
physiological tonicity. Through adsorption of counter ions to the charged surface, neutralisation 
can occur, which reduces charge repulsion and can promote particle aggregation or flocculation.  
This sensitivity of charged particles to the ionic strength of the media can be prevented by surface 
coating with hydrophilic polymers such as PEG, which provide a hydrophilic, steric barrier against 
particle-particle forces of attraction.[315-316] With regard to the four nanoparticle systems studied 
in this chapter, the magnitude of zeta potential values measured, which are only moderately 
negative, accurately reflect the combination of charged species on the particle surface and non-
ionic PEG chains. This will be discussed in greater detail below. 
The two common surface coating/entwining lipids in the four nanoparticles studied in this 
chapter were DPPC and PEG2000-PE. It was observed that increasing the molar content of 
PEG2000-PE resulted in a slight decrease in zeta potential. In general, the incorporation of 
PEGylated lipids (or increase in their percentage of total lipids) has been shown in the literature, 
for example in phospholipid liposomes, to decrease the magnitude of their zeta potential [317]. In 
that same study, the liposomes which were prepared using 80% DPPC and a varying percentage of 
PEG2000-PE with a third lipid (phosphatidylinositol) were found to have zeta potentials of (– 12 
mV to – 4 mV, for 0 – 9 % PEG2000-PE) in 10% PBS in water at 25ºC [317]. These values, which 
were of empty liposomes cannot be compared directly to the zeta potentials of the nanoparticles 
prepared here because of the difference in the core materials and because of the different 
parameters used in the zeta potential measurements (temperature and medium). However, the 
results in general fit well with the zeta potential values measured in our study. 
Both SPNs and Gd-SPNs contained the same core material, and almost the same percentage of 
PEG2000-PE (~30% of total). The difference was in the remaining 70% DPPC, where half of it 
was substituted with Gd-DTPA-BSA in the Gd-SPNs. With a fixed PEG content on both surfaces, 
the introduction of 35% Gd-DTPA-BSA to the surface contributed to a final increase (by ~ -4 mV) 
in the magnitude of the negative zeta potential. DTPA contains three carboxylic groups, which are 
used to complex the gadolinium ions. Any free carboxylic groups, i.e. those not involved in 
complex formation, are therefore responsible for this modest increase in surface charge. 
Likewise, both quantum dots contained the same core content, the same percentage of 
PEGylated lipids, and the same percentage of DPPC, with one quarter of the total PEGylated lipids 
in the cQDs containing carboxylic groups. Introducing carboxylation to the surfaces of the cQDs 
resulted in an increase in their negative zeta potential (by ~ -7 mV), an effect that is similar to that 
of Gd-SPNs. 
When it comes to interactions of the nanoparticles with other objects/molecules present in the 
aqueous medium such as biological species, it has been reported that the more negative the surface 
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charge of the nanosystem, the greater the adsorption of biomolecules to the nanosystem’s surface 
[317-318].  Biomolecule adsorption to particle surfaces may be indirectly monitored by evaluating 
changes to the zeta potential of nanoparticles after incubation with physiologically relevant media.  
In this study, nanoparticles were incubated with phosphate buffered saline containing 8% human 
blood plasma (i.e. platelet-poor plasma; PPP) and the changes to the zeta potential were compared 
with their original values in water (Table 9). Exposure of the nanoparticles to dilute PPP which 
contains human serum proteins did not significantly alter the zeta potential of the SPNs and QDs, 
which were the two nanoparticles species lacking carboxylated moieties in their surface coating. 
However, the zeta potentials of Gd-SPNs and cQDs were found to decrease slightly in 8% PPP, 
which suggests adsorption of some PPP components, likely proteins, onto the nanoparticle surface 
and a neutralisation of some of the surface charge. This observation suggests that the presence of 
anionic groups, such as free carboxyl groups, on the surface of the Gd-SPNs and cQDs attracted 
proteins from the serum and produced some form of protein corona. The implications of this 
opsonisation are that both Gd-SPNs and cQDs may potentially have an altered biodistribution or 
differences in cell interactions compared to their comparator formulations (SPNs or QDs) when 
administered in the body via the intravenous route or if they came into contact with biological 
samples in in-vitro bio-imaging applications. 
Table 9 Zeta potential of the nanoparticles in both water and diluted PPP: 
Nanoparticles Zeta Potential in water (mV) Zeta Potential in 8% PPP (mV) 
SPNs - 12.8 ± 2.0 - 10.7 ± 0.2 
Gd-SPNs - 16.5 ± 1.2 -   8.9 ± 0.7 
QDs - 10.7 ± 2.0 -   9.3 ± 0.2 
cQDs - 17.9 ± 1.5 - 10.4  ± 0.6 
 
4.3.2 Nanoparticle Colloidal Stability in Physiological and Synthetic Media 
Figure 48 and Figure 49 show example size distributions of the SPNs, Gd-SPNs, QDs, and 
cQDs in (1) Chelex
®
 treated/pH adjusted water, (2) cell culture medium (CCM) with 2% foetal 
bovine serum (FBS) supplementation, and (3) 8% human platelet poor plasma (PPP) at 37°C over a 
24 hour period (the data of only six time points, from a total of 30, are shown). Platelet poor plasma 
and CCM contain nanometer sized biological species (proteins and protein aggregates) which are 
DLS detectable. Therefore, the size distributions of a blank sample in dilute PPP (8% PPP in a 
buffer of 20% PBS in distilled water) were also measured (also present in Figure 48 and Figure 49). 
Both SPNs and Gd-SPNs were very stable in water and in CCM with little to no aggregation in 
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both media (showing almost the same single peaked size distribution profile over the 24 hours of 
monitoring, Figure 48). The average diameters of both nanoparticles in water and in CCM were 
very similar (mean z-average of SPNs in water = 117.5 ± 1.12 nm, SPNs in CCM 2%FBS = 113.0 ± 
4.75 nm, Gd-SPNs in water = 117.0 ± 1.45 nm, Gd-SPNs in CCM 2%FBS = 110.8 ± 0.85 nm; n=24 
measurements). The values are consistent with previous results from the extensive colloidal 
stability studies performed by Howes et al. on the same SPNs (prepared in a slightly different 
method).[319] 
The dispersion of the SPNs and Gd-SPNs in 8 % PPP were difficult to interpret due to a 
significant amount of polydisperse colloidal material (~10-100 nm) present in the PPP (SPNs/Gd-
SPNs in 8 % PPP compared to blank in 8 % PPP in Figure 48). Since the hydrodynamic diameters 
of the SPNs were ~120 nm, it was initially hypothesized that the nanoparticle peak would be 
distinguishable over the PPP background signal. At some measurement time points these peaks can 
be observed (peaks 100-1000 nm), however at others the nanoparticle peak seems to merge with 
the background signal, which makes it difficult to interpret the findings regarding particle stability. 
Further in-depth studies need to be conducted to identify the nature of the interactions involved and 
provide more detailed information on particle stability in human serum. These investigations may 
be carried out using a different analytical technique, such as particle tracking analysis, which is not 
sensitive to media composition in the same way that DLS is.  
Similar to the SPNs, the QDs were stable in water; showing a bimodal size distribution in every 
measurement (see Figure 49). The increase in the diameters of the capped QDs in comparison to 
their original 4 nm diameters when non-capped (data given by the manufacturer) is pronounced, 
with the larger peaks situated around the same diameters as those of the SPNs/Gd-SPNs. As 
discussed in the introduction to this chapter, the bimodal size distribution of the QDs in water 
suggests that one fraction of the suspension may be composed of single, capped QDs and the 
remaining fraction comprises micellar systems containing an uneven number of non-capped QDs. 
In water, there was also a non-significant shift of the size distributions to the larger diameters with 
elapsed time (average diameter =92 nm (at t = 0 h), 104 nm (at t = 24 h)).   
Interestingly, Figure 49  shows that the cQDs were not as stable as the QDs in water indicating 
that they tend to interact to some extent and undergo slight instantaneous aggregations. This is 
unexpected since carboxylation of the surface should theoretically prevent nanoparticle aggregation 
by the mechanism of enhanced repulsion of like charges [314]. 
The behaviour of both QDs and cQDs in cell culture medium was not significantly different 
than that in water (Figure 49). For example, both QD species again showed a bimodal distribution 
in CCM, and aggregation or consolidation to larger particle sizes was observed over 24 h. In dilute 
PPP, the nanoparticle signal was also very difficult to detect and the colloidal stability difficult to 
interpret using this method.  Therefore, similar to the SPNs, further studies must be performed in 
ordered to truly characterise the colloidal stability of nanoparticles in human serum. 






Figure 48 SPN and Gd-SPN size distribution profiles over a period of 24-hours at 37°C after 
dispersion in Chelex
®
  treated/pH-adjusted water, cell culture medium (CCM) 
containing 2% FBS, and dilute human platelet poor plasma (8% PPP in 20% PBS, 
n = 1). The size distribution profiles of 8% PPP, n = 1 with a blank sample are also 
presented. 
 




Figure 49 QD and cQD size distribution profiles over a period of 24-hours at 37°C after 
dispersion in Chelex
®
 treated/pH-adjusted water, cell culture medium, and dilute 
human platelet poor plasma (8% PPP in 20% PBS, n = 1) . The size distribution 
profiles of 8% PPP, n = 1 with a blank sample are also presented. 
4.3.3 Nanoparticle-Induced Oxidative Stress and Free Radicals 
The reactivity of substances and oxidation within the living organism has been reported to be an 
important cause of aging and disease.[320] Oxidation and an increase in free radicals within the 
human body was found to damage cells, tissues, and DNA, causing tumour development and 
influencing many illnesses such as cancer, rheumatoid arthritis, intestinal inflammatory diseases, 
and neurodegenerative diseases.[320] The measurement of the oxidative stress of the nanoparticles 
is therefore important in the assessment of their safety. 
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The oxidative stress induced by the four nanoparticles in this study, plus a positive and negative 
nanoparticle control,  were assessed at 37°C by two methods; ascorbic acid (AA) depletion assay 
[321] and electron paramagnetic resonance (EPR) of DMPO which is a free-radical spin trap [322] 
(see Appendix 1 for chemical structures of ascorbic acid and DMPO). Ascorbic acid is an 
antioxidant, it reacts with free metals, reactive oxygen species or light and is oxidised to form 
dehydroascorbic acid. A decrease in the reduced form of ascorbic acid, can be detected and 
quantified by monitoring the UV absorption of a sample at 265 nm. This assay was used to 
determine whether the nanoparticle species included in this study were redox active or contained 
redox active impurities. Titanium dioxide (TiO2) nanoparticles, which do not induce oxidative 
stress or generate free radicals were used as a negative control. Copper oxide (CuO) nanoparticles, 
which are known to induce oxidative stress through release of Cu
+
 ions was included in the study as 
a positive control.  
Preliminary assay development tests were carried out to determine the optimal number of UV 
scans during a given experiment and to check for sources of heavy metal contaminants in the 
system (Figure 50 and Figure 51). It was interesting to observe that ascorbic acid was depleted 
more quickly if the UV absorption was measured more frequently over a given time period in the 
same sample (Figure 50). Therefore, in all final studies, a low frequency of 4 measurements per 
experiment was chosen. In a second experiment, DTPA was added to a fresh sample of SPNs, 
which had been previously observed to induce a high rate of AA depletion (i.e. the sample was 
unexpectedly highly redox active). DTPA is a metal chelator which, if added to the nanoparticle 
suspensions prior to the addition of the ascorbate, can chelate any free metal ions in the solutions 
and inhibit their interaction with the ascorbate. The decrease in the ascorbic acid depletion rate with 
the presence of DTPA in the SPN suspension shown in Figure 51 suggests that the nanoparticles 
were metal contaminated. Prior to this test, the SPNs had been synthesised with old glassware and 
equipment and in normal de-ionised water. The same SPN suspension was then purified (by 
successive washing, which entailed dilution of 1.5 mL SPN suspension in 10 mL of Chelex
®
 
treated water, filtration through a Millipore Amico Ultra-15 3,000 Dalton MWCO centrifugal filter 
and repetition of this process four times), and the AA depletion rate test repeated. The AA 
depletion rate, shown in Figure 51, was found to decrease by 4 fold after SPN purification. 
However, it was still higher than that of the SPN suspension with DTPA. This lead to the decision 
that the nanoparticles prepared for all future biological studies should be synthesised with new 
glassware, in Chelex
®
 treated and pH adjusted water, as well as extensively purified. 
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Figure 50 Ascorbic acid (AA) depletion rate of aqueous SPNs with different exposure times 
to the excitation of the absorption spectrometer over a period of two hours. Values 































Figure 51 Ascorbic acid depletion rate of purified and non-purified SPNs in the presence and 
absence of DTPA. 
Figure 52 shows the AA depletion rates for all nanoparticle suspensions tested, and Table 10 
states the statistical significance p-values between each of the nanoparticles with or without DTPA 
and the controls (using a Student’s paired t-test with a two tailed distribution). As expected, all AA 
depletion rates for SPNs and QDs, which were prepared with the precautions mentioned above and 
extensively purified, were significantly lower than that of CuO nanoparticles, indicating that both 
the SPNs and QDs were not as reactive as the positive control. Interestingly, though, all SPNs and 
QDs showed a slightly, but significantly elevated AA depletion rates compared with TiO2, 
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implying that they did have a slightly higher surface reactivity than the negative control. This 
reactivity could be a result of gadolinium, cadmium or selenium released in small quantities due to 
the fact that Gd-SPN, QDs and cQDs all showed a slight, but significant reduction in AA depletion 
in the presence of the heavy metal chelator, DTPA. Both SPNs and TiO2, however, did not show 
significant differences in AA depletion with or without DTPA, which suggests that the SPNs 
samples, similar to the negative control, did not contain significant amounts of heavy metals. As all 
four nanoparticles were incident to the same metal contamination precautions in their syntheses and 
handling, and they had undergone the exact same purification process as the SPNs, it is well 
understood that the metal contamination is therefore generated by the nanoparticles themselves 
other than any outer cause. 
 
Figure 52 Ascorbic acid depletion assay of the nanoparticles, compared to a blank sample, 
with/without DTPA. CuO and TiO2 are positive and negative controls respectively. 
Statistical significance is noted by (α) for significant difference between 
nanoparticles with/out DTPA, (*) for significant difference between nanoparticles 
and CuO, and (β) for significant difference between nanoparticles and TiO2. Single 
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Table 10 Statistical p-values, obtained using a Student’s paired t-test with a two tailed 
distribution, stating the statistical significance between the nanoparticles with or 
without DTPA in comparison to the positive and negative controls; p-values ˂ 0.05 
denote a significant difference, while p-values ˃ 0.05 (highlighted with red) denote 
a non-significant difference: 
Nanoparticle p-value with CuO p-value with TiO2 
p-value (nanoparticle 
with/out DTPA) 
SPNs 0.005375615 0.018048586 0.33461921 
Gd-SPNs 0.003816073 0.00319423 0.007136606 
QDs 0.01338112 0.002116387 0.009910223 
cQDs 0.018205062 0.002626244 0.032592427 
CuO N/A 0.00323474 0.006810687 




(CuO + DTPA) 
p-value with 
(TiO2 + DTPA) 
p-value (nanoparticle 
with/out DTPA) 
SPNs with DTPA 0.129290758 0.08113347 As above 
Gd-SPNs with DTPA 0.067023518 0.445262924 As above 
QDs with DTPA 0.121544655 0.147254984 As above 
cQDs with DTPA 0.243471244 0.158481537 As above 
CuO with DTPA N/A 0.070693544 As above 
TiO2 with DTPA 0.070693544 N/A As above 
 
Electron paramagnetic resonance was performed (by Mr David Parker, King’s College London) 
to compliment the AA depletion assay. DMPO which is initially EPR silent, acts as a spin trap for 
short-lived free radicals such as •OH and •OOH. Upon contact with a free hydroxyl radical, DMPO 
reacts with it and becomes EPR active with a half-lifetime of minutes (< 2.9 min for •OH and 1 
min for •OOH) [322]. No free radicals were detected with DMPO in the four different nanoparticle 
suspensions under study (section 5.9.6 for experimental procedures). Also no free radicals were 
detected in a more highly concentrated MEH-PPV SPN suspension (ca. 180 µg/mL), which 
reflected the higher concentrations used in the following biological assays. Moreover, exciting the 
nanoparticles at 254 nm and 365 nm prior measurements did not generate any detectable free 
radicals. 
In summary, both the EPR measurements and the AA depletion assay performed with/out the 
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presence of DTPA suggest a low oxidative potential of the SPNs, Gd-SPNs, QDs, and cQDs after 
manufacture (when using manufacturing conditions that reduce heavy metal impurities). EPR also 
suggests that the depletion of the ascorbic acid in the non-DTPA containing nanoparticle solutions 
is most probably attributed to leaching cadmium from the cores of the QDs [86] and escaping 
gadolinium atoms from the surfaces of the Gd-SPNs [226] rather than due to any free radical 
production. Therefore, this study suggests that all four nanoparticles have a low propensity to 
induce oxidative stress following manufacture.  
4.4 Nanoparticle Interactions with Human Blood Components 
4.4.1 Interactions of Nanoparticles with Platelets and their Effect on ADP-induced Platelet 
Aggregation in Isolated Platelets 
Platelet aggregation in isolated human platelet rich plasma (PRP) was assessed using a PAP-4 
Bio-Data Corporation platelet aggregometer, which measures the changes in the optical density of 
100% PRP over time following the addition of the substance of interest. The instrument was 
calibrated by measuring the (high) optical density of each individual donor sample of 100% PRP 
and assigning this value as “0% platelet aggregation”. Next, a sample of platelet poor plasma (PPP) 
was produced from each donor by removing all platelets through centrifugation and measuring the 
(low) optical density of the sample, which is designated by the instrument as “100% platelet 
aggregation”. To perform a sample measurement, the possible agonist, in this case, the 
nanoparticles, was then added to a fresh PRP sample and changes in the optical density of the 
continuously-stirred PRP were monitored over time. 
Three concentrations of nanoparticles were chosen for the assessment of potential to induce 
platelet aggregation (300, 30, and 3 µg/mL PRP), with the highest concentration chosen to reflect a 
concentration of Gd-SPNs which has a considerable relaxation time that is useful in MRI 
applications [97] (section 3.8). In preliminary tests, the addition of nanoparticle suspensions to PRP 
was not observed to induce significant aggregation over a 5 minute time period at the doses tested 
(example in Figure 53). However, because the nanoparticle suspensions of the higher 
concentrations were also optically dense, changes in the measured turbidity may not only reflect 
platelet aggregation, but also particle aggregation. This is a significant disadvantage of the standard 
platelet aggregometer assessment technique when applied to test nanomaterial interactions. Of the 
few studies in the literature, most have not reported direct assessment of nanoparticle-induced 
platelet aggregation, at least at high concentrations, with this technique. However, some studies 
have reported nanoparticle-induced changes to the platelet response to endogenous agonists, such 
as ADP.[278] Therefore, this experiment was also performed.  




Figure 53 Example of platelet aggregation profiles (Aggregometer raw data of one of the 
donors) with the addition of (1) a blank sample, a final concentration of 0.2 µg/mL 
of (2) QDs, (3) SPNs, and (4) Gd-SPNs. 
Figures 54 - 56 show the individual response profiles of platelets isolated from three different 
donors (D1-D3) to 10 μM ADP after incubation with 0, 3, 30 and 300 µg/mL SPNs, Gd-SPNs, 
QDs, and cQDs.  The aggregation profiles from each donor are depicted to highlight the natural 
inter-experiment and inter-individual variation in platelet response to any given agonist. For 
example, platelets of the same donor may show approximately 20% variation in the maximum 
aggregation levels achieved in response to 10 μM ADP, as is depicted by the top panels in Figures 
54 - 56. It is also noticeable that the maximum response between donors is highly variable, with 
80-100% platelet aggregation observed for D1 platelets, 40-60% observed for D2 and only 10-30% 
observed for D3. This means that any influence of nanoparticles on the platelets, must be 
considered as normalised to each individual blood donor. 
The bottom panels of Figures 54 - 56 depict platelet responses to ADP in the presence of 
increasing nanoparticle concentrations (3, 30, and 300 µg/mL PRP). These platelet aggregation 
profiles, although again showing both inter-experiment and inter-individual variation, are similar to 
those of the blank sample, suggesting that the nanoparticles did not influence ADP-induced platelet 
aggregation in a dose-dependent manner. Figure 57 depicts the maximum % platelet aggregation of 
the three donors combined. Values for each nanoparticle dose were normalised by subtracting the 
average of the three maximum response values to ADP alone. The normalised results of the three 
donors were then regarded as three replicates of one experiment (n = 3), these values were 
averaged, and the resulting change in % maximum platelet aggregation was plotted in Figure 57. 
The summarized data show no obvious change in platelet % aggregation vs. increased 
concentration, and the high standard deviations which extend across the baseline for most data, 
suggest that there is no obvious effect of the nanoparticles to the ADP-induced platelet aggregation. 
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These results differ from reports published previously, which will be discussed in greater detail 
below. 
 
Figure 54 Traces from Donor 1 (D1) showing platelet responses to different concentrations of 
nanoparticles (i.e. baseline values over ~ the first minute of the measurement 
profile), and to the addition of 10 µM ADP to platelets in the presence of the 
nanoparticles (i.e. initiation of platelet aggregation curves). The top panel (0 
µg/mL nanoparticles) represents the donor response to 10 μM ADP alone (n = 3 
repetitions). In each graph where nanoparticles are present in the sample, the red 
notations denote (1) SPNs, (2) Gd-SPNs, (3) QDs, and (4) cQDs. 




Figure 55 Traces from Donor 2 (D2) showing platelet responses to different concentrations of 
nanoparticles (i.e. baseline values over ~ the first minute of the measurement 
profile), and to the addition of 10 µM ADP to platelets in the presence of the 
nanoparticles (i.e. initiation of platelet aggregation curves). The top panel (0 
µg/mL nanoparticles) represents the donor response to 10 μM ADP alone (n = 3 
repetitions). In each graph where nanoparticles are present in the sample, the red 
notations denote (1) SPNs, (2) Gd-SPNs, (3) QDs, and (4) cQDs. 




Figure 56 Traces from Donor 3 (D3) showing platelet responses to different concentrations of 
nanoparticles (i.e. baseline values over ~ the first minute of the measurement 
profile), and to the addition of 10 µM ADP to platelets in the presence of the 
nanoparticles (i.e. initiation of platelet aggregation curves). The top panel (0 
µg/mL nanoparticles) represents the donor response to 10 μM ADP alone (A, B, 
and C are n = 3 repetitions). In each graph where nanoparticles are present in the 
sample, the red notations denote (1) SPNs, (2) Gd-SPNs, (3) QDs, and (4) cQDs. 
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Figure 57 Percentage change in ADP-induced maximum % platelet aggregation in the 
presence of the nanoparticles at three different concentrations (3 µg/mL, 30 µg/mL, 
and 300 µg/mL; n = 3) normalised to the average ADP-induced maximum % 
platelet aggregation of each donor when no nanoparticles are present (baseline 
value which is set at a value of 0). 
In previous studies, Geys et al. and McGuinnes et al. used carboxyl/amine capped nanoparticles 
and reported changes in platelet aggregation profiles with comparably high concentrations of their 
surface functionalised nanoparticles [278, 289]. The major difference between these  systems and 
the results from this study is that the cQDs used here have a significantly lower negative zeta 
potential and are also partially PEGylated. As previously mentioned, PEG was reported to 
significantly reduce interactions between nanoparticles and biological species such as proteins and 
cells [210]. Further, it seems that a substantial positive or negative zeta potential value is required 
to activate platelets and induce aggregation. Thus, the moderate number of carboxylic groups 
introduced into the cQD surface coating in this study did not seem sufficient to influence platelet 
aggregation directly. Another important observation from the current study was that the four 
nanoparticles did not indirectly influence the endogenous platelet aggregation pathway in response 
to ADP, as has been demonstrated for other types of nanomaterials including functionalised QDs 
[278]. In summary, the desired passive behaviour of the platelets to the nanoparticles in the isolated 
platelets assays supports their profile as bio-compatible nanomaterials [323]. 
4.4.2 Interactions of SPNs and QDs with Human Whole Blood Components 
Due to the limitations of assessing nanoparticle-induced platelet aggregation using turbidity-
based methods, such as the conventional platelet aggregometer, alternative methods for assessing 
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interactions between nanoparticles and blood components may be useful. For example, 
fluorescence activated cell sorting (FACS) analysis has also been used to assess the activation of 
platelets, neutrophils, and monocytes in response to the presence of nanoparticles [289]. A flow 
cytometer is used to selectively detect and quantify cell surface proteins which are known to be 
upregulated in specific blood cells when they become activated in response to either an endogenous 
or exogenous stimulant.  Using FACS analysis, three major questions were addressed in this study: 
1. Do SPNs and QDs activate platelets? 
2. Do SPNs and QDs promote adhesion of platelets to circulating monocytes? 
3. Do SPNs and QDs activate neutrophils? 
4.4.2.1 Do SPNs and QDs Activate Platelets? 
Platelets are coated with different glycoproteins which play an important role in platelet 
activation and thus reaction with its surroundings (adhesion and aggregation). For example, 
platelets adhere to collagen (available on the cell membranes of endothelial cells) through 
glycoprotein Ia (GPIa) available on their membranes. Platelets also bind to fibrinogen (a soluble 
plasma protein which is converted by the enzyme (thrombin) to fibrin monomers which in turn 
polymerise and cross-link to form insoluble fibrin polymer which leads to blood clotting) and to 
Von Willebrand Factor (VWF - which is an adhesion molecule mostly produced by the endothelial 
cells) through glycoproteins Ib and IIb/IIIa (GPIb and GPIIb/IIIa) also available on the platelets’ 
surface. Non-activated platelets have about 50 – 80 000 GPIIb/IIIa receptors (also called CD41a 
proteins) which do not bind to VWF or fibrinogen, etc. However, upon activation, platelets undergo 
an increase in these glycoprotein receptors which then enable platelet cross-linking with fibrinogen 
bridges. Also, when platelets are activated, other proteins located in their storage granules migrate 
and translocate to their surface facilitating their different interactions. One of these expressed 
proteins on the surface of activated platelets is called P selectin platelet alpha-granule membrane 
protein (CD62P).[261, 324] 
Platelet activation can be detected by the measure of CD62P expression against the measure of 
CD41a. This can be performed by the use of fluorescently labelled animal antibodies which 
recognise the specific human proteins as antigens (i.e. foreign bodies) and therefore bind to 
them.[261] Mouse anti-human CD41a-FITC conjugate (fluorescein isothiocyanate; λex = 488 nm, 
λem = 520 nm; BD Biosciences) can be used to label platelets in a blood sample, and mouse anti-
human CD62P-PE conjugate (R-phycoerythrin; λex = 496 nm, λem = 578 nm; BD Biosciences) can 
be used to label activated platelets in the same sample (each antibody is selectively labelled with a 
fluorophor of different wavelength). The FACS analysis will detect the fluorescence intensity of 
the total labelled antibodies adhering to each platelet surface and provides quantitative information 
on the percentage of activated platelets within a given cell population. 
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Because of the passive behaviour of the human platelets in the presence of the nanoparticles in 
the previous investigation (platelet aggregation in section 4.4.1), it was hypothesised that the 
nanoparticles would not induce upregulation of platelet activation markers. To test this, platelets 
were isolated from four healthy human donors (n = 4) and incubated with 300 μg/mL of the 
different nanoparticle suspension, 0.9% NaCl in water (negative control) or 300 μg/mL 
carboxylated polystyrene beads (cPS; 50 nm; [289]; positive control) prior to incubation with the 
labelled antibodies, CD41a and CD62P. To account for the possibility of fluorescence overlap 
between the nanoparticles and the CD62P signal, it was important that fluorescence from the 
background control samples was subtracted from the fluorescence of each sample containing 
antibodies. Elevated fluorescence levels of the background-corrected (i.e. normalised) CD62P 
signal denoted platelet activation.  Figure 58 depicts the percentage of platelets from a population 
of 100,000 cells which exhibited elevated levels (above the designated threshold value) of CD62P.   
 
Figure 58 The percentage of activated platelet cells from a population of 100,000 after 
incubation with nanoparticles, the negative (0.9% NaCl in water) or positive (cPS) 
controls (data points represent the values from n = 4 donors). 
Figure 58 shows that incubation of the isolated platelets of all four donors with NaCl did not 
show any CD62P expression, which is what was expected from a negative control. However, 
incubating the platelets with cPS (the positive control) only showed an increased CD62P 
expression in the platelets of two donors (from n = 4). This shows the natural variation of platelet 
activation in the platelets of different humans, similar to the variation of ADP-induced platelet 
aggregation investigated previously (section 4.4.1). Because 50% of the donors in this investigation 
did not react positively to cPS, it is advisable to repeat the experiment with a greater number of 
donors in the future to obtain a more significant result. However, because cPS was reported in the 
literature to cause platelet activation [289], the initiation of platelet activation in half the donors in 
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this study is arguably significant, and cPS was still considered a working positive control. 
There was an overlap between the fluorescence spectra of the SPNs and the antibodies used. 
Therefore, it was important to subtract the fluorescence of the SPNs (as background) from the 
fluorescence of the samples containing both SPNs and antibodies. However, this approach did not 
solve the problem adequately since the background fluorescence (platelets + SPNs) varied 
considerably, possibly due to a random distribution of SPNs adhering to the platelet surface.  This 
variability  resulted in non-reliable CD62P expression values. To overcome this problem, this 
fluorescence overlap has to be avoided entirely, probably by the use of SPNs which emit in a 
different wavelength range than the antibodies such as PPE SPNs, or vice versa. 
The fluorescence of the QDs, on the other hand, did not interfere with the results as their 
fluorescence was adequately quenched in these experiments. Therefore, the results of the QDs 
(shown in Figure 58) are reliable and show that both QDs and cQDs did not activate platelets. It is 
again interesting to note that the moderate carboxylation of the cQD surface in combination with 
the PEGylation, did not induce CD62P upregulation as was observed for the carboxylated 
polystyrene nanoparticles both in this study and the study of McGuinnes et al. [289] As stated in 
the previous section, this is most likely due to the combined effect of steric shielding of PEG and 
the moderately low overall surface charge.  In summary, these results correspond well with the 
platelet aggregation study from the previous section and demonstrate that the PEGylated 
phospholipid coating of the nanoparticles under investigation is effective in preventing platelet 
activation and aggregation events. Although the results from the SPNs were inconclusive at this 
point, further studies with a different core material will likely confirm the hypothesis that the 
coating material effectively prevents platelet activation and aggregation.  However, it is valuable to 
note that compared to the QDs, the SPN fluorescence was not quenched in the biological 
environment, but rather was extremely stable and bright, indicating again the potential usefulness 
of the system for bio-imaging applications. 
4.4.2.2 Do SPNs and QDs Promote Platelet-Monocyte Adhesion? 
Similar to the membranes of platelets, monocyte membranes contain specific glycoproteins 
which if detected, can be used to distinguish them from the rest of the blood cells. CD14 is one of 
these glycoproteins. It is a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein 
expressed on monocytes, macrophages, and more weakly on neutrophils.[261] 
Platelet-monocyte adhesion can be detected by the measure of CD41a and CD14 in the same 
population. Mouse anti-human CD14-PE-Cy7 conjugate (R-phycoerythrin; λex = 488 nm, λem = 775 
nm; BD Biosciences) can be used to detect monocytes in a blood sample[289], while mouse anti-
human CD41a-FITC conjugate (fluorescein isothiocyanate; λex = 488 nm, λem = 520 nm; BD 
Biosciences) can be used to detect platelets in the same sample.With the use of FACS analysis, the 
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counted population which emits in the wavelengths of both labels is then considered a population 
of platelet-monocyte aggregates.  
In this component of the analysis, platelet-monocyte adhesion was evaluated in whole blood 
from four healthy human donors (n = 4) also after incubation with the nanoparticles.  Again, 0.9% 
NaCl in water was used as a negative control and commercially available carboxylated polystyrene 
beads (cPS; 50 nm; [289]) were used as a positive control. Briefly, whole blood was incubated for 
five minutes with each nanoparticle or control suspension and divided into two equal volumes.  
One volume was mixed with fluorescently-tagged antibodies against CD41a (the platelet marker) 
and CD14 (the monocyte marker) and the second volume was processed without antibodies as a 
background control (section 5.9.9 for details). FACS was then used to count individual monocytes 
(or monocyte-platelet aggregates) which displayed the CD14 fluorescence signal. The CD41a 
fluorescence signal was measured simultaneously. As discussed previously, to account for the 
possibility of fluorescence overlap between the nanoparticle and the CD41a (platelet) signal, it was 
important that fluorescence from the background control samples was subtracted from each sample 
containing antibodies. Elevated fluorescence levels of the background-corrected (i.e. normalised) 
CD41a signal denoted that one or more platelets had adhered to the surface of the individual 
monocytes counted.  Figure 59 depicts the percentage of monocytes with platelets detected on their 
surface from a population of 3,000 cells.   
 
Figure 59 The percentage of monocytes (from 3,000 cells counted) with one or more platelets 
adhered to the surface after incubation with nanoparticles, the negative (0.9% NaCl 
in water) or positive (cPS) control (n = 4 donors). 
Incubating whole blood with NaCl showed no detectable platelets within the population of 
monocytes (see Figure 59) as expected. As for the positive control, it is well understood that 
platelet-monocyte adhesion is initiated by platelet activation. Therefore, the results obtained from 
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incubation with cPS in this section must follow the results obtained in the previous section. As 
expected, two out of four donors did show an increased CD41a expression within the monocyte 
population (see Figure 59), which means that 50% of the donors showed platelet-monocyte 
adhesion after incubation with cPS. Again, the use of a greater number of replicates (more than 
n=4) is necessary for more significant results for cPS to be considered as a strong positive control. 
The problem of fluorescence overlap in the SPN samples was also apparent here. Therefore, the 
results shown in Figure 59 for both SPNs and Gd-SPNs are not reliable. This was not the case with 
the QDs and cQDs which were already quenched prior to the experiment. Figure 59 shows that 
there was no noticeable CD41a expression within the monocyte population after incubation with 
the QDs and cQDs. This means that both QDs did not cause any platelet-monocyte adhesion. This 
result is comparable to the results of McGuinnes et al. [289] which reported that there was no 
significant difference between their surface modified and non-modified nanoparticles in terms of 
platelet-monocyte aggregate formation. However, McGuinnes et al. did detect platelet-monocyte 
aggregates with all three types of nanoparticles, while we here did not detect any aggregates at all. 
Again, the stealth effect of the partial PEGylation of the QDs and cQDs here could be the reason 
behind this passive behaviour of the blood components. 
4.4.2.3 Do SPNs and QDs Activate Neutrophils? 
Similar to platelets and monocytes, neutrophils have specific glycoproteins which are readily 
expressed on their surfaces. One of which is CD16 (a glycosylphosphatidylinositol (GPI)-anchored 
integral membrane protein expressed on T-cells, neutrophils, and macrophages). Another 
glycoprotein which is upregulated in activated neutrophils is CD11b (αM integrin chain, MAC-1 or 
complement receptor 3). CD11b is a cell surface receptor found on activated (pro-inflammatory) 
neutrophils, which acts as an adhesion molecule to help neutrophils ‘stick’ to the endothelium and 
migrate to inflamed tissues. CD11b is weakly expressed on non-activated neutrophils, but is 
strongly expressed on activated ones.[261] Therefore, the measure of CD11b (with the use of 
mouse anti-human CD11b–Alexa Fluor 700 conjugate (λex = 633 nm, λem = 723 nm; EBiosciences)) 
against CD16 (with the use of mouse anti-human CD16-PE-Cy7 conjugate (R-phycoerythrin; λex = 
488 nm, λem = 775 nm; BD Biosciences)) can give a measure of the percentage of activated 
neutrophils within a blood sample. 
In this experiment, neutrophil activation was evaluated in whole blood from four healthy human 
donors (n = 4) after incubation with the nanoparticles. Briefly, whole blood was incubated for five 
minutes with each nanoparticle or control suspension and divided into two equal volumes.  One 
volume was mixed with fluorescently-tagged antibodies against CD11b (the neutrophil activation 
marker) and CD16 (the neutrophil marker) and the second volume was processed without 
antibodies as a background control (section 5.9.10 for details). FACS was then used to count 
Zeina M. A. Hashim,   PhD Thesis 
107 
 
individual neutrophils which displayed the CD16 fluorescence signal. Expression of CD11b was 
measured simultaneously. Elevated fluorescence levels of the background-corrected (i.e. 
normalised) CD11b signal denoted neutrophil activation.  Figure 60 depicts the percentage of 
activated neutrophils from a population of 3,000 cells.   
 
Figure 60 The percentage of activated neutrophils (from 3,000 cells counted) with elevated 
levels of CD11b after incubation with nanoparticles, the negative (0.9% NaCl in 
water) or positive (cPS) control (n = 4 donors). 
Minor variations in CD11b were detected after incubating the blood samples with both NaCl 
and cPS (Figure 60), with the amount of expressed CD11b with the cPS samples not elevated in 
comparison to NaCl. This suggests that highly carboxylated polystyrene nanoparticles did not 
activate neutrophils and therefore could not be used as a positive control. 
Again, with the overlap of fluorescence problem with the SPN samples which also caused a 
calculated negative response in most of the samples (compared to NaCl – the negative control), no 
reliable information could be depicted about the effect of the SPNs and Gd-SPNs on neutrophil 
activation. 
The QDs however, did showed a possible trend towards a slight elevation in CD11b expression.  
With the lack of fluorescence overlap (because the fluorescence of the QDs was already quenched 
in this experiment), this suggests that the QDs and cQDs might have caused a moderate increase in 
neutrophil activation. However, it is necessary to repeat this experiment with a greater number of 
donors before making a solid conclusion about the QDs’ tendency towards neutrophil activation. 
This was not investigated by McGuinnes et al. [289] nor has been reported elsewhere in the 
literature. 
Zeina M. A. Hashim,   PhD Thesis 
108 
 
4.4.3 Evidence of SPN Interactions with Blood Cells 
As described above, the experiments revealed a very high signal to noise in the detected 
fluorescence from isolated platelets and whole blood after incubation with the SPNs or Gd-SPNs. 
Fluorescence microscope imaging (performed by Dr Lea Ann Dailey, section 5.9.11 for details) of 
platelets, neutrophils, and monocytes incubated with SPNs or Gd-SPNs revealed that the 
nanoparticles were either internalised or adhered to the surfaces of many of the blood components 
(some of the obtained images are shown in Figure 61). We therefore concluded that the high and 
variable fluorescence signal from the SPN interactions with the cells made the process of 
background correction unreliable. Extensive method optimisation was performed to try to 
overcome this issue, without great success. Thus, in order to robustly assess the questions from this 
chapter, future studies must either use alternative semi-conducting polymers with emission spectra 
that do not overlap with the chosen fluorophores of the detection antibodies, or non-fluorescence 
based analytical methods must be employed. 
 
Figure 61 Fluorescence microscope images (20x magnification) of blood components 
incubated with SPNs or Gd-SPNs; (A) SPN fluorescence (λex = 488 nm, λem = 520 
nm; pseudo-coloured green) is detected at the cell membrane of blood neutrophils. 
(B) Gd-SPN fluorescence (λex = 488 nm, λem = 520 nm; pseudo-coloured green) is 
detected both at the cell membrane and in internal compartments of blood 
monocytes. (C) SPN fluorescence (λex = 488 nm, λem = 520 nm; pseudo-coloured 
red) is detected at the cell membrane of blood platelets.  
A surprising and notable observation from the images in Figure 61  is the extent to which SPNs 
interact with different types of blood cells. According to the literature, the PEGylated coating 
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should reduce nanoparticle internalisation by phagocytic cells, such as monocytes and neutrophils 
[306-310]. Further, it is unexpected to see nanoparticles adhering to cell surfaces of both 
leukocytes and platelets. This adhesion may have also interfered with antibody binding to cell 
surface markers in the FACS experiments and should be investigated further in future. However, it 
will also be worthwhile to investigate the impact of PEG density and chain length on the 
interactions between SPNs and blood cells, as this factor may greatly influence nanoparticle 
circulation times and clearance after intravenous administration. 
4.5 Conclusions 
To achieve clinical use of any nanoparticles in the bio-imaging and medical fields, it is 
necessary to assess their safety. In this chapter, selected exploratory investigations were performed 
to assess the interactions of the Gd-SPNs we prepared in chapter 3 along with non-gadolinium 
containing SPNs and similar-lipid coated QDs and carboxylated QDs (cQDs) with components of 
human blood. 
The nanoparticles were synthesised under controlled conditions to avoid metal contamination 
and their optical properties after synthesis were characterised. Then they went through several 
investigations to answer the following questions: 
(a) What surface charge do they have? How does this surface charge change when they are 
exposed to different biological media? 
(b) Are the nanoparticles colloidally stable in different biological and synthetic media? 
(c) What is the status of their oxidative stress? Do they generate any free radicals? 
(d) How do the nanoparticles interact with the different blood components? 
1. Do they cause any platelet aggregation? 
2. Do they affect ADP-induced platelet aggregation? 
3. Do they cause any platelet activation? 
4. Do they cause any platelet-monocyte adhesion? 
5. Do they cause any neutrophil activation? 
In more detail, zeta potential measurements were performed to determine the nanoparticle 
surface charges. Their surfaces were found to be moderately negatively charged, with the negative 
charge increasing on the surfaces of both Gd-SPNs and cQDs. The negative charge was found to 
decrease in dilute platelet poor plasma which indicated adsorption of species on the surfaces of the 
nanoparticles in general and increasingly on the surfaces of both Gd-SPNs and cQDs. 
Nanoparticle colloidal stability in different biological and synthetic media at 37°C was 
monitored for 24 hours. Both SPNs and Gd-SPNs were stable in water and in cell culture medium. 
The QDs were also stable in water, however, the cQDs were not. The cQDs showed evidence of 
aggregation over time which is not what was expected from carboxylated nanoparticles. Adding the 
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QDs and cQDs to cell culture medium (CCM) resulted in a shift of the small distribution towards 
the larger distribution which suggested that CCM acted as a colloidal stabilisers adsorbing on the 
surfaces of the smaller nanoparticles increasing their diameters. Finally, no information was 
gathered from adding the nanoparticles to dilute platelet poor plasma (PPP) as the detected 
diameters had a fluctuating distribution in all samples similar to that of the dilute PPP. 
The nanoparticles were found not to induce platelet aggregation nor affect ADP-induced platelet 
aggregation. Furthermore, FACS analysis showed that both QDs and cQDs did not induce platelet 
activation nor platelet-monocyte adhesion. However, it did show that they do have a tendency to 
activate neutrophils. More experimentation with a greater number of donors is needed to strengthen 
this conclusion. Moreover, there was a significant overlap between the fluorescence of the 
SPNs/Gd-SPNs and the antibodies used in the FACS analysis. With the detection of a variable 
background, it was not possible to depict any reliable information about the SPNs/Gd-SPNs effects 
on the blood components in the three investigations conducted with this anaylsis technique (platelet 
activation, platelet-monocyte adhesion, and neutrophil activation). 
The SPNs and Gd-SPNs were also found to adhere to blood components. The adhesion of the 
organic nanoparticles to the surfaces of the blood components could find an application in the 
future. However, from a safety assessment prospective using fluorescence related detection 
methods such as FACS, such highly fluorescent adhesive nanoparticles are problematic, therefore, 
ways to avoid their interference with the analysis results need to be explored. One way to 
compensate for this problem in the future is to use a different detection method which does not 
depend on optical properties, another way is to use SPNs which do not overlap at the same 
emission region of the markers (such as the blue emitting PPE SPNs), or vice versa. 
Finally, the studies conducted in this chapter represent only a very preliminary approach to 
begin the evaluation of safety necessary for development of these nanoparticles as medical 
diagnostic tools. However, the results and conclusions in this chapter show an encouraging lack of 
reactivity with regard to platelet activation and aggregation events, as well as neutrophil activation.  
Future studies will explore the relationship between surface coating and nanoparticle adherence or 
internalisation into a variety of cells.  Furthermore, cell viability studies and in-vivo safety testing 
must be carried out in the future.  However, this study does highlight how useful it can be to 
perform parallel investigations of nanoparticle manufacture, physicochemical characterisation and 
evaluation with biological systems, with the aim of advancing the development of SPNs as 
potentially safer, more effective alternatives to quantum dots for biomedical imaging applications.   




5.1 Chemicals for the Nanoparticles Syntheses 
5.1.1 Conjugated Polymers and Quantum Dots 
The five commercially available polymers used in the syntheses were: 
1. BEHP-PPV: Poly[2-(2’,5’-bis(2’’-ethylhexyloxy)phenyl)-1,4-phenylenevinylene] 
(minimum MW 30000 g/mol). 
2.  MEH-PPV: Poly[2-methoxy-5-(2-ethylhexyloxy)-1,4-phenylenevinylene] (MW 40000 – 
70000 g/mol). 
3. F8BT: Poly[(9,9-di-n-octylfluorenyl-2,7-diyl)-alt-(benzo[2,1,3]thiadiazol-4,8-diyl)] (MW 
5000 – 8000 g/mol). 
4.  PPE: Poly[2,5-di(3’,7’-dimethyloctyl)phenylene-1,4-ethynylene] (MW 4122 g/mol). 
5.  ADS108GE: Poly[(9,9-dioctyl-2,7-divinylene-fluorenylene)-alt-co-(2-methoxy-5-(2-ethyl-
hexyloxy)-1,4-phenylene)] (MW 111000 g/mol).  
 
All polymers were obtained from Sigma-Aldrich, except for ADS108GE which was obtained 
from American Dye Source, Inc. All polymers were used as received. 
 
The quantum dots used in the nanoparticle-cell interaction studies in chapter 4 were (Lumidot
TM
 
CdSe/ZnS 590), which were obtained from Sigma-Aldrich. 
5.1.2 Surfactants 
The surfactants used in the syntheses of the QD-sized PEG capped/entwined SPNs were: 
1. PEG: Poly(ethylene glycol) (a range of MWs; 300, 200, 8000 g/mol), obtained from Sigma-
Aldrich. 
2.  PEG-dithiol: Poly(ethylene glycol) dithiol (MW 1530 g/mol) obtained from Sigma-
Aldrich. 
 
The lipids used in the syntheses of the SPNs, Gd-SPNs, QDs, and cQDs were: 
1. PEG2000-PE: 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethyleneglycol)-2000] (ammonium salt), obtained from Avanti Polar Lipids. 
2. DPPC: 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, obtained from Avanti Polar Lipids. 
3. Gd-DTPA-BSA: (diethylenetriaminepentaacetic acid)-bis(stearylamide) (gadolinium salt), 
obtained from IQsynthesis, Inc.  
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4. DSPE-PEG2000 carboxylic acid: (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[carboxy(polyethylene glycol)-2000] (ammonium salt)), obtained from Avanti Polar Lipids. 
 
All surfactants were used as received. 
5.2 Nanoparticles Syntheses 
5.2.1 Final Miniemulsion-Evaporation Synthesis of the PEG Capped/Entwined QD-sized 
SPNs 
Five polymers were used to form the nanoparticles; BEHP-PPV, MEH-PPV, F8BT, PPE, and 
ADS108GE. 
In a typical synthesis, 0.424 mg of the conjugated polymer was dissolved in 8 mL of 
dichloromethane (DCM) to form a 40 ppm (by weight) solution. 0.01 g PEG300 was added to 20 
mL of deionised water and stirred in a covered conical flask for ten minutes. The 40 ppm 
conjugated polymer solution was then added drop-wise to the aqueous PEG solution while stirring 
vigorously. The mixture was covered and left to stir vigorously for 10 minutes. Next, the conical 
flask was suspended in a 35 kHz ultrasound bath for 20 minutes. The mixture was covered for the 
first 5 minutes then uncovered. Finally, the emulsified solution was transferred to a beaker and 
stirred rapidly to evaporate the remaining DCM. The solution was then filtered through filter paper 
and centrifuged at 5,600 rcf (10000 rpm) for 10 minutes. The purified aqueous solutions were 
stored in glass vials under light exclusion at room temperature. 
5.2.2 Synthesis of QD-sized SPNs Capped/Entwined with PEG-dithiol 
0.051 g PEG-dithiol was used instead of 0.01 PEG300 in the same synthesis described in 
section 5.2.1 to prepare PEG-dithiol capped/entwined QD-sized MEH-PPV SPNs. 
5.2.3 Final Synthesis of the Bimodal Gd-SPNs 
Four polymers were used to form the nanoparticles; MEH-PPV, F8BT, PPE, and ADS108GE. 
Three lipids were used in the outer shell of the nanoparticles; PEG2000-PE, DPPC, and Gd-DTPA-
BSA. 
In a typical synthesis, 25 mg of the conjugated polymer was dissolved in 8 mL of 
dichloromethane (DCM). 11.2 mg DPPC, 37.4 mg PEG2000-PE, and 13.9 mg Gd-DTPA-BSA 
were added to 25 mL of deionised water in a round-bottom flask. To achieve a homogenous lipid 
suspension in water, the flask was covered and sonicated in a 35 kHz ultrasound water bath which 
was maintained at a temperature below 7°C using ice. All samples were subjected to four 
sonication cycles of 60 seconds each, with 30 second rest periods in between each cycle. The lipid 
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suspension was then magnetically stirred for 1 minute and 0.8 mL of the polymer solution was 
introduced with a syringe over a period of 60 seconds. The flask was covered, stirred vigorously for 
10 minutes, then sonicated for 90 seconds at 7°C. Finally, the open flask was gently stirred 
overnight to promote full DCM evaporation and nanoparticle formation. The nanoparticles 
suspensions were stored in glass vials at 4°C. 
5.2.4 Synthesis of Carboxylated MEH-PPV Gd-SPNs for IgG Linkage  
Carboxylated MEH-PPV Gd-SPNs were synthesised as follows: 25 mg of MEH-PPV was 
dissolved in 8 mL of dichloromethane (DCM). 11.2 mg DPPC, 37.4 mg DSPE-PEG2000, and 13.9 
mg Gd-DTPA-BSA were added to 25 mL of deionised water in a round-bottom flask. To achieve a 
homogeneous lipid suspension in water, the flask was covered and sonicated in a 35 kHz 
ultrasound water bath which was maintained at a temperature below 7°C using ice. All samples 
were subjected to four sonication cycles of 60 seconds each, with 30 second rest periods in between 
each cycle. The lipid suspension was then magnetically stirred for 1 minute and 0.8 mL of the 
polymer solution was introduced with a syringe over a period of 60 seconds. The flask was 
covered, stirred vigorously for 10 minutes, then sonicated for 90 seconds at 7°C. Finally, the open 
flask was gently stirred overnight to promote full DCM evaporation and nanoparticle formation. 
5.2.5 Synthesis of the SPNs and Gd-SPNs for the Nanoparticles’ Interactions with Human 
Blood Studies 
SPNs and Gd-SPNs were prepared as in section 5.2.3. MEH-PPV was used to form the 
polymeric core, and two lipids were used in the outer shell of the SPNs: PEG2000-PE and DPPC. 
In the Gd-SPNs, a third lipid, Gd-DTPA-BSA, was also used. 
In a typical synthesis, 25 mg of the conjugated polymer was dissolved in 8 mL of 
dichloromethane (DCM). For the SPNs: 35.5 mg PEG2000-PE and 20.4 mg DPPC were added to 
25 mL of Chelex
®
 100-treated water in a round-bottom flask. For the Gd-SPNs: 40.4 mg PEG2000-
PE, 9.7 mg DPPC, and 14.1 mg Gd-DTPA-BSA were used. To achieve a homogeneous lipid 
suspension in water, the flask was covered and sonicated in a 35 kHz ultrasound water bath which 
was maintained at a temperature below 7°C using ice. All samples were subjected to four 
sonication cycles of 60 seconds each, with 30 second rest periods in between each cycle. The lipid 
suspension was then magnetically stirred for 1 minute and 0.8 mL of the polymer solution was 
introduced with a syringe over a period of 60 seconds. The flask was covered, stirred vigorously for 
10 minutes, then sonicated for 90 seconds at 7°C. Finally, the open flask was gently stirred 
overnight to promote full DCM evaporation. The resulting aqueous nanoparticle suspensions were 
concentrated (section 5.4 and 5.5), purified (section 5.3), and stored in glass vials at 4°C. 
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5.2.6 Preparation of the Quantum Dots for the Nanoparticles’ Interactions with Human 
Blood Studies 
QDs and cQDs were prepared similar to Dubertret et al. [47] as follows: 200 µL CdSe/ZnS QDs 
in toluene (Lumidot
TM
 CdSe/ZnS 590) was precipitated using 1 mL acetone and 5 minutes 
centrifugation at 3214 G (5000 rpm). For the QDs: 8 mg PEG2000-PE, 2.6 mg DPPC, and 2 mL 
chloroform were stirred in a round-bottom flask for 3 minutes. For the cQDs: 4.3 mg DSPE-
PEG2000 carboxylic acid, 6 mg PEG2000-PE, and 2.8 mg DPPC were used. The lipidic suspension 
was used to dissolve the precipitated QDs and then they were transferred back to the flask and 
stirred for 3 minutes. Chloroform was then evaporated under vacuum, and the flask was dipped in 
an 80°C water bath where the solid material became gel-like. Then, 2 mL Chelex
®
 100-treated 
water was added and the solution was stirred for 10 minutes. The resulting red-coloured aqueous 
QDs suspensions were then purified (section 5.3) and stored in glass vials at 4°C. 
5.3 Purification Techniques 
Excess PEG-dithiol molecules in the QD-sized PEG-dithiol capped/entwined SPNs were 
removed via dialysis with a 2,000 Dalton dialysis membrane (obtained from Sigma-Aldrich). The 
dialysis membrane was filled with 2 mL of the aqueous micellar MEH-PPV SPNs solution and was 
placed in 350 mL of deionised water which was continuously stirred. The dialysis system was kept 
in the dark and the water was changed every two days over a period of 10 days.  
Excess lipids in the SPNs, Gd-SPNs, QDs, and cQDs were removed via dialysis with 
Spectra/Por Float-A-Lyzer G2 MWCO 3.5 – 5 kDa cellulose ester membrane tubes (manufactured 
by Spectrum Laboratories, Inc.) and Chelex
®
 100-treated water. The tubes were immersed in 1 L 
deionised water which was stirred and changed every 24 hours for three days. 
The purified aqueous nanoparticle suspensions were then filtered through 0.2 µm cellulose 
acetate filters to remove any dust or large nanoparticles and stored in glass vials at 4°C.   
5.4 Concentration Techniques 
Concentration of the nanoparticle suspensions was performed using Spectra/Por Float-A-Lyzer 
G2 MWCO 0.1 – 0.5 kDa (cellulose ester membrane tubes) and Spectra/Gel absorbent made of 
polyacylate-polyalcohol (manufactured by Spectrum Laboratories, Inc.). Tubes were filled with 
purified nanoparticle suspensions, covered, and surrounded by the absorbent which gradually 
extracted the aqueous phase. In this manner, 75 mL suspensions were concentrated in subsequent 
steps to 1 mL for the nanoparticle-cell investigation studies in chapter 4. 
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5.5 Concentration Determination Techniques 
5.5.1 Mass Spectrometry to Determine the Concentrations of PEG-dithiol and Gd-DTPA-
BSA 
Before the determination of the concentration of either PEG-dithiol or Gd-DTPA-BSA in the 
SPNs samples, the samples were excessively purified, using the same dialysis techniques described 
in section 5.3. 
An inductively coupled plasma / mass spectrometer (ICP/MS) (Elan 6100 DRC+, Perkin Elmer) 
was used to determine the concentration of sulfur in the purified PEG-dithiol capped/entwined QD-
sized SPNs and the concentration of gadolinium in the purified Gd-SPNs. The concentration of 
PEG-dithiol in the samples was then calculated as half the detected concentration of sulfur since 
each PEG-dithiol molecule contains two sulfur atoms. The concentration of Gd-DTPA-BSA in the 
samples is the same as that of gadolinium because each Gd-DTPA-BSA lipid contains only one 
gadolinium atom. 
5.5.2 Calculations to Determine the Percentage of Surfactant Associated with the SPNs 
after Synthesis 
The above determined concentrations, in section 5.5.1, could not be compared to the initial 
surfactant concentrations used because the dialysis method which was used to purify the samples 
caused an uncontrolled change in the nanoparticles concentration as water molecules were freely 
travelling in to and out of the dialysis tubes. Therefore, to determine the percentage of the 
surfactant of interest associated with the nanoparticles after synthesis (PEG-dithiol in the QD-sized 
SPNs and Gd-DTPA-BSA in the Gd-SPNs), a method which does not require the determination of 
the final nanoparticles concentration was developed as follows: 
 The change in concentration can be estimated by comparing the aqueous SPNs’ absorbances 
before/after purification (at the same wavelength) using the absorbance equation in Beer Lambert 
Law: 
      
where A is the absorbance,    is the wavelength dependant extinction coefficient, L is the path 
length, and C is the concentration of the sample. 
The two equations i (before dialysis) and f (after dialysis) are therefore: 
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For the above relation to be true, the absorbances should be measured under the same 
conditions. 
If all the gadolinium atoms/lipids were associated with and attached to the nanoparticles, then 
the number of gadolinium atoms in the dialysed sample will be the same before and after dialysis. 
In this case, the change in the concentration of gadolinium should be equal to the change in the 










       









       
 
 
The concentration of gadolinium before and after dialysis can be measured by mass 
spectrometry, and the absorbances of the nanoparticles at the same wavelength, before and after 
dialysis, can be determined by absorption spectroscopy. 
The percentage of Gd atoms/lipids incorporated in the Gd micellar SPNs after purification can 










       
                                                       
The same argument applies to the PEG-dithiol percentage in the PEG-dithiol capped/entwined 
QD-sized SPNs. 
5.5.3 A Developed Method to Determine the Final Polymer Concentrations in the Aqueous 
SPNs Samples 
The concentrations of the final polymer nanoparticle suspensions were determined by 
evaporating the water and dissolving the nanoparticles in chloroform (CHCl3) with 1% methanol. 
Using the absorbance/concentration relation given by the Beer-Lambert Law and the specific 
extinction coefficient values of the polymer in CHCl3 + 1% methanol (measured in lab) at the 
wavelength of absorption peaks, the concentrations were determined. 
5.5.4 Concentration Determination of the QDs used in the Nanoparticles’ Interactions with 
Human Blood Studies 
The concentrations of the purified QDs were calculated directly from Beer-Lambert Law after 
measuring their absorbances, and by using their extinction coefficient provided by their 
manufacturer. 
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5.6 Optical Characterisation and Analysis Techniques 
5.6.1 Absorption Spectroscopy 
The solutions were placed in quartz cuvettes (path length = 1 cm), and their absorption spectra 
were analysed (200-800 nm) using a Hitachi U-4100 Spectrophotometer (Hitachi).  
5.6.2 Fluorescence Emission Spectroscopy 
The solutions were placed in quartz cuvettes (path length = 1 cm), and their emission spectra 
were obtained using a LS50B Luminescence Spectrometer (Perkin Elmer). 
5.6.3 Photographs and Excitation with a UV-lamp 
The aqueous nanoparticle solutions were placed in glass vials and were exposed to a 365 nm 
UV-lamp under ambient light exclusion. Their fluorescence was observed and photographed with a 
hand-held 7.1 megapixel SP-55OUZ Olympus camera. Photographs of the nanoparticles in ambient 
light were also captured with the same camera.  
5.6.4 Fluorescence Quantum Yield (QY) Calculations 
The quantum yields (QY) were measured by comparison with suitable fluorescent standards: 
1.  Fluorescein in water (QY = 93% [325]) for F8BT and ADS108GE. 
2.  Atto 390 in water (QY = 90% [326]) for BEHP-PPV and PPE. 
3.  Rhodamine 6G in water (QY = 95% [325]) for MEH-PPV. 
The measurements were carried out with dilute samples (absorbances of absorption peaks below 
0.1) to avoid any concentration related fluorescence quenching such as re-absorption. The 
absorbances at a fixed wavelength (for both sample and standard) and their related emission spectra 
(under excitation with that same wavelength) were taken for successive dilutions (8 – 10 different 
concentrations) under the exact same measurement conditions and settings. A graph was plotted for 
each sample/standard, with the integrals of the emission intensity spectra (y-axis) against their 
relevant absorbances (x-axis). The slopes of the linear fittings were then obtained and the quantum 
yields of the samples were calculated by the equation: 
                         
               
                 
  
5.6.5 Extinction Coefficient Measurements 
The extinction coefficients were estimated using the absorbance values at the peaks of the 
absorption spectra of the nanoparticles in Beer-Lambert Law. The Beer-Lambert Law is given by 
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where   is the transmitted light intensity,    is the incident light intensity,   is the extinction 
coefficient of the sample in (            ),   is its concentration in (       ), and   is the 
pathlength in (  ). 
5.6.6 Fluorescence Lifetime Measurements 
The fluorescence lifetime of MEH-PPV Gd-SPNs was measured by time-correlated single 
photon counting using a Leica TCS SP2 inverted scanning confocal microscope coupled with a 
Becker & Hickl SPC830 card in a 3-GHz, Pentium IV, 1-GB RAM computer running Microsoft 
Windows XP. A pulsed diode laser (Hamamatsu PLP10) with wavelength of 470 nm, pulse 
duration 90 ps, and a repetition rate of 20 MHz was used as the excitation source. The emission 
was collected through a bandpass filter onto a cooled PMC 100-01 photomultiplier detector Becker 
& Hickl, a hybrid detector based on a Hamamatsu H5772P-01 photomultiplier. The fluorescence 
decay was then fitted by a triple exponential decay model using Becker & Hickl SPCImage 
software. The intensity-weighted and amplitude-weighted average fluorescence lifetimes were 
calculated from the multi-exponential decay (by both Dr Klaus Suhling and Dr Pei-Hua 
Chung).[260, 327] 
5.7 Size Measurement Techniques 
5.7.1 Transmission Electron Microscopy (TEM) 
Transmission electron microscopy (TEM) was performed on an FEI Tecnai G2 F20 FE-TEM. 
For TEM imaging of the nanoparticles, the aqueous SPN suspensions were dropcast onto carbon 
coated copper TEM grids. Nanoparticle diameters were measured using ImageJ from at least five 
different TEM images and 400 counts for each sample. 
5.7.2 Dynamic Light Scattering (DLS) for Hydrodynamic Diameters 
In many attempts to measure the true hydrodynamic diameters of the nanoparticles in water 
both Beckman Coulter DelsaTM Nano C Particle Analyser and Malvern Zetasizer Nano ZS were 
used. In both devices, a dynamic light scattering (DLS) technique is used to determine the 
hydrodynamic diameters of the nanoparticles in a substance. Nanoparticles dispersed in any solvent 
undergo Brownian motion which is a random movement of the nanoparticles caused by their 
interaction with the solvent they are dispersed in. The nanoparticles’ velocity in their Brownian 
motion is defined by the translational diffusion coefficient (D) which is related to the nanoparticles’ 
hydrodynamic diameter by the Stokes-Einstein equation: 
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Where   is the Boltzmann constant and   and   are the absolute temperature and viscosity of 
the solvent respectively. 
The translational diffusion coefficient is dependent on the surface structure of the nanoparticles, 
their concentration and the types of ions present in the solvent. The hydrodynamic diameter is 
therefore always larger that the physical diameter of the nanoparticle due to the above factors. 
In DLS, a laser beam is directed towards the cuvette which contains the nanoparticle liquid 
suspensions. The scattered light detected, which is scattered from the surfaces of the moving 
particles, fluctuates due to their Brownian motion. The fluctuations are detected by a digital auto 
correlator and a correlation curve is obtained. The correlation function of the correlation curve is 
directly related to the translational diffusion coefficient, and therefore, it can be used to estimate 
the nanoparticle size distribution. 
By fitting a single exponential to the correlation function, a general z-average diameter 
(cumulant diameter) and an estimation of the width of the size distribution (polydispersity index) 
are obtained. The above results are the most reproducible. However, the cumulants diameter is not 
a true representation of the average hydrodynamic diameters in the sample, but is a general 
indicator of the presence of nanoparticles. 
By fitting multiple exponentials to the correlation curve, a size distribution graph is obtained 
(called the intensity distribution). The intensity distribution is a true representation of the intensities 
of the scattered light from the nanoparticles in the samples. With particles much smaller than the 
wavelength of the used light (less than λ/10), Rayleigh scattering happens. In Rayleigh 
approximation, the intensity of scattered light is relative to six orders of magnitude of the 
nanoparticle’s diameter (     ). This means that a much higher intensity of light is scattered from 
the larger nanoparticles in a polydispersed system. Therefore, the intensity distribution suggests the 
presence of much more of the larger particles than there really is. 
The intensity distribution can be converted into a volume distribution using the Mie Theory 
which requires a pre-knowledge of the nanoparticles refractive index. With an unknown or 
estimated refractive index, an accurate volume distribution cannot be obtained. 
The volume distribution can then be converted to a number distribution assuming that the 
nanoparticles are spherical in shape. If the assumptions and estimations made in the previous 
calculation steps are correct, then the number distribution will be a true representation of the size 
distribution of the hydrodynamic diameters of the nanoparticles and their averages. 
Figure 62 shows that with a sample containing the same number of two sizes of nanoparticles (5 
and 50 nm), the larger particles are detected one million times more than the smaller nanoparticles 
in the intensity distribution, while in the volume distribution they are detected a thousand times 
more. This is really important in polydispersed systems, as the presence of just a few larger 
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particles dramatically skews the results towards the larger species. 
 
Figure 62 The number, volume, and intensity distributions determined by DLS of a sample 
containing the same number of 5 and 50 nm diameter nanoparticles.[328]  
In the DLS measurements conducted for this project, quartz cuvettes were used with freshly 
prepared samples, and three replicates were taken for each sample (n = 3). 
Because the refractive indecies of the nanoparticles are not known, only the cumulants diameter, 
the polydispersity index, and the intensity distribution results could be used. However, as discussed 
earlier, both the cumulants diameter and the intensity distribution average diameters are not the real 
average hydrodynamic diameters of the nanoparticles in the samples. Therefore, we could only use 
those results to identify the presence of nanoparticles, to get a general idea of how polydispersed 
the nanoparticles are, and to study the colloidal stability of the nanoparticles in the same sample. 
In most of our measurements, the DLS intensity distribution average diameter was considered 
instead of the commonly reported cumulants diameter because the measured samples did not 
undergo excessive purification as they were not centrifuged to remove any large particles or dust. 
The large particles were found to skew the cumulants results towards larger diameters giving a 
faulty determination of a significantly larger population than that of the actual, as shown in Figure 
63.  




Figure 63 DLS cumulants results compared to the average diameters of their intensity 
distributions (A) with and (B) without the presence of a second peak with larger 
diameters. 
5.7.3 Nanosight Nanoparticle Tracking Analysis (NTA) for Hydrodynamic Diameter 
A NanoSight LM10 Nanoparticle Tracking Analysis system was used to determine the 
hydrodynamic diameters of the Gd-SPNs. The samples were diluted before measurements, and the 
measurements were carried out by Ms. Agnieszka Siupa in the labs of the NanoSight company.  
5.8 Applications of the Gd-SPNs 
5.8.1 Fluorescence Biomaging and Cellular Uptake Measurements of the Gd-SPNs 
Live cell confocal laser scanning fluorescence microscopy of MEH-PPV Gd-SPNs was 
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performed using the human HeLa cell line (American Type Culture Collection). HeLa cells were 
cultured in phenol red Dulbecco’s modified eagle’s medium (DMEM) supplemented with 10% 
fetal bovine serum (FBS), 1%  non essential amino acids, 1 mM sodium-pyruvate and 0.1 % 
penicillin/streptomycin at 37°C and 5% CO2. The cells were seeded in a 6-well glass bottom plate 
(WaferGen Smartslide-6
TM
 micro-incubator) 24 hours prior to the addition of 20 μl MEH-PPV Gd-
SPNs (initial concentration = 0.05 mg/mL). After overnight incubation, cells were washed 4-5 
times with phenol red-free DMEM to remove Gd-SPNs, which were not associated with or 
internalised by the cells. During imaging, cells were maintained in phenol red-free DMEM at 37°C. 
Image acquisition was carried out using  an inverted Leica TCS SP2 confocal microscope.  
Fluorescence excitation was stimulated by the 488 nm line of a continuous wave Ar
+
 laser through 
a 63x water immersion objective (HCX PL APO, NA = 1.2), with a line scan speed of 400 Hz. 
Emitted fluorescence at 570 – 650 nm was collected through the same objective, dispersed through 
a prism and detected using a photomultiplier. Transmitted light images were collected 
simultaneously.  Gd-SPNs were pseudo-coloured green and images are representative of at least 
three separate experiments. 
Fixed cell confocal laser scanning fluorescence microscopy of MEH-PPV Gd-SPNs was 
performed using the murine macrophage-like J774 cell line (American Type Culture Collection). 
J774 cells were cultured in phenol red Dulbecco’s modified eagle’s medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS), 1%  L-glutamine, 1% sodium-pyruvate and 1% 




 in 8-well 




) 24 hours prior to the addition of 50 μl MEH-
PPV Gd-SPNs suspended in cell culture medium (initial concentration = 0.2 mg/mL). Gd-SPNs 
were incubated with J774 cells for two hours and were subsequently washed 4-5 times with 
phosphate buffered saline (PBS) pH 7.4 to remove Gd-SPNs which were not associated with or 
internalised by the cells. Cells were fixed with 4% paraformaldehyde in PBS and the nuclei stained 
30 min under light exclusion with 4',6-diamidino-2-phenylindole (DAPI). The cells were then 
mounted in glycerine: PBS (1:1) and visualised using a Leica DMIR E2 confocal microscope 
(Leica Microsystems, Milton Keynes, UK).  Fluorescent emissions from DAPI (ex = 205 nm; em 
= 430-480 nm) and Gd-SPNs (ex = 488 nm; em = 570-650 nm) were collected using separate 
channels at a magnification of 63x and at an optical plane selected at half the cell height.  
Instrument gain and offset values were adjusted using the negative control and remained constant 
for all subsequent experiments.  Images obtained from each scan were pseudo-colored blue (DAPI) 
and gold-red (Gd-SPNs), then overlapped afterwards to obtain a multicolored composite image. 
The presented results depict a representative image from at least three experiments. 
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5.8.2 Assessment of MEH-PPV Gd-SPNs Conjugation to IgG Antibodies 
Carboxylated MEH-PPV Gd-SPNs were synthesised (section 5.2.4) and purified from excess 
lipids (section 5.3). Conjugation of the nanoparticles with IgG was performed (by Nicola J. 
Commander, DSTL, Salisbury, UK) using a standard Sulpho-NHS and EDC method (as described 
by Howes et al. [36]). Successful conjugation was confirmed by gel filtration and fluorescence 
detection from washed antibody-coated plates as follows; 100 µl (Gd-SPNs)-IgG solution was 
added to the wells of an immunosorb assay plate. Also 100 µl unconjugated IgG was added to 
separate wells as a negative control. The plate was incubated overnight at 4ºC. Then, it was washed 
5 times with PBS to remove the unbound materials. Fluorescence from the washed wells was then 
analysed at λex = 485 nm and λem = 536 nm. Fluorescence was detected from the wells of the (Gd-
SPNs)-IgG but not from the wells of unconjugated IgG, which means that the nanoparticles were 
tightly bound to the antibodies. 
A simple indirect ELISA test was used to demonstrate that the bound nanoparticles to the 
antibodies did not adversely affect their ability to bind to their target ligands as follows; 
immunosorb plates were coated with diluted antigen (in carbonate buffer) by overnight incubation 
at 4ºC, then blocking with 1% skimmed milk PBS solution for 1 hour at room temperature. Plates 
were then washed in PBS and blotted dry before use. MEH-PPV (Gd-SPNs)-IgG or non-conjugated 
IgG were diluted in 1% skimmed milk PBS-T solution and added to the plates at a range of 
dilutions. The plates were incubated for 1 hour at 37ºC then washed five times in PBS. Diluted goat 
anti-mouse IgG horse raddish peroxidase conjugate (obtained from AbD Serotec; diluted 1/4000 in 
1% Skimmed milk PBS) was then added to the plates and they were incubated at 37ºC for a further 
hour then washed in PBS. 100 µl TMB chromogen / substrate (obtained from Sigma) was added to 
each well in the plates, and the plates were left at room temperature for 10 minutes. The colour 
development was stopped with a stopper solution (also obtained from Sigma), and finally, the 
absorbance of the plates’ wells were detected at 450nm within 30 minutes of stopping. The 
fluorescence intensities were also detected at λex = 485 nm and λem = 536 nm. The strength of the 
antigen-antibody reaction was determined by the intensity of the absorbance of the dye used.  
5.8.3 Assessment of F8BT Gd-SPNs Fluorescence Against Animal Auto-Fluorescence 
A rat pup was euthanized and 100 µL F8BT Gd-SPNs solution was injected subcutaneously into 
its scruff (initial concentration = 110 µg/mL). The rat was then imaged using an IVIS Spectrum 
(Caliper LS, Perkin Elmer) using a range of excitation and emission filters. The image obtained 
from the most optimum settings (excitation filter 465 nm and emission filter 540 nm) was then 
processed using the IVIS Spectrum analytical ‘Image Math’ tool and the background auto-
fluorescence was subtracted resulting in an image detailing the fluorescence solely from the Gd-
SPNs’ emission. (This work was done by Jo Scott, DSTL, Salisbury, UK). 
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5.8.4 Assessment of the Fluorescence of Antibody-Conjugated and Unconjugated MEH-
PPV Gd-SPNs Against Animal Auto-Fluorescence 
Mouse cadavers were injected (by Ms. Nicola J. Commander, DSTL, Salisbury, UK) at three 
locations with either antibody-conjugated MEH PPV Gd-SPNs or unconjugated MEH-PPV Gd-
SPNs as follows: 100 µL MEH-PPV (Gd-SPNs)-IgG solution (neat concentration ~ 1000x diluted 
Gd-SPNs with an initial concentration of ~ 35.6 µg/mL)) was injected into the quadriceps muscle 
of an euthanized mouse, 100 µL MEH-PPV Gd-SPNs solution (concentration ~ 35.6 µg/mL) was 
injected subcutaneously on the ventral surface, and 100 µL MEH-PPV Gd-SPNs solution 
(concentration ~ 35.6 µg/mL) was injected deep into the chest cavity. The mice were transferred to 
the IVIS isolator and were imaged using an IVIS Spectrum (Caliper LS, Perkin Elmer) using a 
range of excitation and emission filters. 
5.8.5 Histopathology of MEH-PPV Gd-SPNs Injected into the Spleens of Euthanized Mice 
Two mouse cadavers were injected with MEH-PPV Gd-SPNs into the spleen (by Ms. Nicola J. 
Commander, DSTL, Salisbury, UK). The spleens were then aseptically removed. One spleen was 
placed into paraformaldehyde fixative and the second one was placed into liquid nitrogen for snap 
freezing. Then both were processed for histopathology. 
5.8.6 MRI T1–weighted Relaxivity Measurements of Gd-SPNs in Water 
MRI was performed at a clinical 3T (Philips, Germany) and at a pre-clinical 7T (Agilent, 
Oxford UK) magnet. The sequence used at the 3T employed two non-selective inversion pulses 
with inversion times ranging from 20ms to 2000ms, followed by eight segmented readouts for eight 
individual images. The two imaging trains result in a set of 16 images per slice with increasing 
inversion times. For T1 mapping the acquisition parameters were: FOV=36x22x8, 
matrix=192x102, in-plane resolution=0.18x0.22mm, measured slice thickness=0.5mm, slices=16, 
TR/TE=9.6/4.9ms, flip angle=10°. The method used at 7T was a Look-Locker [329]. The sequence 
used a 180 degrees pulse to invert the magnetization of the samples. The acquisition started 10ms 
after the application of inversion pulse; TR = 100ms; TReff = 3700ms; 30 repetitions during the 
TReff; TE = 1.5 ms; FOV=30x30mm
2
, 1mm thickness, matrix size = 96x96; 1 average; 1 slice; 4 
phase encoding steps per pulse; scan time ~ 2min. The inversion pulse consisted of a non-selective 
adiabatic 180º of 8 ms while the flip angle of the turbo-FLASH imaging sequence was 20º. 
The R1 values of the samples were calculated using ImageJ software (NIH, Bethesda, MD). The 
images were loaded and fitted for a T1 relaxation curve. R1 values were consequently associated to 
the concentration values using Microsoft Excel. T1 values were computed on a pixel-by-pixel basis 
using an in-house Matlab software [330]. 
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5.9 Interactions with Components of Human Blood 
5.9.1 Nanoparticle Manufacture for Biological Studies 
New glassware, magnetic beads, spatulas, distilled/ metal free filters and membranes, and pH-
adjusted Chelex
®
-treated distilled water were used in the preparation and handling of the 
nanoparticles to minimise heavy metal contamination. Water treatment with Chelex
®
 100 was 
performed as follows: 30 g of Chelex
®
 100 mesh (Chelex
®
 100 sodium salt, Sigma Aldrich) were 
added to 1 L water in a plastic beaker. The water was stirred for at least one hour with non-metallic 
stirring beads and filtered through 0.45 µm cellulose nitrate membrane filter paper. The pH was 
adjusted to 7.0 using concentrated NaOH and HCl solutions (also prepared with the filtered 
Chelex
®
 100-treated water). The treated water was then stored in non-metallic, non-glass containers 
at room temperature until further use. All nanoparticle suspensions were purified and concentrated 
to 4 mg/mL prior to use in biological studies. 
5.9.2 Human Blood Collection and Processing 
Human whole blood samples were collected in citrate buffer from consenting, healthy, aspirin-
free volunteers aged 25-45 years old. Informed consent from all blood donors was obtained and 
procedures were approved by the King’s College London Research Ethics Committee. To separate 
the platelet rich plasma (PRP) from the remaining blood components, 5 mL aliquots were 
centrifuged at 100xg for 20 minutes. To separate the platelet poor plasma (PPP) from PRP, PRP 
aliquots were centrifuged at 1400xg for 10 minutes. Whole blood, PRP and PPP samples were 
stored at room temperature and utilized within 4 hours of collection. 
5.9.3 Nanoparticle Zeta Potential 
Particle zeta potentials were measured using a Zetasizer Nano ZS (Malvern Instruments). Zeta 
potentials were measured both in Chelex
®
 treated, pH adjusted water (using NaOH and HCl) and in 
8% human PPP diluted in a buffer containing 20% phosphate buffered saline (PBS, obtained from 
Oxoid Limited), 80% distilled water, and 0.018% sodium azide (NaN3, obtained from Fluka)). 
Measurements were performed in triplicate. 
5.9.4 Nanoparticle Colloidal Stability Assessment in Physiological and Synthetic Media 
The hydrodynamic diameters of all nanoparticle suspensions were measured at 37°C, over a 
period of 24 hours using the Zetasizer Nano ZS (Malvern Instruments). Nanoparticle stock 
suspensions (4 mg/mL) were diluted to 12.5 µg/mL either in water, phenol-red-free Dulbecco's 
Modified Eagle Medium (DMEM, obtained from Invitrogen) with 2% serum, or 8% human PPP 
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(see section 5.9.3 for 8% human PPP preparation). Size measurements were taken at 10 minute 
intervals for the first hour, then at 1 or 2 hour intervals for the remainder of 24 hours. The 
following instrument settings were used for each measurement: Temperature: 37°C, detection 
angle: 90°, viscosityCCM: 0.738 cP, refractive indexccm: 1.337, viscositywater: 0.6864 cP, refractive 
indexwater: 1.330. 
5.9.5 Oxidative Potential Measured by Ascorbic Acid Depletion 
To assess the oxidative potential of the nanoparticle suspension and confirm that suspensions 
were free of heavy metal contaminants, an in vitro ascorbic acid depletion assay was conducted. 
All SPN and QD nanoparticle suspensions, plus two control nanoparticle species, i.e. copper oxide 
nanoparticles (CuO, positive control; NanoScale Material Inc., USA) and titanium dioxide 
nanoparticles (TiO2, negative control; NanoScale Material Inc., USA) were diluted to a 
concentration of 10 µg/mL in Chelex
®
 100-treated water. A blank sample of Chelex
®
 100-treated 
water was also used as a media control. L-ascorbic acid (Sigma-Aldrich), prepared in Chelex
®
 100-
treated water and adjusted to pH 7, was added to the particle suspensions in a UV flat-bottom 96-
well plate to achieve a final concentration of 0.2 mM. Four wells were allocated for each 
nanoparticle type including one background well (which contained no ascorbic acid). On the same 
plate, an identical set of experiments was conducted in the presence of 0.2 mM DTPA 
(diethylenetriaminepentaacetic acid; a heavy metal chelator). All plates were equilibrated to 37°C 
before measurement of the ascorbic acid absorbance (SpectraMax 190 Microplate Reader, 
Molecular Devices, USA), at 265 nm.  Measurements were taken every 30 minutes for 2 hours. The 
concentration of ascorbic acid at each time point was calculated by subtracting the background 
absorbance values from the control wells and then conversion using a calibration curve. All 
experimental results are presented as the mean and standard deviation of the ascorbic acid depletion 
rate (n = 3 separate experiments). 
5.9.6 Electron Paramagnetic Resonance for Free Radicals Detection 
Spin trap (5-tert-butoxy carbonyl-5-methyl-1-pyrroline-N-oxide) (DMPO, Sigma Aldrich) was 
dissolved in Chelex
®
 100-treated water and was added to each particle suspension resulting in a 
final concentration of 100 mM DMPO and 12.5 µg/mL nanoparticles. Suspensions were 
equilibrated at 37°C and electron paramagnetic resonance (EPR) was performed under light 
exclusion using an EMX Bruker EPR spectrometer. Measurements were carried out with (1) no 
excitation, (2) excitation at 365 nm for 1 minute, and (3) excitation at 254 nm for 1 minute. As a 
negative control, DMPO was added to a blank sample (Chelex
®
 100-treated water), and EPR was 
performed under the same three conditions. Experiments were also repeated at room temperature. 
For a further investigation, the EPR experiment was also performed with a final concentration of 
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180 µg/mL of the SPNs. 
5.9.7 Platelet Aggregation 
Platelet rich plasma (PRP) and platelet poor plasma (PPP) of three healthy human volunteers 
were collected and processed as previously described (section 5.9.2). The concentrations of 
platelets in the PRP were adjusted to 2.6 x 10
8
 platelets/mL using PPP from the same donor. To 
determine whether the presence of nanoparticles will induce aggregation in isolated platelets a 
PAP-4 Bio-Data Corporation Platelet Aggregometer was calibrated to 100% aggregation using PPP 
and 0% aggregation using PRP from each individual donor. Using nanoparticle suspensions with 
concentrations of 4, 0.4 and 0.04 mg/mL, 25 µL of the appropriate suspension (or 0.9% saline 
solution as the negative control) was mixed with 225 µL PRP (final nanoparticle concentrations 
tested were 300, 30 and 3 μg/mL) and turbidity was monitored for 5 minutes at 37°C under 
constant stirring.  
A second experiment was performed to determine whether the presence of nanoparticles will 
influence pathways of platelet aggregation after pharmacological induction. PRP was first exposed 
to nanoparticles (or saline control) at the same concentrations as described above.  After stirring for 
1 minute, 6 µL adenosine diphosphate (ADP; final concentration: 10 µM) were added to induce 
platelet aggregation and turbidity was monitored for 5 minutes. The aggregation profiles for each 
donor, as represented by percentage aggregation after 5 minutes were normalised by dividing the 
sample results by the results of the blank sample and the mean value was calculated from the 
results of the three donors. 
5.9.8 Platelet Activation  
PRP of four donors was isolated as described in section 5.9.2  and diluted to a concentration of 
10
7
 cells/mL in PBS containing 1% bovine serum albumin and 0.1% sodium azide.  Platelets were 
allowed to recover at room temperature for 45 minutes prior to addition of the four particle types 
achieving a final concentration of 300 µg/mL nanoparticles. 0.9% saline was used as a negative 
control and 300 µg/mL carboxylated polystyrene nanoparticles (50 nm in diameter; 
ThermoScientific) were used as positive controls. After 5 min of incubation with the particles, 
platelets were fixed with 100 µL PBS containing 1% bovine serum albumin, 0.5% 
paraformaldehyde and 0.1% sodium azide. Platelets were sedimented via centrifugation (1400xg 
for 10 minutes), resuspended in 100 µL PBS containing 1% bovine serum albumin and 0.1% 
sodium azide, and separated into two 50 µL aliquots. One aliquot (control) was mixed with 1.25 µL 
mouse anti-human CD41a-FITC conjugate (fluorescein isothiocyanate; λex=488 nm, λem=520 nm; 
BD Biosciences).  The second aliquot (sample) was mixed with 1.25 µL mouse anti-human 
CD41a-FITC conjugate and 1.25 µL mouse anti-human CD62P-PE conjugate (R-phycoerythrin; 
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λex=496 nm, λem=578 nm; BD Biosciences).  Isotype controls were conducted for both antibodies. 
CD41a is the alpha integrin chain gpIIb/IIIa transmembrane complex recognized on the surface of 
human platelets and is stably expressed in platelets, making it a suitable platelet marker.  CD62P 
(P-selectin) functions as a cell adhesion molecule and translocates to the surface of activated 
platelets, making it a suitable marker for platelet activation.  Following 20 minutes incubation 
under light exclusion at room temperature, 500 µL PBS containing 1% bovine serum albumin and 
0.1% sodium azide was added to the samples. 
Platelet activation was measured using a Cytomics FC500 MPL flow cytometer (Beckman 
Coulter).  Platelets were discriminated from free particles by setting the forward scatter threshold to 
10 (side scatter to 0) and gating for CD41a-positive events (threshold fluorescence intensity >1 
arbitrary units). 10,000 CD41a-positive events were counted for each sample and the fluorescence 
intensity (FI) of the FITC-marker was plotted against the FI of the CD62P (PE)-marker. The 
percentage platelets from each particle and isotype control showing a FI > 1 (a.u.) for the CD62P 
(PE)-marker were subtracted from the percentage of platelets showing a FI > 1 (a.u.) for the CD41a 
(PE)-marker in each sample. Data from n = 4 separate donors are reported. 
5.9.9 Platelet-Monocyte Adhesion  
In a procedure similar to that described in the previous section, the percentage of platelet – 
monocyte adhesion was quantified as follows: the four nanoparticles were added to 100 µL of 
blood achieving a final concentration of 300 µg/mL nanoparticles. 0.9% saline was used as a 
negative control and 300 µg/mL carboxylated polystyrene nanoparticles (50 nm in diameter; 
ThermoScientific) were used as positive controls. The nanoparticle-blood mixture was then 
separated into two aliquots. One aliquot (control) was mixed with 1.25 µL mouse anti-human 
CD14-PE-Cy7 conjugate (R-phycoerythrin; λex=488 nm, λem=775 nm; BD Biosciences). The 
second aliquot (sample) was mixed with 1.25 µL mouse anti-human CD41a-FITC conjugate 
(fluorescein isothiocyanate; λex=488 nm, λem=520 nm; BD Biosciences) and 1.25 µL mouse anti-
human CD14-PE-Cy7 conjugate. Isotype controls were conducted for both antibodies. CD41a is 
the alpha integrin chain gpIIb/IIIa transmembrane complex recognized on the surface of human 
platelets and is stably expressed in platelets, making it a suitable platelet marker.  CD14 is a 
glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein recognized on the surface of 
human monocytes and is stably expressed in monocytes, making it a suitable monocyte marker. 
Following 20 minutes incubation under light exclusion at room temperature, 500 µL OptiLyse C 
solution (Beckman Coulter) was added to the samples.  
Platelet-monocyte adhesion was measured using a Cytomics FC500 MPL flow cytometer 
(Beckman Coulter). Monocytes were discriminated from free particles by setting the forward 
scatter threshold to 150 (side scatter to 0) and gating for CD14-positive events (threshold 
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fluorescence intensity >1 arbitrary units). 3,000 CD14-positive events were counted for each 
sample and the fluorescence intensity (FI) of the PE-Cy7-marker was plotted against the FI of the 
CD41a (FITC)-marker. The percentage cells from each particle and isotype control showing a FI > 
1 (a.u.) for the CD41a (FITC)-marker were subtracted from the percentage of cells showing a FI > 
1 (a.u.) for the CD14 (PE-Cy7)-marker in each sample. Data from n = 4 separate donors are 
reported. 
5.9.10 Neutrophil Activation 
In a procedure similar to that described in the previous section, the percentage of activated 
neutrophils was quantified as follows: the four nanoparticles and carboxylated polystyrene 
nanoparticles (50 nm in diameter; ThermoScientific) were added to 100 µL of blood achieving a 
final concentration of 300 µg/mL nanoparticles. 0.9% saline was used as a negative control and 
carboxylated polystyrene beads were investigated as a positive control. The nanoparticle-blood 
mixture was then separated into two aliquots. One aliquot (control) was mixed with 1.25 µL mouse 
anti-human CD16-PE-Cy7 conjugate (R-phycoerythrin; λex=488 nm, λem=775 nm; BD 
Biosciences). The second aliquot (sample) was mixed with 1.25 µL mouse anti-human CD11b–
Alexa Fluor 700 conjugate (λex = 633 nm, λem = 723 nm; EBiosciences) and 1.25 µL mouse anti-
human CD16-PE-Cy7 conjugate. Isotype controls were conducted for both antibodies. CD16 (PE-
Cy7) is a glycosylphosphatidylinositol (GPI)-anchored integral membrane protein expressed on T-
cells, neutrophils, and macrophages, making it a suitable neutrophil marker.  CD11b functions as a 
cell adhesion molecule and translocates to the surface of activated neutrophils, making it a suitable 
activated neutrophil marker. Following 20 minutes incubation under light exclusion at room 
temperature, 500 µL OptiLyse C solution (Beckman Coulter) was added to the samples.  
Neutrophil activation was measured using a Cytomics FC500 MPL flow cytometer (Beckman 
Coulter). Neutrophils were discriminated from free particles by setting the forward scatter to 150 
(side scatter to 0) and gating for CD16 (PE-Cy7)-positive events (threshold fluorescence intensity 
>1 arbitrary units). 3,000 CD16-positive events were counted for each sample and the fluorescence 
intensity (FI) of the CD16 (PE-Cy7)-marker was plotted against the FI of the CD11b-marker. The 
percentage cells from each particle and isotype control showing a FI > 1 (a.u.) for the CD11b-
marker were subtracted from the percentage of cells showing a FI > 1 (a.u.) for the CD16 (PE-
Cy7)-marker in each sample. Data from n = 4 separate donors are reported. 
5.9.11 Confocal Laser Scanning Microscope Imaging of Blood Cells Incubated with SPNs 
and Gd-SPNs  
Whole blood was incubated with the SPNs and Gd-SPNs (a final concentration of 300 µg/mL 
nanoparticles) for 20 minutes at room temperature. Then 500 µL OptiLyse C solution ((Beckman 
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Coulter) was added to the samples to fix the cells and the nuclei stained 30 min under light 
exclusion with 4',6-diamidino-2-phenylindole (DAPI). Cells were deposited onto glass slides using 
a cytospin centrifuge, embedded in FluorSave
®
 (Merck Millipore), and visualised using a Leica 
DMIR E2 confocal microscope (Leica Microsystems, Milton Keynes, UK).  Fluorescent emissions 
from DAPI (ex = 205 nm; em = 430 - 480 nm) and SPNs/Gd-SPNs (ex = 488 nm; em = 570 - 650 
nm) were collected using separate channels at a magnification of 20x and at an optical plane 
selected at half the cell height.  Instrument gain and offset values were adjusted using the negative 
control (i.e. NaCl treated whole blood) and remained constant for all subsequent experiments.  
Images obtained from each scan were pseudo-colored blue (DAPI) and red or green (SPNs/Gd-
SPNs), then overlapped afterwards to obtain a multi-colored composite image. The presented 
results depict representative images from n = 4 different donors. 
  




In this thesis, the synthesis, characterisation, and preliminary nanoparticle-cell interaction 
investigations of monomodal and bimodal semiconducting polymer nanospheres was discussed. 
These organic nanoparticles could be proposed as alternatives to inorganic quantum dots 
specifically for bio-imaging applications, as they demonstrate superior optical brightness and 
fluorescence stability. Preliminary investigations of SPN interactions with human whole blood 
components show some promise for enhanced biocompatibility, but further studies must be carried 
out before making more conclusive statements about SPN safety. More details are presented in the 
Summary and Evaluation section followed by Future Work. 
6.1 Summary and Evaluation 
According to the literature, quantum dots (QDs) have been extensively investigated as bio-
imaging agents due to the fact that the nanoparticles are a few nanometers in diameter with a 
narrow size distribution, are available in the commercial market, and their optical properties which 
surpass those of conventional imaging agents. However, many toxicological issues were raised 
about the safety of their use in such applications because of their composition. Therefore, alongside 
the work done in modifying the quantum dots to overcome this problem, other types of 
nanoparticles emerged such as semiconducting polymer nanoparticles (SPNs). 
SPNs are newly emerging nanomaterials which are synthesised from conjugated polymers, and 
are reported to have larger diameters than QDs with relatively broader size distributions. To be 
suitable alternatives to QDs, the size problem had to be addressed and SPNs with QD-sizes had to 
be prepared. This problem was studied thoroughly in the first part of this thesis; with modifications 
to the miniemulsion-evaporation synthesis method used by our group and by others, PEG 
capped/entwined SPNs with diameters as small as 2 nm were prepared from five commercially 
available conjugated polymers. The concentration and molecular weight of PEG was found to 
greatly influence the reaction yield, and the prohibition of DCM evaporation during the 
miniemulsion process was found to be an important factor in the control and success of the 
synthesis outcomes. PEG-dithiol was also used in one variant of the syntheses, allowing the 
purified sample to be examined by mass spectrometry (using sulfur as a reporter), confirming the 
inclusion of a significant number of PEG molecules in the nanoparticles. The nanoparticles were 
characterized by TEM, absorption and emission spectroscopy, and were found to be stable in 
solution for months. Although those QD-sized SPNs had desirable size distributions, they suffered 
from great fluorescence quenching. However, due to their estimated high extinction coefficients, 
they were still considered bright.  
 In the second part of this thesis, another imaging functionality was added to the SPNs by 
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capping/entwining them with gadolinium containing amphiphilic molecules. The approximately 30 
nm diameter bimodal nanoparticles (Gd-SPNs) had better size distributions and better fluorescent 
properties in comparison to the bimodal iron-oxide SPNs prepared previously by our group. They 
were readily taken up by both the human cell line, HeLa, and murine macrophage-like J774 cells as 
demonstrated by confocal laser scanning microscopy. The nanoparticles had desirable fluorescence 
properties, such as high fluorescence stability with little or no photo-bleaching after multiple cell 
image acquisitions or long storage periods. Their fluorescence was also found to be distinguishable 
from the auto-fluorescence of animal tissue, which makes them excellent imaging agents. 
However, this was dependent on both nanoparticle concentration and depth within the animal. The 
nanoparticles were also found to be MRI active generating a linear relationship between T1–
weighted relaxation rates and gadolinium concentrations with calculated relaxivities of     
                    at 3T, and                 
        at 7T. 
The third and final part of this thesis investigated interactions between human whole blood 
components and both monomodal and bimodal SPNs in comparison to QDs capped with similar 
capping agents. These studies are an excellent starting point to examine the safety of SPNs as 
alternatives to QDs in the biological and medical fields, as they represent a relevant biological 
environment into which nanoparticle imaging agents may be administered. Our preliminary studies 
revealed that organic and inorganic nanoparticles with exposed pendant carboxyl groups attracted 
protein adsorption to the particle surface, as suggested by decreases to their zeta potential values. In 
contrast, surface coatings without carboxyl groups were not altered measurably by incubation with 
media containing proteins. Moreover, the nanoparticles did not generate any DMPO-detectable free 
radicals, and were found to have little-to-no oxidative stress in comparison to CuO nanoparticles. 
Introducing the nanoparticles to isolated human platelets was found not to induce any aggregation 
nor affect ADP-induced aggregation. Also, introducing the inorganic nanoparticles to whole blood 
was found, by flow cytometry (FACS), not to induce any platelet activation nor platelet-monocyte 
adhesion, but a possible tendency to activate neutrophils was seen. Interestingly, while the 
fluorescence of the inorganic nanoparticles was substantially quenched by all biological media, 
SPN fluorescence remained bright and stable throughout.  
6.2 Future Work 
Now that the synthesis methods in preparation of PEG-capped SPNs and SPNs capped/entwined 
with amphiphilic molecules were refined, syntheses using different polymers and surfactants can be 
tested. By using infra-red emitting polymers, for example, the problem of tissue auto-fluorescence 
interference with the nanoparticles’ emission in-vivo can be resolved. Also, by combining different 
functional surfactants, the synthesis of trifuctional SPNs might be achieved. However, the results of 
this study demonstrate that it is important to control surface charge with all modifications, as highly 
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negative or positive charges will promote non-specific binding of biological species to the 
nanoparticles. In the future, a continuation of SPN safety investigations should be conducted on the 
organic nanoparticles before making any conclusions about their safety for use in the medical and 
bio-imaging fields. With regard to the inconclusive results generated from the FACS analysis of 
platelet and neutrophil activation described in this thesis, experiments are currently underway with 
the PPE polymer, which has already been shown to avoid fluorescence interference with common 
antibody labels, thus overcoming the methodological challenges identified in this study.  
Preliminary results from these new investigations indicate that, as expected, no platelet activation, 
platelet-monocyte adhesion or neutrophil activation is observed. Finally, the SPNs synthesised in 
fulfilment of this thesis were mainly proposed for medical and biological use. However, SPNs can 
be prepared and tested in other non-medical applications such as the newly growing organic 
electronics field.   
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Appendix 1  Chemical Structures of Some Chemicals 





Figure 64 The chemical structure of DPPC. 
 
 
Figure 65 The chemical structure of PEG2000-PE. 
 
 












Figure 67 The chemical structure of DTPA. 
 
 
Figure 68 The chemical structure of ascorbic acid (left) and dehydroascorbic acid (right). 
 
 
Figure 69 The chemical structure of DMPO. 
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Appendix 2  Definitions of Some Relevant Biological Terms 
 
 
Endocytic : able to carry endocytosis.[261] 
Endocytosis : is the process by which the surface membrane of a cell, usually with a specific 
particle bound to its receptor, is invaginated forming a vesicle containing the 
particle and some extracellular fluid.[261] 
Epithelial cell : is the surface cell of skin or mucous membrane.[261] 
Phagocytic : able to carry phagocitosis.[261] 
Phagocytosis : is a specialised form of endocytosis in which larger particles and cells are 
engulfed and ingested.[261] 
Neutrophil : is a type of leukocyte (i.e. white blood cell) with a lobed nucleus and granular 
cytoplasm (cytoplasm means: the part of the cell that surrounds the nucleus). 
Neutrophils have neutrophilic granules, i.e. granules which are neither strongly 
acidophilic nor strongly basophilic.[261] 
Monocyte : is a type of leukocyte (i.e. white blood cell). It is a mature cell of the 
monocyte/macrophage lineage, and is derived from a promonocyte and 
matures into a tissue macrophage.[261] 
Macrophage : is the end cell of a monocyte/macrophage lineage. It is found mainly in tissues 
and is phagocytic, acting as a defence cell against infection.[261] 
 
